



Republic of Kenya

Kenya Essential Medicines List 2016

Ministry of Health

Kenya **Essential** **Medicines** **List 2016**

Kenya Essential Medicines List 2016

Published by the Ministry of Health
June 2016

Ministry of Health
Afya House, Cathedral Rd
Box 30016-00100
Nairobi, Kenya
+254 20 271 7077
pshealthke@gmail.com
www.health.go.ke

Any part of this document may be freely reviewed, quoted, reproduced, or translated in full or in part, provided that the source is acknowledged.

It may not be sold, or used for any commercial purpose.

Users of this publication are encouraged to send comments, queries and proposals for amendment¹ to the following address from which additional information and copies may be obtained:

The Chief Pharmacist
Ministry of Health
chiefpharmoh@gmail.com

¹ Proposals for amendments to the list should be submitted using the KEML Proposed Amendment Form (p77)

Table of Contents

Foreword	iii
Preface.....	vii
Rationale for development of the KEML.....	vii
The Kenya Essential Package for Health (KEPH).....	vii
The KEML in the context of devolved health care	viii
The WHO Model List of Essential Medicines	ix
The National Medicines and Therapeutics Committee (NMTC)	ix
The KEML development process.....	x
Challenges faced during the review and revision process.....	xv
Recommendations for future KEML review and revision.....	xviii
KEML revision & amendment procedure	xix
Presentation of information.....	xxi
Core list.....	xxi
Specialist list	xxi
Level of use	xxii
Abbreviations & acronyms	xxiii
Essential Medicines List (EML) background information	1
Enhancing access to essential medicines (EM)	1
Benefits of an EML to a country.....	1
Essential medicines selection criteria	3
Main uses of the KEML.....	3
Summary of main changes in KEML 2016	7
Kenya Essential Medicines List 2016	31
1. Anaesthetics	31
2. Medicines for pain and palliative care	32
3. Antiallergics and medicines used in anaphylaxis	33
4. Antidotes and other substances used in poisonings	34
5. Anticonvulsants/antiepileptics.....	34
6. Anti-infectives.....	35
7. Antimigraine medicines	43
8. Antineoplastics and immunosuppressives.....	44
9. Antiparkinsonism medicines.....	48

KEML 2016

10. Medicines affecting the blood.....	48
11. Blood products of human origin and plasma substitutes	50
12. Cardiovascular medicines	50
13. Dermatologicals (topical)	52
14. Diagnostic agents	53
15. Antiseptics and disinfectants.....	54
16. Diuretics.....	54
17. Gastrointestinal medicines	54
18. Hormones, other endocrine medicines and contraceptives.....	56
19. Immunologicals	58
20. Muscle relaxants (peripherally-acting) and cholinesterase inhibitors.....	59
21. Ophthalmologicals.....	60
22. Oxytocics and antioxytocics	61
23. Dialysis solutions.....	61
24. Medicines for mental and behavioural disorders	61
25. Medicines for respiratory disorders.....	63
26. Solutions correcting water, electrolyte and acid–base disturbances	64
27. Vitamins and minerals.....	65
28. Ear and nose medicines	65
29. Specific medicines for neonatal care	66
30. Medicines used in joint diseases	66
31. Preparations for parenteral nutrition	67
32. Preparations for managing severe acute malnutrition.....	67
33. Medicines for other conditions.....	67
Annex 1: Contributors to KEML 2016 Development.....	69
Annex 2: References	74
Annex 3: KEML Amendment Proposal Form	77
Annex 4: ToRs for the TWG on Review & Update of the KEML.....	79
Annex 5: The National Medicines & Therapeutics Committee (2014)....	80
Index.....	83

Foreword

This update of the Kenya Essential Medicines List (KEML) is most welcome. It is a key tool which should effectively be used to promote access to essential medicines, and through their correct selection, management and use to achieve maximum therapeutic benefit and optimise patient outcomes.

The KEML is an investment guide - a guide for the investment of healthcare funds in financing the most appropriate medicines to achieve therapeutic aims in response to prioritised public health need.

It is also meant to guide policy, focus of attention and resources (time, financial, technical and human) in areas and activities which support the above aims, such as training, quality assurance, financing & insurance, regulation & monitoring, appropriate use (including control of antimicrobial resistance), operational research and local production.

As such the KEML must be fully responsive to the aims and objectives of national health policies and strategies. In this respect, the KEML has incorporated the most current guidance to adequately address the heavy but gradually decreasing burden of communicable diseases (such as malaria, TB and HIV). In addition, particular attention has been paid to medicines to manage the ever-increasing numbers of those with non-communicable diseases (especially heart disease, diabetes, cancers and chronic respiratory diseases) which already account for over half of hospital admissions and deaths. Furthermore, medicines for other key (but often neglected or less well managed) areas of public health such as albinism and jiggers, have been included in this KEML.

The evidence for listing medicines on the KEML 2016 was derived from a globally coordinated process of the World Health Organization (WHO), which develops the Model List of Essential Medicines, and makes the relevant information and knowledge available to countries for their own adaptation. The National Medicines and Therapeutics Committee

KEML 2016

(NMTC), through a Technical Working Group (TWG) coordinated the adaptation of the evidence, and extensive stakeholder consultations for the updated KEML.

The KEML should therefore be used with confidence and commitment as a highly relevant, evidence-based and up to date reference document. The systematic and well-managed consensus process through which it has been produced has ensured the incorporation of current evidence-based best therapeutic practice backed by extensive scientific data and robust application of selection criteria. Therefore the selection of the items listed is well justified and suitably adapted to the prevailing health sector context.

The KEML is meant to guide medicines investments for all relevant actors in Kenya. Because of the strong evidence base, the KEML represents best practice in the selection of medicines for optimum therapeutic outcomes. Therefore, it is applicable to, and recommended for use by policymakers and public sector providers at national and county levels, by private, faith-based and NGO actors, and by development partners.

The listing of medicines in a national list such as the KEML is only the initial step of a series of measures which must be implemented to ensure that the expected benefits and substantial health impact are realised.

Given its critical importance, the Ministry of Health is committed to support the KEML and to institutionalize the underlying principles and concepts, in respect of evidence-based priority-setting for medicines and other health technologies.

This arduous and technically complex task was completed well only through the sustained commitment and dedicated work of many individuals who contributed their time and expertise at the various stages of its development.

KEML 2016

On behalf of the Ministry of Health, I would wish to acknowledge and sincerely thank all the contributors, reviewers and editors who have made this KEML a reality².

I also wish to thank WHO for the solid and objective evidence base and ready guidance, and for ongoing policy guidance to optimize the KEML as a priority-setting tool for Universal Health Coverage (UHC).

Finally I would like to thank the USAID-MSH/Health Commodities and Services Management Programme (HCSM) for their financial and technical support and the DANIDA Health Sector Programme Support (HSPS) for continuous technical advice throughout this complex process.

The KEML provides a key tool in support of efforts to attain equity and high standards in healthcare. It is intended to guide medicines development, production, procurement and supply, prescribing, dispensing and use, as well the development, monitoring and evaluation of strategies, thereby enhancing Appropriate Medicines Use (AMU).

It is for use by all disciplines of healthcare workers, general practitioners, specialists and healthcare management personnel as well as students and interns.

This KEML comes at a time when Kenya is defining strategies to attain the Sustainable Development Goals (SDGs)³, to which the country is committed. In this regard, access to medicines and vaccines is one of the cornerstones of universal health coverage (UHC), and is critical to the achievement of the health-related SDGs.

² See Annex 1 (p69) for a list of all the individuals involved


³ Goal 3 is 'Ensure healthy lives and promote well-being for all at all ages' with a key target 'Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all'

KEML 2016

The KEML is a key component of the Kenya Essential Package for Health (KEPH), which defines the comprehensive priority services and interventions for UHC.

The regular and consistent use of the KEML can be expected to improve healthcare, and to contribute to the attainment of the Constitutional right to health.

I therefore strongly encourage all relevant health professionals to make the best use of this KEML in their daily work, to provide feedback on its use, and any suggestions towards its improvement and future revisions.



Dr Cleopa Mailu

Cabinet Secretary for Health

Preface

Rationale for Development of the KEML

Healthcare management and therapeutics are highly dynamic fields, with new approaches, treatment protocols and therapeutic products entering the market on a continuous basis. Providing comprehensive healthcare services to the population requires heavy investments, which constitute a major and ever-increasing cost to governments, households and individuals. Therefore, effective mechanisms are needed to prioritize the various health interventions and products, in order to maximize therapeutic benefits and optimize patient outcomes. Such mechanisms must be anchored on the best available scientific evidence of cost-effectiveness, in order to objectively guide investment decisions.

In this regard, clinical management guidelines, national formularies and essential medicines lists should be developed to guide and standardize healthcare delivery and these should be regularly updated to keep pace with best practice, and to optimize investments in healthcare.

The Kenya Essential Medicines List was last revised and produced in 2010, but there was no effective mechanism for promoting and monitoring its use, and for subsequent regular review and revision. Consequently, this important guide to best practice in medicines selection became progressively outdated and consequently its relevance and usefulness in the health sector gradually diminished.

The Kenya Essential Package for Health (KEPH)

KEPH⁴ is a life-cohort based approach to the delivery of healthcare services, which defined in a comprehensive manner, the services which the sector is to prioritize so as to maintain health at all the different stages of life. It defines the priority services that are necessary to be

⁴ For details of KEPH see Health Sector Strategic and Investment Plan (KHSSP) July 2013- June 2017, The Second Medium Term Plan for Health: Transforming Health: Accelerating Attainment of Health Goals
(Available at http://www.who.int/pmnch/media/events/2013/kenya_hssp.pdf)

KEML 2016

provided at 6 distinct levels of care – from the community level up to tertiary hospitals - for each of 6 defined life cohorts: pregnancy and the newborn (up to 2 weeks), early childhood (to 5 years), late childhood (6-12 years), adolescence and youth (13-24 years), adulthood (25-59 years) and the elderly (60+ years).

KEPH also provides the framework for referral of clients across the sector providers, and it aims to improve utilization of health services at lower levels of care, beginning at the community level, as well as networking among providers and facilities across the different levels and between the public and non-public providers. KEPH also guides the types of medicines and other health inputs to be made available at each level and for each cohort, in line with the services to be provided and the corresponding expertise for the level, as defined in the sector norms and standards.

The revised KEML strives to align with these strategic orientations in the health sector.

The KEML in the Context of Devolved Health Care

As described in the following sections, the KEML 2016 is derived from a robust and globally recognized process of scientific assessment of efficacy, safety and quality; as well as cost-effectiveness evaluation. The investments required for such evaluations are massive, and the processes require standardization of the evidence, in order to promote uniformity in clinical care, disease control and public health protection.

Therefore, the KEML is a critical tool in ensuring the right to health by ensuring optimum therapeutic interventions. Because of this, for the national and county governments, the KEML 2016 should be the basis for selecting the medicines for procurement using public funds.

Furthermore, the national and county governments have a duty to ensure that essential medicines are available within the context of a functioning health system, at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford.

To attain this, it is imperative that national and county governments develop sustainable solutions for financing essential medicines through

increased budget allocations for health, and robust priority-setting mechanisms to optimize efficiency of the health budget. This should be accompanied by the regular updating of the KEML through a robust and evidence-based national process.

The WHO Model List of Essential Medicines

WHO is the secretariat for the Expert Committee on Selection and Use of Essential Medicines, the group of experts responsible for revising and updating the Model List of Essential Medicines (EML) and the Model List of Essential Medicines for Children (EMLc). Every medicine listed is vetted for efficacy, safety and quality, and is subjected to a comparative cost-effectiveness evaluation with other alternatives in the same class of medicines. WHO updates the lists every two years and the lists have become an important guide for governments and institutions around the world, in the development of their own essential medicines lists.

The 2015 edition (ie. the 19th EML and 5th EMLc) includes *inter alia* ground-breaking new treatments for hepatitis C, various cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB). Placing a new medicine on the WHO EML is a first step towards improving access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.

The purpose of the Model List is to provide guidance for the prioritization of medicines from a clinical and public health perspective. The hard work begins with efforts to ensure that those medicines are actually available to patients. This requires collaborative effort between governments, the private sector, civil society, WHO and other international partners.

The National Medicines and Therapeutics Committee (NMTC)

The role of NMTCs is critically important in identifying appropriate medicines for use throughout the system and for guiding the use of those medicines. When operating well, a NMTC is the leading clinical coordinating body, as well as the reference point for all activities with medicines-related components. They are considered a vital important structure for ensuring evidence-based therapeutics, as part of a comprehensive quality of care program.

KEML 2016

The first NMTC was established after the formulation of the Kenya National Drug Policy in 1994 but since then, the functioning of the NMTC has been erratic and ineffective, because of inadequate understanding of its critical role and multiple functions, a perception that it was primarily a pharmaceutical body, and a focus only on the intermittent development of therapeutic documents such as essential medicines lists and clinical guidelines rather than the provision of continuous advice and guidance on medicines and health technologies management and utilisation.

It has suffered from a lack of enabling legislation, which would entrench the evidence-based guidance into decision-making for healthcare financing and service provision. Going forward, the Ministry of Health is committed to actively supporting all NMTC-coordinated initiatives to ensure that these challenges are minimised, in order to obtain the maximum value from its work including review and revision the KEML.

In addition, healthcare institutions and facilities are encouraged to form similar medicines therapeutics committees (MTCs), to promote evidence-based processes that ensure the selection and use of those medicines that address the needs and priorities of the community in that area.

The KEML Development Process⁵

a) Background

Kenya developed its first Essential Medicines List in 1981. Over the years, the Essential Medicines List (EML) concept has become increasingly entrenched into the health system, with successive revisions of the KEML in 1993, 2003 and 2010. Although the KEML review and development process has encountered various challenges (see below), the document is nevertheless considered a key policy and reference for the sector, and efforts are constantly made to ensure that it is updated, effectively disseminated and its regular and routine use promoted.

⁵ The first Kenya Essential Medical Supplies List (KEMSL) was simultaneously developed alongside the KEML with the two retreats involving both TWGs and continuous close coordination between the two processes

b) Past experience with KEML 2010

The previous KEML (2010) was successfully developed by an ad-hoc technical working group under the supervision of the then NMTC, following a well-managed process. It was the product of extensive, diligent, highly creditable and relevant work, but it suffered from a number of challenges which compromised the expected benefits.

These included: insufficient distribution & dissemination; inadequate advocacy & promotion of its multiple uses and potential benefits; absence of monitoring & evaluation to guide future revision and lack of active solicitation of feedback from users to verify its continuing relevance.

In the following years, the NMTC became dormant and suffered from uncertainties, disruption and un-coordination during a period of enormous changes and restructuring within the health sector. These changes included the promulgation of the Constitution 2010, various re-organizations of the Ministry of Health, and the onset of devolution. As a result, the intended 2-yearly review did not take place.

Further, the potential impact of the KEML as a guideline is limited by the lack of enabling legislation to mandate evidence-based cost-effectiveness evaluation in the determination of the public financing of medicines. This lack of legal status of the KEML (and the associated clinical guidelines) has also contributed to a failure to establish sustainable structures and processes within the health system, for the necessary periodic, regular and timely update. Consequently, these health system gaps have led to increasing obsolescence, ever-decreasing relevance of, and low levels of adherence to, these very useful tools.

c) Preliminary review

As a result of the above, the intended 2-yearly review did not take place. Preparatory work for updating the KEML started in late 2012, using an advance copy of the WHO Model List (ML) 2013, and compiling all the comparisons and deviations with the KEML 2010, as a key review tool and focus for selection discussions.

d) Re-establishment of the NMTC

In February 2014, after months of preparation, the NMTC⁶ was reconstituted and members appointed by the Principal Secretary. The composition of the membership was closely guided by best practice in this area to ensure the correct representation of all key MoH departments. The NMTC responsibilities were described as: policy development in the evaluation, selection & use of medicines & health products; standards & guidelines development & dissemination; rational prescribing and cost-effective use; IEC for health providers in matters related to medicines & their use.

In the following months, the NMTC had numerous meetings and two retreats in the course of which TORs were developed, 7 Technical Working Groups (TWGs) established (with their own TORs & members identified) and a prioritised action plan developed to guide the sequence of work in multiple areas of interest. Amongst these TWGs was one for the review and update of the KEML and another for the preparation of a first ever Kenya Essential Medical Supplies List (KEMSL) covering the selection of non-medicines items.

e) Preparation of key KEML review tools

In December 2014, the new WHO Model List 2015 (19th edition for adults, 5th edition for children) was made available online, necessitating a complete re-review of the KEML 2010 in comparison with this, and also with the Kenyatta National Hospital Formulary which was produced in 2013, and which gave an additional useful comparison representing a more recent picture of medicines utilisation in Kenya than the KEML 2010.

Work on preparing the tools which would be required for the eventual review and update of the KEML proceeded throughout 2015. The key tools developed as spreadsheets were

- a Yes List (comparing the WHO ML with the KEML 2010 and identifying all items on the ML but not the KEML for consideration for possible inclusion)

⁶ See Annex 5 for details

- a No List comparing the KEML 2010 with the ML and identifying all items on the KEML but not the ML for consideration for deletion

f) Establishment of the review Technical Working Groups

In September 2015, again after several months of preparation, the TWGs for the KEML and KEMSL were established with the required representative membership (in line with WHO guidelines) appointed by the Director of Medical Services.

Following this a secretariat was established to support the TWGs and developed Standard Operating Procedures (SOPs) for the review & update process of the KEML and the preparation of the KEMSL. These were adapted from WHO SOPs for Guidelines Development which involve the establishment of a robust, scientific methodology in order to ensure the production of a credible and reliable output anchored firmly in best scientific (evidence-based) practice. Given the time available and deadlines applicable for the current review, it was not possible to fully implement the SOP this time around, but key review and selection principles and methodologies were identified for implementation by the TWGs. To make the methodology explicit and set the rules for the process, ten key criteria were identified for application during the selection process as detailed on p.3

In November 2015, as preparation for the forthcoming review retreat, the members of both TWGs were assembled for an intensive induction meeting which oriented them to essential medicines concepts and guided them through the selection principles, criteria, process and tools (with adaptations to include medical supplies) and completed planning for the retreat.

g) Undertaking the KEML review

Following this, in relation to the KEML, discussions were held with national disease control programmes⁷, two 3-day retreats were convened with the TWGs and numerous consultations made with

⁷ HIV/AIDs, TB, Malaria, Cancer, Palliative Care, Reproductive Health, and Vaccines

specialists in all key therapeutics areas⁸. Using the WHO Model List and the tools developed for the review, and through careful application of Essential Medicines principles and selection criteria, discrepancies and issues requiring clarification were identified and discussed and consensus reached on required amendments to the KEML.

In regard to the retreats, members of the TWGs were reminded of the steps to be followed and the criteria to be applied. They also each signed a Declaration of Interest form to ensure transparency, impartiality and objectivity in their work. At the retreats members of the KEML TWG carried out a systematic and thorough review of each Essential Medicines item by item, and section by section, having received relevant inputs from the consultations.

During the course of the review process important practice issues (especially relating to current irrational use of medicines or medical supplies by health professionals) were identified for urgent attention.

Following incorporation of all the agreed changes, the updated drafts of the KEML was circulated to the TWG members for final review and confirmation of its completeness and correctness and a few corrections made based on comments received.

h) Feedback to stakeholders

A month after the second retreat, a half-day meeting was convened at which key stakeholders⁹ were taken through the draft KEML, its process of development and intended multiple uses.

Participants expressed appreciation for the high quality and thoroughness of the work done, but were most concerned that the KEML should (this time) be fully implemented in order to achieve the intended benefits and maximum therapeutic impact. They were

⁸ These included antimalarials, psychotherapeutics, anaesthetics, dermatologicals, ophthalmologicals, anti-cancer medicines, ARVs, cardiology, immunologicals, nutritional products, radiologicals, ENT medicines, gastroenterology, hepatitis, renal medicines/dialysis fluids, and endocrinology

⁹ Including senior MoH management, heads of national disease control programmes, CEOs of major hospitals, regulatory and supply organisation officials, some County Executives for Health or their representatives, and NMTC members

informed that a comprehensive implementation plan would be put together to ensure that this would indeed be the case.

i) Finalisation of the document for printing

Simultaneous post-retreat work was completed to produce a print-ready version for signing-off by the Cabinet Secretary, prior to printing, official launch and dissemination.

Challenges faced during the review and revision process

Despite the systematic, scientific approach and best efforts of the TWG, a number of challenges presented themselves during the process of review and revision of the KEML including:

- ***Lack of required information.*** For certain proposed items information was missing or incomplete in terms of such aspects as: (relative) cost, availability, cost-effectiveness, numbers of patients expected to require/benefit from the item (to assist in making a judgement on public health priority), limited published scientific information on an item and its use, and lack of written submissions for proposed list amendments. These constraints highlight a lack of the health technology assessment (HTA) required to ensure fully evidence-based (scientific) selection (ie. investment) decisions and thus robust justification for each of these decisions
- ***Inadequate orientation of some contributors to essential medicines concepts.*** Although members of the TWG were well-oriented having undergone an intensive and comprehensive induction programme, most of the specialists engaged to provide inputs into the process had not had the benefit of such orientation. Efforts were made to provide a brief explanation of the purpose of the KEML and the key criteria to be applied, but not surprisingly many proposals were received which, although mostly representing good clinical practice, did not fit the criteria for listing as an essential medicine on the KEML
- ***Inconsistencies between the national treatment guidelines, hospital formulary and essential medicines lists.*** Although the Clinical

Management and Referral Guidelines¹⁰ (2009) and the Kenyatta National Hospital Formulary (2013) were produced in good faith and through extensive and inclusive technical consultative processes, the management of the processes was not fully in line with best international good practice as for example defined by the *WHO Handbook for Guideline Development*¹¹ and the resulting output inevitably compromised by this. For example, the documents contain many more medicines than are listed on the WHO Model List, some non-recommended and obsolete medicines and multiple medicines class members, eg. numerous beta-blockers, where best practice would dictate identifying a first choice medicine and strictly limited, well-justified second-line options.

The Clinical Management and Referral Guidelines were not fully responsive to essential medicines criteria in the selection of medicines for use in managing the conditions covered and have, with the passage of time, inevitably become progressively obsolete. Thus they are not well-aligned with the new KEML and are in need of urgent review and update following a well-defined, systematic and evidence-based process.

The NMTC is expected to oversee the next review of the clinical guidelines following a Standard Operating Procedure being prepared in line with WHO recommendations¹² and international best practice. The NMTC will also be expected to supervise the preparation of a *National Formulary* derived from the KEML. This is also urgently required to provide all the necessary prescribing and other information on the medicines in the KEML to ensure (together with the clinical guidelines) that they are used appropriately, so as to derive the maximum therapeutic benefit.

- **Time constraints.** Lengthy delays in undertaking the required regular review of the obsolete KEML 2010 and the increasing urgency to

¹⁰ *Clinical Management and Referral Guidelines* for Level 1 Community, for Levels 2-3 Primary Care, and for Levels 4-6 Hospitals (3 books) (Ministry of Health, 2009)

¹¹ Available at http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf

¹² See *Handbook for Guideline Development*, WHO 2012 (available at http://www.who.int/kms/guidelines_review_committee/en/)

produce an updated list as soon as possible - for example, to guide medicines procurement decisions and improve current medicines utilisation practices – meant that the full SOP for the review and revision process could not be applied for the current version. Thus, compromises had to be made to enable the process to be completed expeditiously. For example, it was not possible to insist on full written justifications to be submitted in support of list amendment proposals. Nor was it feasible to place proposals in the public domain for review and comment.

- **Prohibitive costs.** This was probably the greatest challenge facing selection decisions and it presents a major dilemma. A medicine may satisfy all other criteria but be unaffordable given the likely continuing limited resources available for medicines procurement for the public health system. It was the considered opinion of the TWG that no matter how effective a medicine might be, if its cost was so prohibitive as to be out of consideration for public sector procurement, there was no point listing it on the KEML. However, it is intended that medicines costs will be closely monitored and future selection decisions reconsidered accordingly as part of the planned continuous review process.

For medicines already on the WHO Model List, the above challenges did not apply, since the ML incorporates best current practice backed up by extensive scientific evidence.

So the major criteria remaining to be considered were: is the proposed medicine required/suitable for use in Kenya, is it (cost-)effective and is it (likely to be) available. The bigger challenge involved medicines not on the Model List.

For these, a selection decision was based on a reasonable judgement given the best available information - with a proviso that the NMTC monitors the effect of the decision, utilisation and impact of the medicine, and strives to obtain more supportive evidence for its continued inclusion in the list.

Recommendations for future KEML review and revision

- **Legal establishment of the NMTC.** In the context of the SDGs, the KEML and the clinical guidelines are critical tools for the attainment of UHC. Therefore, in order to ensure that health financing decisions are based on sound and robust evidence, it is imperative that the NMTC and its associated processes of economic evaluation become legally entrenched into the health system, through an appropriate statutory committee or agency
- **Full application of the SOP** for the KEML review and revision process including: the requirement for written amendment proposals backed up by scientific justification, greater involvement of stakeholders in general and key stakeholders in particular, publishing of announcements of the process, invitations for submissions and amendment proposals on the Ministry of Health website, and early commissioning of expert (specialist) reviews of priority sections of the list
- **Development of the required health technology assessment¹³ (HTA) capacity** to facilitate comprehensive and complete assessment of medicines proposed for addition to the list, particularly where these are not on the WHO Model List (which have been subjected to adequate HTA to support their inclusion)
- **Regular review and proper alignment.** The KEML should be kept under constant review and a new edition published every 2 years in line with the updates of the WHO Model List (ML). It is important that efforts be made to ensure that future editions of the national clinical guidelines and KEML are properly aligned, in order to realize the full benefits of evidence-based health care
- **Continued and intensified advocacy** for the KEML, and improved awareness and application of essential medicines principles,

¹³ HTA is 'Health technology assessment (HTA) is a multidisciplinary activity that systematically examines the technical performance, safety, clinical efficacy, and effectiveness, cost, cost-effectiveness, organizational implications, social consequences, legal, and ethical considerations of the application of a health technology' [Report from the EUR-ASSESS Project, *Int J Technol Assess Health Care* 1997, 13(2)]

especially in making medicines selection decisions in preparation of clinical guidelines, essential medicines lists and formularies

- **Active monitoring and assessment** of the utilisation of the KEML for the uses described on p3, and of the utilisation and impact of listed medicines, especially those which are newly introduced
- **Utilise the NMTC as a key resource in contributing to the development of health financing strategies.** Kenya is reviewing its health financing strategy to move towards insurance-based financing, as part of the reforms to facilitate UHC. A key requirement is to ensure that the health interventions and technologies listed in the KEPH are derived from systematic and objective cost-effectiveness evaluation. In this regard, it is important that clear criteria be established to guide evidence-based decision-making on which medicines and other health technologies can be procured and/or reimbursed with public funds. The current NMTC processes and procedures provide a good starting point, and can be further refined by adapting from similar successful processes in other countries

KEML Revision & Amendment Procedure

It is anticipated that the KEML will be *reviewed constantly*, and the full list updated at least every 2 years, depending on the nature and extent of cumulative amendments required. Urgent amendments will be disseminated as required through the already established coordination forums or other mechanisms for communication within the healthcare system.

The NMTC (or an equivalent statutory entity) will undertake the review and revision of future editions of the Clinical Guidelines and KEML. In this strictly evidence-based process, the NMTC will be well guided by:

- feedback obtained from operational research on KEML use in each of the key medicines management areas identified in the **Main Uses of the KEML** section on p.3
- reports on KEML use obtained through feedback by users and during the course of supportive supervision
- MoH-approved changes in disease management protocols (with concurrent changes to the relevant Clinical Guidelines)

KEML 2016

- changes made to the biannual WHO Model Lists
- results of other relevant health research into disease management and medicines utilisation
- new information provided by medicines manufacturers on their products
- new information arising through quality assurance systems, eg. pharmacovigilance and post-market surveillance
- KEML Amendment Proposal Forms (see p77) received from users

In order to understand fully the relevance and wide range of application of the KEML, readers are urged to become familiar with the **Main Uses of an EML** as summarised on p.3 and to study the **Selection Criteria** used as listed on p.3. This will definitely enrich the review & revision needed to keep the KEML relevant and useful as a tool for improving the quality, reliability and cost-effectiveness of health care services.

Presentation of Information

Medicines on the KEML are listed by broad therapeutic categories (Sections). Within each Section, medicines appear in alphabetical order and with the appropriate dosage forms indicated. The listing does not imply preference for one medicine over another.

Core List

The Core List represents the priority needs for the health-care system. Medicines on the Core List are:

- Considered to be the most efficacious, safe and cost-effective for the relevant conditions
- Those which do not require specialist inputs (see **Specialist List** below)
- Expected to be routinely available in health facilities (at the appropriately designated levels of care)
- Expected to be affordable to the majority of the population. All efforts should be made to ensure **equitable access** to medicines on the Core List (and the most critical Specialist List items).

Priority conditions corresponding to the Core List were identified on the basis of current and anticipated future public health relevance and their potential for safe and effective treatment.

Specialist List

These items listed in *italics* are essential medicines for priority conditions for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed.

No level of use is indicated for such items as the level at which particular required specialist inputs are available will vary over time depending on the level of development of, and investment in, the health system in response to the aim of greatly improving access to specialist services.

Special efforts should be made to acquire Specialist List items, with particular priority on those recommended as 1st line medicines.

Level of Use

This indicates the **lowest level** of the healthcare delivery system at which each particular medicine may reasonably be expected to be appropriately used (ie. after correct diagnosis and a correct decision on management of the condition according to current best therapeutic practice).

It is thus the *lowest level* at which the medicine is expected to be available for use (ie. distributed, stored, prescribed and dispensed).

The current levels are as follows:

- 1 = Community Health Services
- 2 = Dispensary/Clinic
- 3 = Health Centre
- 4 = Primary Hospital¹⁴
- 5 = Secondary Hospital¹⁵
- 6 = Tertiary Hospital¹⁶

¹⁴ Formerly District Hospitals, now (Sub-)County Hospitals

¹⁵ Formerly Provincial Hospitals, now County Referral Hospitals

¹⁶ National (Referral) Hospitals

Abbreviations & Acronyms

Used in the text:

ADRs	Adverse Drug Reactions
EM	Essential Medicine
KEPH	Kenya Essential Package for Health
MTC	Medicines & Therapeutics Committee (Institutional)
NMTC	National MTC
TWG	Technical Working Group

Used in the KEML table:

ads	adsorbed
amp	ampoule
conc	concentrate(d)
BP	British Pharmacopoeia (current edition)
DT	Dispersible tablet
e/c	enteric-coated (tablet)
f/c	film coated (tablet)
HCl	hydrochloride salt
hyd	hydrogen
IM	intramuscular
Inj	injection
IU	international units
IV	intravenous
m/r	modified (prolonged, delayed, slow) release
n/a	not applicable
MU	mega (million) units
PFI	powder for injection (to be reconstituted with diluent)
PFOL	powder for oral liquid (to be reconstituted with diluent)
SC	subcutaneous
sod	sodium
TU	Tuberculin units

Essential Medicines List (EML)

Background Information

Enhancing Access to Essential Medicines (EM)

Access to Essential Medicines is a core component of the *right to health*, and a requisite to the attainment of national health goals. This national Essential Medicines List (EML) defines the priority focus for investment in medicines by the public health sector, towards ensuring the provision of equitable healthcare to the population in line with defined sector policies, strategies, norms and standards.

This EML is based on the Concept of **Essential Medicines**, defined by WHO as:

- those that meet **priority health care needs** of the population
- carefully and systematically selected using an *evidence-based process* with due consideration of:
 - **public health relevance**
 - clear evidence on **efficacy** and **safety**
 - comparative **cost-effectiveness**
- meant to be always available in a functioning health-care system:
 - in **adequate amounts**
 - in **appropriate dosage forms**
 - with **assured quality** and **adequate information**
 - at an **affordable price** for the individual & community

This EML is derived from the WHO Model List #19 (Adults) and #5 (Children) of 2015 and various national guidelines for specific conditions (eg. malaria, hepatitis, TB/leprosy, HIV/AIDS, STI, and IMCI) which represent the best current therapeutic practice in each of the priority conditions covered

Benefits of an EML to a Country

Priority Setting

The EML represents priority-setting on two levels:

KEML 2016

- Careful identification of the priority health interventions, and the careful selection of a limited range of EM results in a higher quality of care, better medicines management (including improved quality) and more cost-effective use of health resources

General benefits

- Many studies show the positive impact of clinical guidelines and EMLs on the availability and proper use of medicines within health care systems. This is very important in resource-poor settings where public sector medicines availability is often erratic
- Measures to ensure regular EM supply will result in real health gains and in increased public confidence in health services - and in the government of the day

Specific benefits

- **Supply system:** use of an EML leads to easier and more-efficient procurement, storage, distribution, stock management & record keeping; lower stocks (smaller item range, predictable procurement with reduced level of safety stocks); better quality assurance (can focus on fewer items); easier dispensing (greater familiarity with fewer items); more effective local production (efficiency in producing fewer items for a more predictable market)
- **Prescribing:** use of an EML enables prescriber training to be more focused & easier to deliver, more experience to be gained with fewer medicines, production of more focused medicines information (eg. National Formulary), minimizing of irrational treatment alternatives and better recognition of adverse drug reactions (ADRs)
- **Cost:** use of an EML should lead to lower treatment costs (through selection of the most cost-effective items), more competition (through identification of key items for national investment and therefore a substantial market for potential suppliers) and lower supplies management costs (fewer items to manage)
- **Patient Use:** use of an EML will result in focused education efforts on fewer, well known medicines, improved patient knowledge on medicines use, increased treatment adherence and improved medicines availability

Essential Medicines Selection Criteria

Inclusion of a medicine on the EML should be considered if the medicine, as far as reasonably possible, meets the following criteria:

1. **Relevance/Need:** *Public health relevance and contributes towards meeting the priority health care needs of the population*
2. **Safety:** *Scientifically proven and acceptable safety (side-effects & toxicity) in its expected way of use*
3. **Comparative Efficacy:** *Proven and reliable efficacy compared with available alternatives (based on adequate and scientifically sound data from clinical studies)*
4. **Quality:** *Compliance with internationally acceptable quality standards, as recognized by the national medicines regulatory authority - currently the Pharmacy and Poisons Board (including stability under expected conditions of storage & use)*
5. **Performance:** *Sufficient evidence of acceptable performance in a variety of settings (eg. levels of health care)*
6. **Comparative cost-benefit:** *a favourable cost-benefit ratio (in terms of total treatment costs) compared with alternatives*
7. **Single ingredient:** *Unless there is no suitable alternative available, a medicine should have only a single active ingredient*
8. **Local Suitability/Appropriateness:** *Preference should be given to a medicine which is well known to health professionals, suitable for local use (eg. dose-form, staff training, support facilities) and socio-culturally appropriate (eg. method of use/administration)*
9. **Pharmacokinetic Profile:** *Wherever possible the medicine should have favourable pharmacokinetic properties (absorption, distribution, metabolism and excretion; drug interactions)*
10. **Local Production:** *Wherever possible the medicine should have the possibility of being manufactured locally (for improved availability, reduced procurement costs)*

Main Uses of the KEML

The KEML is a cornerstone of the national healthcare system, and a key component of both the national health and national pharmaceutical

policies. It is a vitally important tool and reference source for guiding the management of common health conditions in the country, as well as the management and utilization of medicines at national, county and institutional (health facility) levels.

The KEML aims to support the smooth functioning of the healthcare system and radically improve the availability and appropriate use of medicines, for improved health status of the population. The health sector will realize the full benefits of the KEML when it is routinely, appropriately and fully utilized in the following key areas:

1. **Healthcare Financing & Medicines Supply Budgeting:** The KEML should be used as a basis for prioritization of investment of available healthcare finances and, together with careful & systematic quantification of needs, for the estimation of required annual medicines supply budgets *at all levels of the healthcare system*. It should also form the basis for medicines financing by development partners.
2. **Health Insurance Schemes:** Medicines are a major cost element in healthcare financing for Government, insurance schemes and partners. As the sector elaborates a comprehensive healthcare financing system, the KEML should be used as the basis for expanding coverage or reimbursement of medicines costs (e.g. positive lists with 100% reimbursement only for items on the EML).
3. **Procurement, Supply & Distribution (including Donations):** The KEML should be used as a basis for determining medicines procurement requirements for all health care levels, ie. from dispensary level, to county level and up to the national referral level. This applies equally to public procurement by the national and county governments as well as procurement by the faith-based, NGO, private sector and other actors. The strong evidence-base for expected clinical benefits will help to guide investment of scarce health resources towards providing the most appropriate medicines, to patients and the public.

Use of the KEML will help focus management efforts on a needs-based and prioritized list of critical items, and can greatly improve the functioning and efficiency of medicines supply & distribution systems. The KEML should be used as a basis for pre-printed order forms for the pull system of medicines supply to health facilities. The *level of use (LOU)* designation should be used to guide the supply and use of medicines at the appropriate levels of care, as defined in KEPH.

4. **Donations:** potential medicines donors and recipients should use the KEML to determine the most appropriate types and presentations of medicines for donation to meet public health priorities, including health emergencies. This should be done in line with up-to-date national guidelines on donation of medicines and health products.
5. **Healthcare Workforce Development:** up-to-date clinical guidelines and the KEML should be key references in the training of health care personnel, to provide correct orientation on evidence-based management of health conditions, as well as the appropriate prescribing, dispensing and medicines utilisation. This includes formal and in-service training, as well as continuing professional education for medical, pharmaceutical and nursing professionals. Use of these tools can help to correctly orientate health service delivery towards optimal utilization of medicines.
6. **Medicines Regulation & Monitoring (including Quality Assurance):** The KEML should be used as a basis for ensuring an effective system of regulation of all activities involving medicines (including import, export, local production, registration, levels of distribution/use, quality monitoring, post-market surveillance [pharmacovigilance], prescribing and dispensing). The KEML should guide medicines regulatory decision-making, aimed at enhancing access to Essential Medicines. This may include fast-track registration and incentives to stimulate local pharmaceutical production of items listed on the KEML. Information that is comprehensive and unbiased should be made available to health workers and the public and due emphasis

placed on market surveillance for quality, safety and efficacy of items listed on the KEML.

- 7. Appropriate Use of Medicines:** The KEML should be used as a basis for designing strategies and initiatives to promote the correct use of medicines by health professionals, patients and the public. Such activities should focus on promoting and improving utilization of Essential Medicines (on the KEML) as the most appropriate for attaining maximum health benefits.

In particular the KEML should be used as the focus of related surveys, studies, operational research by the National Medicines & Therapeutics Committee (NMTTC) and institutional MTCs, with the aim of improving the availability, affordability, prescribing, dispensing and use of medicines for greater public health impact. It should also be used as a basis for appropriate and effective additional monitoring and control measures applicable to items designated on the list for *restricted use* only.

Antimicrobial Resistance and Antibiotic Use Policies: The KEML should be used to restrict antibiotic availability in health facilities to those selected as the most appropriate for use at each level in the current circumstances and context of changing resistance patterns. Systematic data through drug efficacy monitoring and pharmacovigilance, should inform future review of the KEML.

- 8. Medicines Policy Monitoring & Operational Research:** up-to-date clinical guidelines and the KEML should be used to identify parameters for monitoring, evaluation and operational research in the health sector, with the aim of ensuring the continued relevance of medicines and pharmaceutical policies to current health care requirements; as well as establishing the required evidence base for effective, systematic and regular KEML review and revision.
- 9. Pharmaceutical Manufacturing:** the KEML should be used as a basis for local manufacturing decisions focusing on priority public health items and formulations. Incentives for local production should primarily target products listed on the KEML.

Summary of Main Changes in KEML 2016

The process of developing this KEML has resulted in significant changes to the items listed in the KEML 2010. The changes comprise additions of medicines that were previously not on the list, deletions of medicines that are either considered obsolete, or where other alternatives are considered more cost-effective based on available evidence; as well as changes to presentations to facilitate better administration and use.

The summary below highlights the main changes made in preparation of the KEML 2010.

Amendments Summary¹⁷

Deletions from KEML 2010	131
Additions to KEML 2016	337
Net increase	206

KEML 2016 Totals

Total drugs ¹⁸	452
Total presentations ¹⁹	620
Total list entries	687

¹⁷ These are expressed in terms of entries, ie. in a few cases there may be more than one list entry for a given item

¹⁸ Drug combinations are counted separately

¹⁹ ie. all dose-forms, strengths, sizes of items; there are 67 multiple entries giving the total of 687 entries on the KEML

Kenya Essential Medicines List 2016

Kenya Essential Medicines List 2016

Additions

#	Item Added	Indication/Notes
1.1.1.2	Isoflurane	Inhalational anaesthesia; improved adverse effect profile; replaced halothane in some countries
1.1.1.3	Medical air inhalation (medicinal gas)	Useful substitute for nitrous oxide in patients sensitive to oxygen toxicity
1.1.2.2	Propofol injection 10mg/mL	IV anaesthesia (alt: thiopentone); improved adverse effect profile, more rapid recovery; useful for diagnostic sedation
1.2.2	a) Lidocaine HCl injection 2% (30mL vial) (preservative-free)	Replaces lignocaine HCl injection 1% (can be diluted to make 1% as required)
	b) Lidocaine HCl topical solution 2% (spray bottle)	Replaces lignocaine topical solution 4%
1.3.2	Chlorphenamine maleate injection ²⁰ 10mg/1mL amp	Allergic reactions to morphine
1.3.5	Fentanyl injection 50 micrograms/mL	Useful intraoperative medication (rapid onset, short-acting)
1.3.3	a) Midazolam injection 1mg/1mL amp	Replace diazepam presentations (faster onset and recovery)
	b) Midazolam oral liquid 2mg/mL [c]	
	c) Midazolam tablet 7.5mg	
2.1.3	a) Paracetamol injection 10mg/mL (100mL vial)	Post-operative analgesia only
2.2.2	b) Morphine oral liquid 1mg/mL	Severe chronic pain
	c) Morphine oral liquid 10mg/mL	
	d) Morphine tablet 30mg (prolonged-release)	
2.3.4	c) Diazepam gel or rectal solution 5mg/mL (0.5mL tube)	Alternative presentation (where oral route not possible)
2.3.5	Gabapentin tablet 300mg	Improved symptom management in palliative care
2.3.6	a) Haloperidol injection 5mg/1mL amp	
	b) Haloperidol tablet 5mg	
2.3.7	Hyoscine butylbromide injection 20mg/mL	
2.3.9	Lactulose oral liquid 3.1-3.7mg/5mL [c]	
2.3.11	Loperamide capsule 2mg	

²⁰ Added to this section (was already listed elsewhere in KEML 2010)

KEML 2016

#	Item Added	Indication/Notes
2.3.12	a) Metoclopramide injection 5mg/mL b) Metoclopramide oral liquid 5mg/5mL	Improved symptom management in palliative care
2.3.13	c) Metoclopramide tablet 10mg c) Midazolam oral liquid 2mg/mL [c] d) Midazolam tablet 7.5mg	
2.3.14	a) Ondansetron injection 2mg/mL [c] b) Ondansetron tablet 4mg [c]	
3.1	a) Cetirizine oral liquid 5mg/5mL b) Cetirizine tablet 10mg	Replaces deleted chlorphenamine (better adverse effect profile)
4.1.1	Activated charcoal PFOL 50g	Replaces activated charcoal tablet 250mg as preferred presentation
4.2.3	a) Deferasirox tablet 100mg b) Deferasirox tablet 400mg	Iron poisoning
4.2.4	Flumazenil injection 100mcg/mL	Benzodiazepine poisoning
4.2.6	Protamine sulphate injection ²¹ 10mg/mL	Heparin overdose
4.2.9	a) Ethanol injection 100% b) Ethanol oral liquid 95-96%	Methanol poisoning
4.2.10	Fomepizole sulphate injection 5mg/mL	Methanol poisoning
4.2.12	Pralidoxime chloride PFI 1g	Organophosphate poisoning
4.2.14	Sodium nitrite injection 30mg/mL	Cyanide poisoning
4.2.15	Sodium thiosulphate injection 250mg/mL	
5.2	Diazepam gel or rectal solution 5mg/mL	Replaces diazepam injection in children (preferable presentation)
5.3	Gabapentin tablet 300mg	Focal seizures
5.4	Lorazepam injection 4mg/mL	Replaces diazepam injection in adults (recommended 1 st line parenteral anticonvulsant, better adverse effects profile)
5.6	a) Phenobarbital sodium injection 30mg/1mL amp [c]	Paediatric emergencies
5.9	a) Lamotrigine tablet 25mg	Refractory epilepsy
5.9	b) Lamotrigine tablet 100mg	
6.1.2.1	Albendazole tablet 400mg (chewable) ²²	Required for current management protocols

²¹ Added to this section (was already listed elsewhere in KEML 2010)

²² Added to this section (was already listed elsewhere in KEML 2010)

KEML 2016

#	Item Added	Indication/Notes
6.1.2.2	Diethylcarbamazine tablet 100mg	
6.2.1.1	a) Amoxicillin tablet 250mg (dispersible, scored)	Replaces PFOL 125mg/5mL
6.2.1.2	a) Amoxicillin + clavulanic acid tablet 200mg + 28.5mg (DT, scored)	Replaces PFOL 250mg + 62.5mg/5mL
	b) Amoxicillin + clavulanic acid tablet 875mg + 125mg	Replaces tablet 625mg
6.2.1.3	Benzathine benzylpenicillin PFI 900mg (1.2MU) vial	Preferred presentation; replaces 1.44g (2.4MU) vial
6.2.1.5	Cefazolin PFI 1g vial	For restricted use in surgical premedication prophylaxis
6.2.1.9	Phenoxymethylpenicillin tablet 250mg	For restricted use in sickle-cell prophylaxis & rheumatic heart disease prophylaxis (as alternative to benzathine penicillin where this is unsuitable)
6.2.1.11	a) Imipenem + cilastin PFI 250mg + 250mg vial	For specialist 2nd line use only in life-threatening hospital-acquired infections due to suspected or proven multi-drug resistant organisms
	b) Imipenem + cilastin PFI 500mg + 500mg vial	
6.2.2.2	a) Ciprofloxacin oral liquid 250mg/5mL [c]	For use in children
6.2.2.9	Tinidazole tablet 500mg ²³	Alternative to metronidazole; longer action permits single daily dosing for improved adherence
6.2.2.10	Ciprofloxacin solution for IV infusion 2mg/mL (50mL bottle) (as lactate) [c]	Required additional dose form for use in children
6.2.3.1	a) Clofazamine capsule 50mg	For use in recommended national treatment regime
	b) Clofazamine capsule 100mg	
6.2.4.9	b) Rifampicin + isoniazid + pyrazinamide + (RHZ) [c] 75mg + 50mg + 150mg	Required paediatric dose-form
6.2.4.12	Bedaquiline tablet 100mg	For specialist use in MDR TB
6.2.4.13	Capreomycin PFI 1g vial	
6.2.4.14	Cycloserine tablet 250mg	
6.2.4.15	Delamanid tablet 50mg	
6.2.4.17	Levofloxacin tablet 500mg (scored)	
6.2.4.18	Linezolid tablet 600mg	
6.2.4.19	Moxifloxacin tablet 400mg	
6.2.4.20	p-aminosalicylic acid granules 4g	

²³ Added to this section (was already listed elsewhere in KEML 2010)

KEML 2016

#	Item Added	Indication/Notes
6.2.4.21	Prothionamide tablet 250mg	
6.2.4.22	Rifabutin capsule 150mg	For specialist use in MDR TB
6.3.1	Clotrimazole vaginal tablet 500mg	Replaces 200mg (improved adherence)
6.4.1.1	Aciclovir PFI 250mg vial	Required additional presentation
6.4.1.4	a) Tenofovir disoproxil fumarate (TDF) tablet 150mg b) Tenofovir disoproxil fumarate (TDF) tablet 200mg	Required for updated HIV management regimes
6.4.2.2.1	a) Efavirenz tablet 200mg b) Efavirenz tablet 400mg c) Efavirenz tablet 600mg	
6.4.2.2.2	a) Etravirine tablet 25mg b) Etravirine tablet 100mg	
6.4.2.3.1	Atazanavir + ritonavir tablet 300mg + 100mg	
6.4.2.3.2	a) Darunavir (TCM) oral liquid (susp) 100mg/mL b) Darunavir tablet 75mg (f/c) c) Darunavir tablet 100mg (f/c) d) Darunavir tablet 600mg (f/c)	
6.4.2.3.4	a) Ritonavir oral liquid 400mg/5mL b) Ritonavir tablet 100mg (heat-stable)	
6.4.2.4.1	Raltegravir tablet 25mg Raltegravir tablet 100mg Raltegravir tablet 400mg (f/c)	
6.4.2.5.1	a) Abacavir + lamivudine tablet 60mg + 30mg b) Abacavir + lamivudine tablet 120mg + 60mg c) Abacavir + lamivudine tablet 600mg + 60mg	
6.4.2.5.2	a) Efavirenz + lamivudine + tenofovir tablet 400mg + 300mg + 300mg b) Efavirenz + lamivudine + tenofovir tablet 600mg + 300mg + 300mg	
6.4.2.5.3	Emtricitabine + tenofovir tablet 200mg + 300mg	
6.4.2.5.4	Lamivudine + tenofovir tablet 300mg + 300mg	
6.4.2.5.5	a) Lamivudine + zidovudine tablet	

KEML 2016

#	Item Added	Indication/Notes
	30mg + 60mg	
6.4.3.1	Ganciclovir PFI 500mg vial	Cytomegalovirus retinitis (CMV)
6.4.3.2	a) Ribavirin tablet 200mg (film coated) b) Ribavirin tablet 400mg (film coated)	Viral haemorrhagic fevers and hepatitis C
6.4.4.1.1	Pegylated interferon alfa-2a injection 180 micrograms (vial or prefilled syringe)	Hepatitis B
6.4.4.1.2	Tenofovir disoproxil fumarate tablet 300mg	
6.4.4.2.1	Pegylated interferon alfa-2a injection 180 micrograms (vial or prefilled syringe)	Hepatitis C
6.4.4.2.2	a) Ribavirin tablet 200mg (f/c) b) Ribavirin tablet 400mg (f/c)	
6.5.3.1.1	b) Artemether + lumefantrine tablet 20mg + 120mg (dispersible) c) Artemether + lumefantrine tablet 80mg + 480mg	For patients <24kg For patients >35kg; reduced pill burden
6.5.3.1.2	a) Artesunate injection 30mg vial b) Artesunate injection 60mg vial	Reduced waste in paediatric use For 1 st line treatment of severe malaria
6.5.3.1.3	Dihydroartemisinin + piperazine (DHA+PPQ) tablet (scored) 40mg + 320mg	For 2 nd line treatment of uncomplicated malaria (only after confirmed treatment failure with artemether + lumefantrine)
6.5.3.1.5	Primaquine tablet 7.5mg	For radical cure of P. vivax infection
6.5.3.2.2	Proguanil HCl tablet 100mg	For malaria prophylaxis in sicklers and TSS
6.5.4.2	Sulfadoxine + pyrimethamine tablet 500mg + 25mg	Use instead of deleted sulphadiazine and pyrimethamine
7.1.3	Paracetamol suppository 125mg [c]	Required paediatric presentation
8.1.2	Ciclosporin capsule 100mg	For reduced pill burden with higher doses
8.1.3	a) Methylprednisolone PFI 125mg (as sodium succinate) b) Methylprednisolone PFI 500mg (as sodium succinate)	Kidney transplantation
8.1.4	a) Mycophenolic acid tablet 180mg (as mycophenolate sodium) e/c b) Mycophenolic acid tablet 360mg (as mycophenolate sodium) e/c	
8.1.5	Prednisolone tablet 5mg	Kidney transplantation
8.1.6	a) Tacrolimus concentrate for IV infusion 5mg/1mL amp	Kidney transplantation (induction phase; when vomiting, and oral route not possible in postoperatively)

KEML 2016

#	Item Added	Indication/Notes
8.1.6	b) Tacrolimus capsule 500 micrograms c) Tacrolimus capsule 1mg d) Tacrolimus capsule 5mg	Kidney transplantation; various strengths required for titrated dose reduction
8.2.1	Alendronic acid tablet 70mg	See list entry for indications
8.2.6	a) Capecitabine tablet 150mg b) Capecitabine tablet 500mg	See list entry for indications
8.2.7	b) Carboplatin injection 10mg/mL (45mL vial)	See list entry for indications
8.2.10	a) Cyclophosphamide PFI 200mg vial	See list entry for indications
8.2.12	Dacarbazine PFI 200mg vial	See list entry for indication; replaces 100mg vial
8.2.15	a) Docetaxel injection 10mg/mL (2mL vial) b) Docetaxel injection 10mg/mL (8mL vial)	See list entry for indications
8.2.16	a) Doxorubicin PFI 10mg vial	See list entry for indications
8.2.18	a) Filgrastim injection 120 micrograms/0.2ml prefilled syringe b) Filgrastim injection 300 micrograms/0.5ml prefilled syringe	See list entry for indications
8.2.20	a) Gemcitabine PFI 200mg vial b) Gemcitabine PFI 1g vial	See list entry for indications
8.2.21	a) Hydroxycarbamide (hydroxyurea) capsule 250mg	See list entry for indication
8.2.22	a) Ifosfamide PFI 1g vial b) Ifosfamide PFI 2g vial	See list entry for indications
8.2.23	Imatinib tablet 400mg	See list entry for indications
8.2.24	a) Irinotecan injection 20mg/mL (2mL vial) b) Irinotecan injection 20mg/mL (5mL vial)	See list entry for indication
8.2.26	Melphalan tablet 2mg	See list entry for indications
8.2.27	Mesna injection 100mg/mL (2mL amp)	See list entry for indications
8.2.29	a) Oxaliplatin inj. 2mg/mL (25mL vial) b) Oxaliplatin inj. 2mg/mL (50mL vial)	See list entry for indications
8.2.30	a) Paclitaxel injection 6mg/mL (5mL vial) b) Paclitaxel injection 6mg/mL (16.7mL vial)	See list entry for indications
8.2.32	a) Rituximab injection 10mg/mL	See list entry for indications

KEML 2016

#	Item Added	Indication/Notes
	(10mL vial)	
8.2.32	b) Rituximab injection 10mg/mL (50mL vial)	See list entry for indications
8.2.33	Thalidomide capsule 100mg	See list entry for indications
8.2.34	a) Trastuzumab PFI 150mg vial b) Trastuzumab PFI 440mg vial	See list entry for indications
8.2.35	Vinblastine sulphate injection 1mg/mL (10mL vial)	See list entry for indications
8.2.36	a) Vinorelbine injection 10mg/mL (1mL vial) a) Vinorelbine injection 10mg/mL (5mL vial)	See list entry for indications
8.2.37	Zoledronic acid injection 800 micrograms/mL (5mL vial)	See list entry for indications
8.3.1	Anastrozole tablet 1mg	Post-menopausal breast cancer
8.3.2	Bicalutamide tablet 50mg	See list entry for indication
8.3.3	b) Dexamethasone tablet 500 micrograms	See list entry for indication
8.3.4	Diethylstilboestrol (DES) tablet 5mg	See list entry for indication
8.3.5	a) Goserelin implant 3.6mg b) Goserelin implant 10.8mg	See list entry for indications
8.3.7	Methylprednisolone PFI 500mg	See list entry for indications
8.3.8	a) Prednisolone oral liquid 15mg/5mL [c]	See list entry for indications
8.3.9	Tamoxifen tablet 20mg (as citrate)	See list entry for indications
8.4.1	Finasteride tablet 5mg	Benign prostatic hyperplasia
8.4.2	Tamsulosin tablet 400 micrograms	
9.2	a) Levodopa + carbidopa tablet 100mg + 10mg b) Levodopa + carbidopa tablet 250mg + 25mg	Parkinsonism (1 st line)
9.3	a) Pramipexole tablet 180 micrograms b) Pramipexole tablet 700 micrograms	Refractory parkinsonism
10.1.1	Ferrous salt oral liquid (drops) 25mg/mL elemental iron	Required paediatric presentation
10.1.3	a) Folic acid tablet 400 micrograms	Periconceptual prevention of first occurrence of neural tube defects
10.2.2	a) Phytomenadione (Vit K1) injection 1mg/1mL amp [c] b) Phytomenadione (Vit K1) injection 10mg/mL (5mL amp)	Prevention of neonatal vitamin K deficiency bleeding (replaces 10mg/0.2mL amp) Warfarin-associated bleeding

KEML 2016

#	Item Added	Indication/Notes
10.2.4	Tranexamic acid injection 100mg/mL (5mL amp)	Prevention/treatment of bleeding associated with excessive fibrinolysis
10.2.6	a) Enoxaparin injection (prefilled syringe) 40mg/0.4mL	Safe, effective and more convenient alternative to heparin; no requirement for routine monitoring
	b) Enoxaparin injection (prefilled syringe) 80mg/0.8mL	
10.2.9	a) Warfarin sodium tablet 0.5mg	<i>Required low dose presentation, especially for paediatric use</i>
10.3.1	a) Deferasirox tablet 100mg	Iron overload
	b) Deferasirox tablet 400mg	
10.3.2	Deferoxamine mesilate PFI 500mg vial	
10.3.3	a) Hydroxycarbamide (hydroxyurea) capsule 250mg	Sickle cell disease
	b) Hydroxycarbamide capsule 500mg	
11.1.1	Plasma, fresh frozen	New section added in line with WHO Model List
11.1.2	Platelets	
11.1.3	Red blood cells	
11.1.4	Whole blood	
11.2.1.4	a) Normal immunoglobulin injection IV 5% protein solution (100mL vial)	Primary immune deficiency & Kawasaki disease
	b) Normal immunoglobulin injection IV 10% protein solution (100mL vial)	
11.3.1	Polygeline IV infusion 3.5% (500mL)	<i>Plasma volume expansion; replaces dextran 70%</i>
12.1.1	a) Carvedilol tablet 6.25mg	Replace atenolol tablet 50mg; improved benefit/risk profile
	b) Carvedilol tablet 12.5mg	
12.1.3	Isosorbide dinitrate tablet 20mg	Useful longer acting vasodilator
12.2.1	a) Carvedilol tablet 6.25mg	Replace atenolol tablet 50mg; improved benefit/risk profile
	b) Carvedilol tablet 12.5mg	
12.2.4	b) Verapamil tablet 80mg (scored)	Replaces 40mg for better dose flexibility
12.2.6	Epinephrine injection 100 micrograms/mL (10mL amp)	Cardiac arrest
12.3.2	a) Carvedilol tablet 6.25mg	Replaces atenolol tablet 50mg; improved benefit/ risk profile
	b) Carvedilol tablet 12.5mg	
12.3.6	Losartan tablet 50mg	1 st line antihypertensive with improved adverse effect profile and prolonged action
12.4.1	a) Carvedilol tablet 6.25mg	Useful additions as per WHO Model List
	b) Carvedilol tablet 12.5mg	
12.4.3	b) Furosemide oral liquid 20mg/5mL [c]	Useful paediatric presentation

KEML 2016

#	Item Added	Indication/Notes
12.4.5	Spironolactone tablets 25mg (scored)	Useful addition as per WHO ML
12.5.1.2	Clopidogrel tablet 75mg	Useful addition as per WHO ML
12.6.1	Atorvastatin tablet 20mg (scored)	Useful addition as per WHO ML
13.1.2	Terbinafine HCl cream 1%	Refractory fungal infections
13.2.1	Aciclovir cream 5% (5g)	Herpes infections
13.2.4	Mupirocin ointment 2% (15g)	Prophylaxis during dialysis procedures
13.3.2	Clobetasone butyrate ointment 0.05%	Very potent topical steroid
13.3.3	Crotamiton cream 10%	Pruritis (especially after scabies)
13.3.4	Desonide gel 0.05%	Mild topical steroid
13.3.6	Mometasone furoate ointment 0.1%	Potent topical steroid
13.3.7	Tacrolimus ointment 0.03%	Moderate-severe atopic eczema, especially if refractory
13.5.1	Benzoyl peroxide gel 5%	Acne vulgaris
13.5.2	Coal tar + salicylic acid ointment 2% + 2%	Psoriasis
13.6.2	Crotamiton cream 10%	Scabies and related pruritis
13.6.3	Ivermectin tablet 6mg (scored)	Refractory scabies
13.7.2	White soft paraffin 100%	Jiggers
13.8.1	Sunscreening cream or lotion UVB-SPF 30+	Albinism & photodermatoses
14.1.1	Fluorescein test strip 0.6mg	Replaces fluorescein eye drops 1%
14.2.4	Iopromide injection (solution for IV infusion) 150-370mg iodine/mL	Required radiocontrast media
14.3.1	Gadobutrol IV injection (solution) 1 mmol/mL	New section: MRI contrast media
14.3.2	Gadodiamide IV injection (solution) 0.5 mmol/mL	
14.3.3	Gadopentate dimeglumine IV injection (solution) 0.5 mmol/mL	
15.1.1	b) Chlorhexidine gel 4% (as digluconate 7.1%) [c]	Umbilical cord care
15.2.1	Alcohol-based hand rub solution, isopropyl alcohol 75% (500mL dispenser)	Hand hygiene; key element of infection prevention & control
16.2	b) Furosemide oral liquid [c] 20mg/5mL	For paediatric use
16.5	Spironolactone tablet 25mg	Potassium-sparing diuretic
17.1.1	Lansoprazole dispersible tablet 15mg	For paediatric use
17.1.2	b) Omeprazole PFI 40mg vial	Severe peptic ulcer; and peptic ulcer when oral route is not possible

KEML 2016

#	Item Added	Indication/Notes
17.2.2	a) Domperidone oral liquid 5mg/5mL	Alternative for young children who cannot tolerate metoclopramide or who require an oral liquid antiemetic
	b) Domperidone tablet 10mg	Alternative for adult patients who cannot tolerate metoclopramide
17.2.4	a) Ondansetron injection 2mg/mL base as HCl (2mL amp)	Recommended 1 st line treatment for post-operative nausea & vomiting (PONV)
	b) Ondansetron tablet (orally disintegrating) 4mg (base equivalent)	
17.2.5	Dexamethasone tablet 500 micrograms	Continuation oral steroid after initial parenteral therapy
17.3.1	Mesalazine tablet 400mg (e/c)	Supersedes sulfasalazine (deleted); improved side-effect profile
17.3.2	Prednisolone tablet 5mg	Chronic inflammatory bowel disease
17.4.1	b) Bisacodyl suppository 10mg	Alternative presentation when oral route not appropriate
17.5.2	ORS (4 sachets) + zinc sulphate tablets 20mg dispersible (10) co pack	Required for updated treatment protocols
17.5.3	Rehydration solution for malnutrition (ReSoMal) PFOL (sachet for 1L)	Required for updated treatment protocols
18.2.1	Testosterone gel 1%	Required for treatment of disorders of sexual development
18.3.1.2	Levonorgestrel tablet 30 micrograms	Required for current family planning protocols
18.3.2.1	Estradiol cypionate + medroxyprogesterone acetate injection 5mg + 25mg	Required for current family planning protocols
18.3.2.2	b) Medroxyprogesterone acetate (DMPA) depot injection (SC) 104mg/0.65mL (prefilled syringe)	Required for current family planning protocols
18.3.3.2	Levonorgestrel-releasing Intrauterine system (LNG-IUS), reservoir with 52mg	Required for current FP protocols
18.3.6.1	Progesterone-releasing vaginal ring 2.074g	Required for current FP protocols
18.4.1	Conjugated oestrogens tablets 0.3mg	Required for treatment of delayed puberty
18.5.2	Gliclazide tablet 40mg	For patients >60 years & as 2 nd line in others if glibenclamide not suitable
18.5.5	Insulin, rapid acting injection 100 IU/mL (10mL vial) (lispro, aspart or glulisine)	For restricted paediatric use, where a particularly rapid effect is required

KEML 2016

#	Item Added	Indication/Notes
18.7.1	Medroxyprogesterone acetate tablet 5mg	For menstrual conditions and endometriosis
18.8.3	Lugol's iodine oral liquid ~130mg total iodine/mL [c]	For pre-operative use in hyperthyroidism
18.8.4	Propylthiouracil tablet 50mg	For 2 nd line use if carbimazole not tolerated/recommended
19.3.3	HPV vaccine injection (suspension) 1mL vial (2 doses)	Required for current vaccination protocols
19.3.6	Polio vaccine (IPV) injection 5mL vial (10 doses)	Required for current vaccination protocols
19.3.8	Rotavirus vaccine (oral suspension) 1.5mL (single dose)	Required for current vaccination protocols
19.3.11	Cholera vaccine (oral suspension) 1.5mL vial (single dose)	For use in epidemics
19.3.17	Varicella vaccine (PFI + diluent) 0.5mL vial (single dose)	For use in high-risk groups
19.3.18	Pneumococcal vaccine (23-valent adsorbed conjugate) injection (suspension) 0.5mL vial (single dose)	For specialist use in high-risk groups
20.1	Atracurium besilate injection 10mg/mL	Neuromuscular blocker (short-intermediate duration)
20.2	Cisatracurium injection 2mg/mL (10mL vial)	Neuromuscular blocker (intermediate duration; replaces vecuronium)
20.3	Glycopyrronium bromide + neostigmine metilsulfate injection 500 micrograms + 2.5mg/1mL amp	Reversal of non-depolarising neuromuscular blockade (especially young and elderly patients)
20.5	Pancuronium bromide injection 2mg/mL	Neuromuscular blocker (required for its long duration of effect)
21.1.3	Aciclovir eye ointment 3%	Ophthalmic herpes
21.1.4	Azithromycin dihydrate eye drops 1.5%	Trachomatous conjunctivitis
21.1.5	Ciprofloxacin eye drops 0.3% (as HCl)	Corneal ulcers
21.1.6	Econazole eye drops 1%	Fungal keratitis
21.2.1	b) Prednisolone tablet 5mg	Ophthalmic malignancies
21.2.2	Prednisolone eye drops 1% (acetate)	Deeper ocular inflammation
21.2.3	Ketorolac trometamol eye drops 0.5%	Ocular inflammation where steroids are contraindicated
21.2.4	Methylprednisolone PFI 1g vial (as sod. succinate)	Optic neuritis
21.2.5	Triamcinolone acetonide injection (aq. suspension) 40mg/1mL amp	Severe allergic conjunctivitis, diabetic retinopathy, intermediate uveitis, post-op in

KEML 2016

#	Item Added	Indication/Notes
		<i>paediatric eye surgery</i>
21.4.3	Dorzolamide eye drops 2% (as HCl)	Open-angle glaucoma, in patients resistant to beta-blockers
21.4.4	Latanoprost eye drops 0.005%	Raised intra-ocular pressure in open-angle glaucoma; ocular hypertension
21.5.1	Atropine sulfate eye drops 0.5%	Replaces 1% as preferred strength
21.5.2	Tropicamide eye drops 0.5%	Short-term dilation
21.5.3	Epinephrine eye drops 2% (as HCl)	Rapid dilation during eye surgery in non-hypertensive patients
21.6.1	Sodium cromoglicate eye drops 2%	Allergic conjunctivitis, vernal kerato-conjunctivitis
21.7.1	Bevacizumab injection 25mg/mL (4mL vial)	Diabetic retinopathy
23.2.2	Haemodialysis solutions, parenteral (of appropriate composition)	Haemodialysis
24.1.1	b) Chlorpromazine HCl tablet 50mg	Especially for geriatrics when smaller doses may be required
24.1.2	Flupentixol decanoate injection (oily, depot) 20mg/mL (2mL amp)	Combined antipsychotic + antidepressant effect
24.1.4	Haloperidol oral liquid 2mg/mL	Paediatric presentation and for clandestine administration ²⁴ to uncooperative patients
24.1.5	Olanzapine PFI 10mg vial	2nd generation antipsychotic; much improved adverse effect profile; useful for patients refractory to, or intolerant of, older antipsychotics
24.1.6	Quetiapine tablet 200mg (scored)	Improved adverse effect profile compared with olanzapine and useful antidepressant effects
24.1.7	a) Zuclopenthixol acetate injection (oily) 50mg/1mL (2mL amp) b) Zuclopenthixol acetate injection (depot, oily) 200mg/1mL amp	For calming agitated/aggressive patients
24.1.7	Chlorpromazine HCl injection 25mg/mL (2mL amp) [c]	Specialist list when used in children
24.1.8	a) Clozapine tablet (scored) 25mg b) Clozapine tablet (scored) 100mg	Useful 2 nd line option for unresponsive patients
24.1.9	a) Haloperidol injection 5mg/1mL amp b) Haloperidol tablet (scored) 5mg	Specialist list when used in children
24.1.10	Risperidone tablet 1mg	Useful 2 nd line option (especially in

²⁴ Only after obtaining written guardian consent

KEML 2016

#	Item Added	Indication/Notes
		<i>persistently aggressive patients)</i>
24.2.1.3	Fluoxetine tablet (scored) 20mg [c]	Complementary list when used in children
24.2.1.4	Venlafaxine capsule 75mg	Useful alternative to tricyclics without their sedative & antimuscarinic side-effects
24.2.2.2	Lithium carbonate tablet 400mg (modified release)	Replaces tablet 300mg; improved adherence/management
24.2.2.3	a) Valproic acid (sodium valproate) tablet 200mg (enteric-coated)	Increased dosage flexibility
24.3.1	Bromazepam tablet 3mg (scored)	Anxiety with agitation (replaces diazepam)
24.4.1	Clomipramine HCl capsule 25mg	Obsessive-compulsive disorders
24.5.1	Diazepam tablet 5mg	Alcohol dependency
24.5.2	a) Nicotine chewing gum 2mg b) Nicotine chewing gum 4mg	Smoking cessation
24.5.3	a) B vitamins high potency injection IM b) B vitamins high potency injection IV	Alcohol dependence
24.5.4	a) Buprenorphine + naloxone tablet (sublingual) 2mg + 500 micrograms b) Buprenorphine + naloxone tablet (sublingual) 8mg + 2mg	Opioid dependence
24.5.6	Naltrexone tablet 50mg	
24.6.1	Methylphenidate tablet 10mg	Attention deficit hyperactivity disorder (ADHD)
25.1.5	Formoterol fumarate + budesonide dry powder inhaler 6 micrograms + 200 micrograms/metered dose	Refractory chronic asthma
25.1.6	a) Ipratropium bromide inhalation (aerosol) 20 micrograms/metered dose b) Ipratropium bromide nebuliser solution 250 micrograms/1mL unit dose vial	COPD and refractory paediatric asthma
25.1.7	a) Montelukast (as sod. salt) granules 4mg sachet b) Montelukast (as sod. salt) tablet 10mg	Stepped management of asthma
26.1.2	ORS + zinc sulphate co-pack 500mL sachets (4) + zinc sulph tab 20mg (10)	Dehydration in children
26.1.3	Rehydration solution for malnutrition (WHO formula - ReSoMal) sachet (powder for making 1L solution)	Dehydration in patients with malnutrition
26.2.2	b) Potassium chloride injectable	Severe hypokalaemia

KEML 2016

#	Item Added	Indication/Notes
	solution 15% (10mL amp) [c]	
26.2.6	Sodium chloride injectable solution 3% (hypertonic) (10mL amp)	Bronchiolitis in children; hyponatremia in renal conditions
27.1	Calcium carbonate tablet (chewable) 1.25g	Calcium deficiency, eg. in chronic renal disease & rickets
27.3	Cholecalciferol (Vit D ₃) oral liquid (drops) 400 IU/mL [c]	Deficiency states
27.4	Ergocalciferol (Vit D ₂) tablet 1.25mg (50,000 IU)	Deficiency states
27.5	Pyridoxine HCl (Vit B ₆) tablet 50mg	Replaces 25mg (was in Complementary List)
27.8	Cholecalciferol (Vit D ₃) injection IM (oily) 300,000 IU/1mL amp	Severe deficiency states
28.1.2	Hydrogen peroxide solution (ear drops) 5%	Wax softening and removal
28.1.3	Ciprofloxacin HCl + betamethasone sodium solution (ear drops) 0.3% + 0.1%	Infected otitis externa with inflammation and eczema
28.1.4	Clotrimazole solution (ear drops) 1%	Otitis externa with fungal infection
28.2.1	Liquid paraffin nasal drops 100%	Nasal canal dryness (eg. rhinitis sicca)
28.2.2	Sodium chloride nasal drops 0.9%	Nasal congestion
28.2.3	Budesonide nasal spray 100 micrograms/metered dose	Allergic & vasomotor rhinitis
29.2.1	Dexamethasone injection 4mg/mL (as sodium phosphate)	In new Section 29.2; for enhancing neonatal lung maturity
30.1.1	Allopurinol tablet 300mg (scored)	Replaces tablet 100mg
30.2.3	Leflunomide tablet 20mg	For use when methotrexate and sulfasalazine cannot be used
30.3.1	Aspirin tablet 300mg (scored)	In new Section 30.3 Juvenile joint disease
31.3	Total parenteral nutrition (TPN) (amino acids + lipids + glucose + electrolytes) infusion (emulsion) (triple-chamber)	Required for providing TPN
32.1	Ready to use therapeutic food (RUTF) oral paste standard formula (500 kcal sachet)	In new Section 32: Preparations For managing Severe Acute Malnutrition
32.2	F-75 therapeutic milk PFOL for approx.. 600mL (standard formula 102.5g sachet)	
32.2	F-100 therapeutic milk PFOL for approx.. 600mL (standard formula 114g sachet)	

Deletions²⁵

Section	Item Deleted	Reason/Notes
1.2	Bupivacaine injection 0.25%	Not required, use 0.5% (dilute as required)
	Lignocaine injection 1%	2% preferred (dilute if 1% required)
	Lignocaine HCl topical solution 4% (in spray bottle)	Replaced by lidocaine HCl topical solution 2% (spray bottle)
	Lignocaine + adrenaline injection 1% + 1:80,000	Not required
	Lignocaine dental cartridge 2%	Not required
	Lignocaine topical solution 10% spray	Not required (use 2%)
1.3	Diazepam injection 5mg/mL	Replaced by preferred midazolam preparations (faster onset and recovery)
	Diazepam tablet 5mg	
	Promethazine oral liquid 5mg/5mL	Efficacy, obsolete (better alternatives available, eg. midazolam)
	Hyoscine hydrobromide injection 400 micrograms/mL	Not required (use atropine)
2.1	Diclofenac injection 25mg/mL	Not recommended, increased risk of cardiovascular adverse effects (use ibuprofen)
	Diclofenac suppository 100mg	
2.2	Paracetamol suppository 60mg	Not required (use 125mg)
	Morphine oral liquid 10mg/5mL	Not required (use 1mg/mL or 10mg/mL)
	Morphine tablet 60mg (prolonged-release)	Not required (use 30mg)
2.3	Allopurinol tablet 100mg	Replaced by tablet 300mg (scored) in new section 30
	Cyclizine injection 50mg/mL	Not used/required (alternatives available)
	Cyclizine 50mg	
	Docusate sodium capsule 100mg	
	Docusate sodium oral liquid 50mg/5mL	
3	Chlorphenamine inj 10mg/mL	Replaced by cetirizine (better adverse effect profile)
	Chlorphenamine oral liquid 2mg/5mL	
	Prednisolone tablet 25mg	Not required for this indication
	Aminophylline injection 25mg/mL	Not recommended (safer & more effective alternatives available)

²⁵ Note that deletion of a medicines is specific to a particular section/use and not necessarily the whole list (eg. chlorphenamine injection has been deleted from section 3 but added to section 1.3)

KEML 2016

Section	Item Deleted	Reason/Notes
5	Diazepam injection 5mg/mL	Replaced by lorazepam injection
	Ethosuximide oral liquid 250mg/5mL	Not required
	Ethosuximide tablet 250mg	
6.1.1	Niclosamide tablet, chewable 500mg	Not required
6.1.2	Ivermectin tablet, scored 6mg	Not required
6.2.1	Amoxicillin PFOL 125mg/5mL	Replaced by tablet 250mg dispersible, scored (preferred presentation)
	Amoxicillin + clavulanic acid PFOL 250mg + 62.5mg/5mL	Replaced by DT, scored 200mg + 28.5mg
	Amoxicillin + clavulanic acid tablet 625mg	Replaced by tablet 875mg + 125mg
	Ampicillin PFI 500mg	Minimal use, high levels of resistance
	Benzathine penicillin PFI 1.44g (2.4MU) in 5mL vial	Replaced by 900mg (1.2MU) vial (preferred presentation)
	Benzympenicillin PFI 3g (5MU) vial	Not required (use 600mg 1MU vial)
	Cefuroxime injection 750mg vial	Not recommended, poorly tolerated, high cost (use amoxicillin + clavulanic acid)
	Cefuroxime tablet 250mg	
6.2.2	Chloramphenicol capsule 250mg	Not required for updated protocols
	Chloramphenicol injection PFI 1g	
	Chloramphenicol oral liquid 125mg/5mL	
	Erythromycin PFOL 125mg/5mL	Replaced by preferred azithromycin (better tolerated, simpler dose regime, improved cost benefit)
	Erythromycin tablet 250mg	
6.2.4	Metronidazole tablet 400mg	Use 200mg (improved cost benefit)
	Isoniazid tablet (scored) 50mg	Replaced by oral liquid 50mg/5mL
	Ethambutol oral liquid 25mg/mL	Not required
	Ofloxacin tablet 200mg	Not required (use levofloxacin or moxifloxacin)
	Streptomycin PFI 1g vial	Not required for updated TB regimes
6.3	Clotrimazole vaginal tablet 200mg	Replaced by 500mg (single dose, improved adherence)
6.4.2.1	Abacavir oral liquid 100mg/5mL	Not required in updated treatment protocols
	Didanosine PFOL 100mg packet	
	Didanosine PFOL 167mg packet	
	Didanosine PFOL 250mg packet	
	Didanosine capsule 125mg (e/c, unbuffered)	
	Didanosine capsule 200mg (e/c, unbuffered)	

KEML 2016

Section	Item Deleted	Reason/Notes
	Didanosine capsule 250mg (e/c, unbuffered)	Not required in updated treatment protocols
	Didanosine tablet 25mg (buffered, chewable, dispersible)	
	Didanosine tablet 50mg (buffered, chewable, dispersible)	
	Didanosine tablet 100mg (buffered, chewable, dispersible)	
	Didanosine tablet 150mg (buffered, chewable, dispersible)	
	Didanosine tablet 200mg (buffered, chewable, dispersible)	
	Stavudine capsule 15mg	
	Stavudine capsule 20mg	
	Stavudine capsule 30mg	
	Tenofovir tablet 300mg	
	Zidovudine capsule 100mg	
	Zidovudine oral liquid 50mg/5mL	
	Zidovudine tablet 300mg	
6.4.2.2	Efavirenz capsule 50mg	
	Efavirenz capsule 100mg	
	Efavirenz oral liquid 150mg/5mL	
6.4.2.3	Lopinavir + ritonavir capsule 133.3mg + 33.3mg	
	Lopinavir + ritonavir tablet 200mg + 50mg	
6.4.2.4	Efavirenz + emtricitabine + tenofovir tablet 600mg + 200mg + 300mg	
	Lamivudine + nevirapine + stavudine tablet 150mg + 200mg + 30mg	
	Lamivudine + stavudine tablet 300mg + 300mg	
6.5.3.1	Artemether oily injection 80mg/1mL amp	Use artesunate as 1 st line for severe malaria
	Doxycycline tablet 100mg	No longer required for malaria treatment (use AL) but retained for prophylaxis
6.5.4	Dapsone tablet 100mg	Not used/required (use cotrimoxazole + sulfadoxine/pyrimethamine [SP])
	Pyrimethamine tablet 25gm	
	Sulphadiazine tablet 500mg	

KEML 2016

Section	Item Deleted	Reason/Notes
8.2	Cisplatin injection 1mg/mL, 10mL vial	Not required (use 50mL vial)
	Dacarbazine PFI 100mg	Replaced by PFI 200mg vial (as citrate)
	a) Etoposide capsule 100mg	Not used/required (use injection)
	Vincristine PFI 1mg vial	Not used/required
	Vincristine PFI 5mg vial	
8.3	Methylprednisolone injection (aq. suspension) 40mg/1mL	Replaced by PFI 500mg vial (as sod.succinate)
9	Biperiden tablet 2mg (HCl)	Not used/required (benzhexol retained)
10.2	Phytomenadione (Vit K1) injection 10mg/mL in 0.2mL amp	Replaced by 1mg/1mL amp presentation
11.1	Dextran 70 injection solution 6%	Replaced by preferred polygeline IV infusion 3.5% 500mL pack
12.1	Atenolol tablet 50mg	Replaced by carvedilol tablet 6.25mg and 12.5mg (better benefit/risk profile)
	Verapamil tablet 40mg	Not used/required
12.2	Atenolol tablet 50mg	Replaced by carvedilol tablet 6.25mg and 12.5mg (better benefit/risk profile)
	Verapamil tablet 40mg	Replaced by 80mg (scored)
12.3	Atenolol tablet 50mg	Replaced by carvedilol tablet 6.25mg and 12.5mg (better benefit/risk profile)
12.5	Streptokinase PFI 750,000 IU vial	Not used, not cost-effective
13.3	Calamine lotion 15%	Obsolete preparation (use crotamiton cream or appropriate steroid cream)
13.5	Coal tar solution 5%	Not available/used (use coal tar 2% + salicylic acid 2% ointment)
	Dithranol ointment 1%	Not available/required
	Salicylic acid solution 5%	Not available/required
14.1	Fluorescein eye drops 1%	Replaced by fluorescein test strips 0.6mg
16.4	Mannitol injectable solution 10%	Not required; use 20%
17	Magnesium trisilicate co tablet, chewable 370mg	No evidence of benefit compared with placebo (safe and effective alternative available - omeprazole)
	Ranitidine injection 25mg/mL	Superseded by omeprazole
	Ranitidine tablet 150mg	
	Promethazine oral liquid 5mg/5mL	Not used/required (less effective than available alternatives)
	Sulfasalazine suppository 500mg	Not used/required
	Sulfasalazine tablet 500mg	Superseded by mesalazine
18.1	Prednisolone tablets 5mg	Not used/required

KEML 2016

Section	Item Deleted	Reason/Notes
18.3.1	Ethinylestradiol + norethisterone tablet 35 micrograms + 1mg	Use ethinylestradiol + levonorgestrel tablet 30 micrograms + 150 micrograms
18.3.2	Norethisterone enantate oily solution 200mg/1mL ampoule	Not used in current family planning protocols
20	Vecuronium bromide PFI 10mg vial	Replaced by cisatracurium (better adverse effect profile)
21.4	Pilocarpine eye drops 2%	Rarely used (use dorzolamide eye drops)
	Timolol eye drops 0.25%	Not useful/effective (use 0.5%)
21.5	Atropine sulfate eye drops 1%	Not preferred (use 0.5%)
24.2.2	Carbamazepine tablet 100mg	Not required (use 200mg scored)
	Lithium carbonate tablet 300mg	Replaced by 400mg (modified release)
24.3	Diazepam tablet 5mg	Replaced by bromazepam tablet 3mg (scored); more effective in managing somatic anxiety
24.5	Clonidine tablet 100 micrograms	Not being used
25.1	Beclomethasone inhalation (aerosol) 50 micrograms/dose	Not required (use 100 micrograms/dose inhaler)
	Salbutamol oral liquid 2mg/5mL	Not recommended
	Salbutamol tablet 4mg	Not recommended
26.1	Potassium chloride powder for dilution to make 7.5% oral solution	Not used
26.2	Sodium hydrogen carbonate (bicarbonate) injectable solution 1.4% (isotonic)	Not required
27	Ascorbic acid tablet 50mg	Not required
	Ergocalciferol oral drops 400 IU/0.6mL dose	Replaced by cholecalciferol oral liquid (drops) 400 IU/mL [c]
	Nicotinamide (Vit B ₃) tablet 50mg	Not required
	Cholecalciferol tablet 10 micrograms (400 IU)	Replaced by oral liquid (drops) 400 IU/mL [c]
	Pyridoxine HCl (Vit B ₆) tablet 10mg	Replaced by tablet 50mg (scored)
	Pyridoxine HCl (Vit B ₆) tablet 25mg	
28	Acetic acid solution (ear drops) 2% in alcohol	Not used/required
	Polyvidone iodine mouthwash 1%	
29	Aminoacids infusion 3%	Not used/required (other strengths available)

Kenya Essential Medicines List 2016

#	Drug	Dose-form	Size/strength	Level
1. ANAESTHETICS				
1.1 General anaesthetics & oxygen				
1.1.1 Inhalational anaesthetics				
1.1.1.1	Halothane	Inhalation (250mL)		4
1.1.1.2	Isoflurane	Inhalation (250mL)		4
1.1.1.3	Medical air	Inhalation (medicinal gas)		4
1.1.1.4	Nitrous oxide	Inhalation (medicinal gas)		4
1.1.1.5	Oxygen	Inhalation (medicinal gas)		2
1.1.2 Injectables				
1.1.2.1	Ketamine hydrochloride	Injection	50mg/mL (10mL vial)	4
1.1.2.2	Propofol ²⁶	Injection	10mg/mL (20mL vial)	4
1.1.2.3	Thiopental sodium	PFI	500mg vial	4
1.2 Local anaesthetics²⁷				
1.2.1	Bupivacaine HCl	Injection	a) 0.5% (10mL vial)	4
		Injection (spinal) ²⁸	b) 0.5% (5mg/mL) + glucose 8% (80mg/mL) (4mL amp)	
1.2.2	Lidocaine HCl	Injection	a) 2% (30mL vial)	2
		Topical solution	b) 2% (spray bottle)	
1.2.3	Lidocaine HCl + epinephrine (adrenaline)	Dental cartridge	2% + 1:80,000 (1.8mL cartridge)	4
Specialist List				
1.2.4	Ephedrine HCl ²⁹	Injection	30mg/1mL amp	
1.3 Pre- and intra-operative medication and sedation for short-term procedures				
1.3.1	Atropine sulphate	Injection	1mg/1mL amp	3
1.3.2	Chlorphenamine maleate ³⁰	Injection	10mg/1mL amp	3
1.3.3	Midazolam	a) Injection (as HCl)	1mg/mL (5mL vial)	3
		b) Oral liquid [c] ³¹	2mg/mL (as HCl)	3
		c) Tablet	7.5mg (as maleate)	3

²⁶ Thiopental may be used as an alternative where propofol is not available

²⁷ For spinal, epidural, caudal or IV regional anaesthesia, use **preservative-free** injections

²⁸ Also referred to as 'heavy spinal'; may also be available with glucose 7.5% (75mg/mL)

²⁹ For specialist use in spinal anaesthesia during caesarean sections for prevention of hypotension

³⁰ Use only for managing pre- and intra-operative allergic reactions

³¹ With graduated oral dispenser; 2.5mg/mL presentation may be available and used as an alternative

KEML 2016

#	Drug	Dose-form	Size/strength	Level
1.3.4	Morphine	Injection	10mg/1mL amp (HCl or sulphate)	3
Specialist List				
1.3.5	Fentanyl ³²	Injection (as citrate)	50 micrograms/mL (2mL amp)	
2. MEDICINES for PAIN and PALLIATIVE CARE				
2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)				
2.1.1	Aspirin	Tablet	300mg	2
2.1.2	Ibuprofen ³³	a) Oral liquid [c]	100mg/5mL	2
		b) Tablet	200mg	2
2.1.3	Paracetamol ³⁴	a) Injection ³⁵ (for IV infusion)	10mg/mL (100mL vial)	4
		b) Oral liquid [c]	125mg/5mL ³⁶	1
		c) Suppository [c]	125mg	2
		d) Tablet (scored)	500mg	1
2.2 Opioids				
2.2.1	Codeine phosphate ³⁷	Tablet	30mg	3
2.2.2	Morphine ³⁸	a) Injection	10mg/1mL amp (HCl or sulphate)	4
		Oral liquid (HCl or sulphate)	b) 1mg/mL	4
			c) 10mg/mL	4
			d) Tablet (m/r)	30mg (sulphate)
2.3 Medicines for other common symptoms in palliative care				
2.3.1	Amitriptyline	Tablet	25mg	4
2.3.2	Bisacodyl	a) Tablet	5mg	4
		b) Suppository	10mg	4
2.3.3	Dexamethasone	a) Injection	4mg/1mL amp (as sod. phosphate)	4
		b) Tablet	2mg [c]	4
2.3.4	Diazepam	a) Injection	5mg/mL (2mL amp)	4
		b) Oral liquid	2mg/5mL	4
		c) Gel or rectal	5mg/mL (0.5mL tube)	4

³² Restricted for intra-operative use **only**

³³ Do not use for children <3 months old

³⁴ Not for anti-inflammatory use (no proven benefit)

³⁵ Use only for post-operative analgesia

³⁶ Alternative strength: 120mg/5mL

³⁷ Only use for adults

³⁸ May also be prescribed by specially trained palliative care professionals

KEML 2016

#	Drug	Dose-form	Size/strength	Level
		solution ³⁹ [c]		
2.3.4	Diazepam	d) Tablet (scored)	5mg	4
2.3.5	Gabapentin	Tablet	300mg	4
2.3.6	Haloperidol	a) Injection	5mg/1mL amp	4
		b) Tablet	5mg	4
2.3.7	Hyoscine butylbromide	Injection	20mg/1mL amp	4
2.3.8	Hyoscine hydrobromide [c]	Injection	400 micrograms/1mL amp	4
2.3.9	Lactulose [c]	Oral liquid	3.1-3.7mg/5mL	4
2.3.10	Loperamide	Capsule	2mg	4
2.3.11	Metoclopramide	a) Injection	5mg/mL (2mL amp)	4
		b) Oral liquid	5mg/5mL	4
		c) Tablet	10mg	4
2.3.12	Midazolam	Injection	a) 1mg/mL	4
			b) 5mg/mL	4
		c) Oral liquid	2mg/mL [c]	4
		d) Tablet	7.5mg	4
2.3.13	Ondansetron [c] ⁴⁰	a) Injection	2mg/mL (2mL amp) (as HCl)	4
		b) Tablet	4mg (as HCl)	4
3. ANTIALLERGICS and MEDICINES used in ANAPHYLAXIS				
3.1	Cetirizine HCl	a) Oral liquid	5mg/5mL	2
		b) Tablet	10mg	2
3.2	Dexamethasone	Injection	4mg/1mL amp (as disod. phosphate)	4
3.3	Epinephrine (adrenaline)	Injection	1mg/1mL amp ⁴¹ (as HCl or hyd.tartrate)	2
3.4	Hydrocortisone	PFI	100mg vial (as sod. succinate)	2
3.5	Prednisolone	a) Oral liquid [c]	15mg/5mL	4
		b) Tablet	5mg	4
Specialist List				
3.6	Chlorphenamine maleate ⁴²	Injection	10mg/1mL amp	

³⁹ If not available, use diazepam injection solution 5mg/mL instead, administered rectally by syringe – *without the needle!*

⁴⁰ Use only in children >1 month old

⁴¹ Strength may also be expressed as 1 in 1,000 or 0.1%

⁴² Use only as premedication for prevention of hypersensitivity reactions to paclitaxel

KEML 2016

#	Drug	Dose-form	Size/strength	Level
4. ANTIDOTES and OTHER SUBSTANCES used in POISONINGS				
4.1 Non-specific				
4.1.1	Activated charcoal	PFOL	50g	2
4.2 Specific				
4.2.1	Acetylcysteine	Injection	200mg/mL (10mL amp)	4
4.2.2	Atropine sulphate	Injection	1mg/1mL amp	4
4.2.3	Deferasirox	Tablet	a) 100mg	4
			b) 400mg	4
4.2.4	Flumazenil	Injection	100 micrograms/mL (5mL amp)	4
4.2.5	Naloxone hydrochloride	Injection	400 micrograms/1mL amp	4
4.2.6	Protamine sulphate	Injection	10mg/mL (5mL amp)	4
Specialist List				
4.2.7	Deferoxamine mesilate	PFI	500mg vial	
4.2.8	Dimercaprol ⁴³	Injection (in oil)	50mg/mL (2mL amp)	
4.2.9	Ethanol ⁴⁴	a) Injection	100% (10mL amp) ⁴⁵	
		b) Oral liquid ⁴⁶	95-96%	
4.2.10	Fomepizole sulphate	Injection	5mg/mL (20mL amp)	
4.2.11	Penicillamine ⁴⁷	Tablet	250mg	
4.2.12	Pralidoxime chloride	PFI	1g vial	
4.2.13	Sodium calcium edetate	Injection	200mg/mL (5mL amp)	
4.2.14	Sodium nitrite ⁴⁸	Injection	30mg/mL (10mL amp)	
4.2.15	Sodium thiosulphate ⁴⁹	Injection	250mg/mL (50mL amp)	
4.2.16	Succimer ⁵⁰	Capsule	100mg	
5. ANTICONVULSANTS/ANTIEPILEPTICS				
5.1	Carbamazepine	a) Oral liquid [c]	100mg/5mL	4
		b) Tablet	200mg (cross-scored)	4

⁴³ To be phased out as better alternatives are available

⁴⁴ Pharmaceutical grade (ie. BP, EP, USP); for use in methanol poisoning

⁴⁵ Also known as dehydrated or absolute alcohol; for administration as a 10% solution in glucose 5% IV infusion

⁴⁶ For dilution (1 part + 4 parts water) before use as a 20% solution; if unavailable use ethanol 40% solution (eg. vodka)

⁴⁷ Use with close monitoring

⁴⁸ Use focused on areas where cyanide poisoning is more prevalent

⁴⁹ Use focused on areas where cyanide poisoning is more prevalent

⁵⁰ Also called dimercaptosuccinic acid (DMSA)

KEML 2016

#	Drug	Dose-form	Size/strength	Level
5.2	Diazepam [c]	Gel or rectal solution ⁵¹	5mg/mL (0.5mL tube)	2
5.3	Gabapentin	Tablet	300mg	4
5.4	Lorazepam ⁵²	Injection	4mg/1mL amp	2
5.5	Magnesium sulphate ⁵³	Injection	500mg/mL (50%) (10mL amp))	2
5.6	Phenobarbital sodium	Injection	a) 30mg/1mL amp [c] ⁵⁴	2
			b) 200mg/1mL amp	2
5.7	Phenytoin sodium	c) Tablet (scored)	30mg	2
		a) Injection	50mg/mL (5mL vial)	4
		b) Oral liquid	30mg/5mL	4
		Tablet (f/c)	c) 25mg	4
5.8	Valproic acid (sodium valproate)		d) 100mg	4
		a) Oral liquid	200mg/5mL	4
		Tablet (e/c)	b) 200mg	4
			c) 500mg	4
Specialist List				
5.9	Lamotrigine	Tablet	a) 25mg b) 100mg	
6. ANTI-INFECTIVES				
6.1 Anthelmintics				
6.1.1 Intestinal anthelmintics				
6.1.1.1	Albendazole ⁵⁵	Tablet (chewable)	400mg	1
6.1.1.2	Praziquantel	Tablet (scored)	600mg	2
6.1.2 Antifilarials				
6.1.2.1	Albendazole ⁵⁶	Tablet (chewable)	400mg	1
6.1.2.2	Diethylcarbamazine dihydrogen citrate (DEC)	Tablet (scored)	100mg	4
6.1.3 Antischistosomes and other antitrepatodes				
6.1.3.1	Praziquantel	Tablet (scored)	600mg	2

⁵¹ If not available, use diazepam injection solution 5mg/mL instead, administered rectally by syringe – *without the needle!*

⁵² Use always with close monitoring

⁵³ Use only in management of pre-eclampsia; provides 5g per 10mL amp

⁵⁴ Use in paediatric emergencies

⁵⁵ Do not use in 1st trimester

⁵⁶ Do not use in 1st trimester

KEML 2016

#	Drug	Dose-form	Size/strength	Level
6.2 Antibacterials				
6.2.1 Beta Lactams				
6.2.1.1	Amoxicillin	a) DT ⁵⁷ (scored)	250mg	2
		b) Capsule	500mg	2
6.2.1.2	Amoxicillin + clavulanic acid ⁵⁸	a) DT (scored)	200mg + 28.5mg	3
		b) Tablet	875mg + 125mg (1g)	3
6.2.1.3	Benzathine benzylpenicillin	PFI	900mg (1.2MU) vial	2
6.2.1.4	Benzylpenicillin ⁵⁹ (sodium or potassium)	PFI	600mg (1MU) vial	2
6.2.1.5	Cefazolin ⁶⁰	PFI	1g vial	4
6.2.1.6	Cefixime ⁶¹	Tablet	400mg (as trihydrate)	2
6.2.1.7	Ceftriaxone ^{62, 63} (as sodium salt)	Injection	a) 250mg [c]	2
			b) 1g	2
6.2.1.8	Flucloxacillin (as sodium salt)	a) Capsule	250mg	4
		b) PFI	500mg vial	4
		c) PFOL	125mg/5mL	4
6.2.1.9	Phenoxymethylpenicillin ⁶⁴ (as potassium salt)	Tablet	250mg	4
Specialist List				
6.2.1.10	Ceftazidime ⁶⁵ (as pentahydrate)	PFI	a) 250mg vial	
			b) 1g vial	
6.2.1.11	Imipenem + cilastin ⁶⁶	PFI	a) 250mg + 250mg vial	
			b) 500mg + 500mg vial	

⁵⁷ Dispersible tablet

⁵⁸ Also called co-amoxiclav; strength may be expressed as the total of the components

⁵⁹ Use only at Level 2 facilities in pre-referral management of a very sick child (with gentamicin)

⁶⁰ Use only in surgical prophylaxis (patients >1mth)

⁶¹ Use at Level 2 restricted to syndromic management of STIs only

⁶² Do not administer with calcium; avoid in infants with hyperbilirubinaemia; only use if infant is >41 weeks corrected gestational age

⁶³ Use at Level 2 restricted to STI syndrome management only

⁶⁴ Use only in sickle-cell prophylaxis and as an alternative to benzathine penicillin where this is not tolerated in prophylaxis of rheumatic heart disease

⁶⁵ For specialist 2nd line use only where required laboratory diagnostic support and clear antibiotic use protocols are available

⁶⁶ For specialist 2nd line use only in treatment of life-threatening hospital-based infections due to suspected or proven multi-drug resistant organisms; imipenem present as monohydrate, cilastin as sodium salt

KEML 2016

#	Drug	Dose-form	Size/strength	Level
6.2.2 Other antibacterials				
6.2.2.1	Azithromycin ⁶⁷	a) Tablet (scored)	250mg (anhydrous)	2
		b) PFOL	200mg/5mL	2
6.2.2.2	Ciprofloxacin	a) Oral liquid [c]	250mg/5mL (anhydrous)	3
		b) Tablet	250mg (as HCl)	2
6.2.2.3	Clarithromycin ⁶⁸	Tablet (scored)	500mg	4
6.2.2.4	Cotrimoxazole (sulfamethoxazole + trimethoprim)	a) Injection ⁶⁹	96mg/mL (10mL amp)	2
		b) Oral liquid	240mg/5mL	2
		c) Tablet (scored)	480mg	2
6.2.2.5	Doxycycline ⁷⁰	Tablet	100mg (as hyclate)	2
6.2.2.6	Gentamicin	Injection (as sulphate)	a) 10mg/mL (2mL vial) ⁷¹	2
			b) 40mg/mL (2mL vial) ⁷²	2
6.2.2.7	Metronidazole	a) Injection	5mg/mL (100mL vial)	3
		b) Oral liquid	200mg/5mL (as benzoate)	2
		c) Tablet (f/c)	200mg	2
6.2.2.8	Nitrofurantoin	Tablet	100mg	4
6.2.2.9	Tinidazole ⁷³	Tablet (f/c)	500mg	2
Specialist List				
6.2.2.10	Ciprofloxacin	Solution for IV infusion [c]	2mg/mL (50mL bottle) (as lactate)	
6.2.2.11	Clindamycin ⁷⁴	a) Capsule	150mg (as HCl)	
		b) Injection	150mg/mL (2mL vial) (as phosphate)	
		c) Oral liquid [c]	75mg/5mL (as palmitate)	
6.2.2.12	Vancomycin ⁷⁵	PFI	250mg vial (as HCl)	

⁶⁷ Use at Level 2 restricted to STI syndromic management and penicillin hypersensitive patients only

⁶⁸ Use only in combination drug regimes for treatment of *H. pylori* infection

⁶⁹ Use only in treatment of pneumocystis pneumonia (PCP) and toxoplasmosis

⁷⁰ Use in children <8 years only for life-threatening infections if there is no alternative

⁷¹ Use only for pre-referral management of a very sick child (with benzylpenicillin)

⁷² Use only in 2nd line syndromic management of STI

⁷³ Useful longer-acting alternative to metronidazole in treatment regimes where single daily doses may be used to improve adherence

⁷⁴ For specialist use only in bone & joint infections and secondary bacterial infections in viral parotitis

KEML 2016

#	Drug	Dose-form	Size/strength	Level
6.2.3 Antileprotics⁷⁶				
6.2.3.1	Clofazamine	Capsule	a) 50mg b) 100mg	4 4
6.2.3.2	Dapsone	Tablet	25mg	4
6.2.3.3	Rifampicin	Capsule/Tablet	a) 150mg b) 300mg	4 4
6.2.4 Antituberculosis medicines⁷⁷				
Individual drugs				
6.2.4.1	Ethambutol (E)	Tablet	a) 100mg (dispersible) b) 400mg	2 2
6.2.4.2	Isoniazid (H)	Oral liquid Tablet	a) 50mg/5mL [c] b) 100mg c) 300mg	2 2 2
6.2.4.3	Pyrazinamide (Z)	Tablet	400mg	2
6.2.4.4	Rifampicin (R)	Capsule	a) 150mg b) 300mg	2 2
Fixed-dose combinations (FDCs)				
6.2.4.6	Isoniazid + ethambutol (HE)	Tablet	150mg + 400mg	2
6.2.4.7	Rifampicin + isoniazid (RH)	Tablet	a) 150mg + 75mg b) 75mg + 50mg [c]	2 2
6.2.4.8	Rifampicin + isoniazid + ethambutol + (RHE)	Tablet	150mg + 75mg + 275mg	2
6.2.4.9	Rifampicin + isoniazid + pyrazinamide + (RHZ)	Tablet	a) 150mg + 75mg + 400mg b) 75mg + 50mg + 150mg [c]	2 2
6.2.4.10	Rifampicin + isoniazid + pyrazinamide + ethambutol (RHZE)	Tablet	150mg + 75mg + 400mg + 275mg	2
Specialist List				
6.2.4.11	Amikacin	PFI	500mg vial (as sulphate)	
6.2.4.12	Bedaquiline	Tablet	100mg	
6.2.4.13	Capreomycin	PFI	1g vial (as sulphate)	
6.2.4.14	Cycloserine	Tablet	250mg	
6.2.4.15	Delamanid	Tablet	50mg	
6.2.4.16	Kanamycin	PFI	1g vial (as sulphate)	

⁷⁵ Use only in endocarditis & other serious methicillin-resistant *staphylococcus aureus* (MRSA) infections

⁷⁶ Use only in combination, never individually

⁷⁷ Antituberculosis treatment must *always* be with FDCs +/- additional individual drugs

KEML 2016

#	Drug	Dose-form	Size/strength	Level
6.2.4.17	Levofloxacin	Tablet (scored)	500mg	
6.2.4.18	Linezolid	Tablet	600mg	
6.2.4.19	Moxifloxacin	Tablet	400mg	
6.2.4.20	p-aminosalicylic acid (PAS)	Granules	4g sachet	
6.2.4.21	Prothionamide	Tablet	250mg	
6.2.4.22	Rifabutin (RFB ₃)	Capsule	150mg	
6.3 Antifungals				
6.3.1	Amphotericin B ⁷⁸	PFI	50mg vial (as sodium deoxycholate)	4
6.3.2	Clotrimazole ⁷⁹	Vaginal tablet	500mg	2
6.3.3	Fluconazole	Capsule	a) 50mg ⁸⁰	2
			b) 200mg	4
		c) Injection ⁸¹	2mg/mL (100mL bottle)	4
		d) Oral liquid [c]	50mg/5mL	4
6.3.4	Griseofulvin	Tablet	125mg	2
6.3.5	Nystatin	Oral liquid (suspension)	100,000 IU/mL	2
6.4 Antivirals				
6.4.1 Antiherpes medicines				
6.4.1.1	Aciclovir	Tablet	200mg (scored)	2
Specialist List				
6.4.1.2	Aciclovir ⁸²	PFI	250mg vial (as sodium salt)	
6.4.2 Antiretrovirals				
6.4.2.1 Nucleoside/nucleotide reverse transcriptase inhibitors (NRTI)				
6.4.2.1.1	Abacavir (ABC)	Tablet	300mg	2
6.4.2.1.2	Lamivudine (3TC)	a) Oral liquid	50mg/5mL	2
		b) Tablet	150mg	2
6.4.2.1.3	Stavudine (d4T)	Tablet	30mg	2
6.4.2.1.4	Tenofovir disoproxil fumarate (TDF)	Tablet	a) 150mg	2
			b) 200mg	2
			c) 300mg	2
6.4.2.1.5	Zidovudine (ZDV or AZT)	a) Oral liquid	50mg/5mL	2
		b) Tablet	300mg	2

⁷⁸ Only use in invasive fungal infections

⁷⁹ Use as alternative to fluconazole in pregnancy

⁸⁰ Use at Level 2 restricted to STI syndromic management only

⁸¹ Use only in cryptococcal meningitis

⁸² Use only in viral encephalitis

KEML 2016

#	Drug	Dose-form	Size/strength	Level
6.4.2.2 Non-Nucleoside/nucleotide reverse transcriptase inhibitors (NNRTI)				
6.4.2.2.1	Efavirenz (EFV or EFZ)	Tablet	a) 200mg (double-scored)	2
			b) 400mg	2
			c) 600mg	2
6.4.2.2.2	Etravirine (ETV)	Tablet	a) 25mg	4
			b) 100mg	4
6.4.2.2.2	Nevirapine (NVP)	a) Oral liquid	10mg/mL	2
		b) Tablet	200mg	2
6.4.2.3 Protease inhibitors				
6.4.2.3.1	Atazanavir + ritonavir	Tablet	300mg + 100mg	2
6.4.2.3.2	Darunavir (TCM)	a) Oral liquid (susp)	100mg/mL	2
		Tablet (f/c)	b) 75mg	2
			c) 150mg	2
			d) 600mg	4
6.4.2.3.3	Lopinavir + ritonavir (LPV/r)	a) Oral liquid	400mg + 100mg/5mL	2
		b) Tablet (heat-stable)	200mg + 50mg	2
6.4.2.3.4	Ritonavir	a) Oral liquid	400mg/5mL	2
		b) Tablet (heat-stable)	100mg	2
6.4.2.4 Integrase inhibitor				
6.4.2.4.1	Raltegravir	Tablet	a) 25mg	2
			b) 100mg	2
			c) 400mg (f/c)	2
6.4.2.5 Fixed-dose combinations (FDCs)				
6.4.2.5.1	Abacavir + lamivudine (ABC + 3TC)	Tablet	a) 60mg (as sulphate) + 30mg ⁸³	2
			b) 120mg (as sulphate) + 60mg	2
			c) 600mg (as sulphate) + 60mg	2
6.4.2.5.2	Efavirenz + lamivudine + tenofovir ⁸⁴ (EFV + 3TC + TDF)	Tablet	a) 400mg + 300mg + 300mg	2
			b) 600mg + 300mg + 300mg	2
6.4.2.5.3	Emtricitabine + tenofovir	Tablet	200g + 300mg	2

⁸³ This strength is being phased out

⁸⁴ Tenofovir disoproxil fumarate (TDF)

KEML 2016

#	Drug	Dose-form	Size/strength	Level
6.4.2.5.4	Lamivudine + tenofovir (3TC + TDF)	Tablet	300mg + 300mg (disoproxil fumarate)	2
6.4.2.5.5	Lamivudine + zidovudine (3TC + ZDV)	Tablet	a) 30mg + 60mg	2
			b) 150mg + 300mg	2
6.4.2.5.6	Lamivudine + nevirapine + zidovudine (3TC + NVP + ZDV)	Tablet	a) 30mg + 50mg + 60mg	2
			b) 150mg + 200mg + 300mg	2
6.4.3 Other antivirals				
Specialist List				
6.4.3.1	Ganciclovir ⁸⁵	PFI	500mg vial	
6.4.3.2	Ribavirin ⁸⁶	Tablet (film-coated)	a) 200mg	
			b) 400mg	
6.4.4 Antihepatitis medicines ⁸⁷				
6.4.4.1 Hepatitis B medicines				
Specialist List				
6.4.4.1.1	Pegylated interferon alfa-2a	Injection (vial or prefilled syringe)	180 micrograms	
6.4.4.1.2	Tenofovir disoproxil fumarate (TDF)	Tablet	300mg ⁸⁸	
6.4.4.2 Hepatitis C medicines				
Specialist List				
6.4.4.2.1	Pegylated interferon alfa-2a	Injection (vial or prefilled syringe)	180 micrograms	
6.4.4.2.2	Ribavirin ⁸⁹	Tablet (film-coated)	a) 200mg	
			b) 400mg	
6.5 Antiprotozoals				
6.5.1 Antiamoebic & anti giardia Medicines				
6.5.1.1	Diloxanide ⁹⁰	Tablet	500mg (furoate)	2
6.5.1.2	Metronidazole	a) Injection	500mg/100mL vial	3
		b) Oral liquid	200mg/5mL (as benzoate)	2

⁸⁵ Use in management of cytomegalovirus retinitis (CMV)

⁸⁶ Use in treatment of viral haemorrhagic fevers and, in combination with pegylated interferon, in treatment of hepatitis C

⁸⁷ This section will be revised following the review and update of national hepatitis management guidelines in line with new WHO recommendations

⁸⁸ TDF equivalent to 245mg tenofovir disoproxil

⁸⁹ Use also in treatment of viral haemorrhagic fevers

⁹⁰ Use only in patients >25kg

KEML 2016

#	Drug	Dose-form	Size/strength	Level
6.5.1.2	Metronidazole	c) Tablet	400mg (scored)	2
6.5.1.3	Tinidazole ⁹¹	Tablet	500mg	2
6.5.2 Antileishmaniasis medicines				
6.5.2.1	Amphotericin B	PFI	50mg vial (as sodium deoxycholate)	4
6.5.2.2	Paromomycin ⁹²	Injection solution (IM)	375mg base/mL (as sulphate) (2mL amp)	4
6.5.2.3	Sodium stibogluconate ⁹³	Injection	100mg/mL (100mL vial)	4
6.5.3 Antimalarials				
6.5.3.1 Curative				
6.5.3.1.1	Artemether + lumefantrine ⁹⁴ (AL)	a) Tablet ⁹⁵	20mg + 120mg	1
		b) Tablet (dispersible) ⁹⁶	20mg + 120mg	1
		c) Tablet ⁹⁷	80mg + 480mg	1
6.5.3.1.2	Artesunate ⁹⁸	Injection	a) 30mg vial ⁹⁹	2
			b) 60mg vial ¹⁰⁰	2
		Rectal capsule ¹⁰¹	100mg	2
6.5.3.1.3	Dihydroartemisinin + piperazine (DHA+PPQ) ¹⁰²	Tablet (scored)	40mg + 320mg	3
6.5.3.1.4	Quinine	a) Injection ¹⁰³	300mg/mL (2mL amp) (hydrochloride)	2

⁹¹ Useful for giardia (2g single dose); may also be used for other indications as a longer acting alternative to metronidazole

⁹² Use only in combination with sodium stibogluconate; also called aminosidine

⁹³ Use only in combination with paromomycin

⁹⁴ Do not use in 1st trimester of pregnancy (use oral quinine)

⁹⁵ Use for patients 24-35kg

⁹⁶ Use for patients <24kg

⁹⁷ Use for patients >35kg

⁹⁸ Always follow artesunate treatment (24 hours minimum) with a 3-day course of artemether + lumefantrine (once the patient can take oral medication)

⁹⁹ Co-packed with 0.5mL amp of sodium bicarbonate 5% (50mg/mL) and 2.5mL amp of sodium chloride 0.9% (9mg/mL) as diluents

¹⁰⁰ Co-packed with 1mL amp of sodium bicarbonate 5% (50mg/mL) and 5mL amp of sodium chloride 0.9% (9mg/mL) as diluents

¹⁰¹ Use for management of severe malaria **only** if parenteral artesunate is not available

¹⁰² Use only as 2nd line medicine for *confirmed* uncomplicated malaria treatment failure with 1st line AL

¹⁰³ Use only for severe malaria when 1st line artesunate injection is not available

KEML 2016

#	Drug	Dose-form	Size/strength	Level
6.5.3.1.4	Quinine	b) Tablet (f/c) ¹⁰⁴	300mg (sulphate or bisulphate)	2
6.5.3.1.5	Primaquine ¹⁰⁵	Tablet	7.5mg (as diphosphate)	4
6.5.3.2 Prophylactic				
6.5.3.2.1	Doxycycline ¹⁰⁶	Capsule	100mg (as HCl)	2
6.5.3.2.2	Proguanil hydrochloride ¹⁰⁷	Tablet	100mg	4
6.5.3.3 Intermittent presumptive treatment in pregnancy (IPTp)				
6.5.3.3.1	Sulfadoxine + pyrimethamine	Tablet	500mg + 25mg	2
6.5.4 Antipneumocystosis and antitoxoplasmosis medicines				
6.5.4.1	Cotrimoxazole	a) Injection	96mg/mL (5mL amp)	4
		b) Oral liquid	240mg/5mL [c]	4
		c) Tablet	480mg	4
6.5.4.2	Sulfadoxine + pyrimethamine	Tablet	500mg + 25mg	4
6.5.5 Antitrypanosomal medicines				
6.5.5.1 African trypanosomiasis				
a) Treatment of 1st stage				
6.5.5.1.1	Pentamidine isetionate	PFI	200mg vial	4
<i>Specialist List</i>				
6.5.5.1.2	Suramin sodium	PFI	1g vial	
b) Treatment of 2nd stage				
<i>Specialist List</i>				
6.5.5.1.3	Melarsoprol	Injection	3.6% solution (5mL amp) (= 180mg)	
7. ANTIMIGRAINE MEDICINES				
7.1 Acute attack				
7.1.1	Aspirin	Tablet	300mg	2
7.1.2	Ibuprofen ¹⁰⁸	Tablet	200mg	2
7.1.3	Paracetamol	a) Oral liquid [c]	125mg/5mL ¹⁰⁹	1
		b) Suppository [c]	125mg	1
		c) Tablet (scored)	500mg	1

¹⁰⁴ Use only for uncomplicated malaria treatment in 1st trimester of pregnancy

¹⁰⁵ Use only for radical cure of *P. vivax* infection (14 day course)

¹⁰⁶ Use only in patients >8 years; for prophylaxis in non-immune visitors to endemic areas

¹⁰⁷ Use only for prophylaxis in patients with sickle-cell disease and tropical splenomegaly syndrome (TSS)

¹⁰⁸ Do not use in children < 3 months old

¹⁰⁹ 120mg/5mL is an alternative strength

KEML 2016

#	Drug	Dose-form	Size/strength	Level
7.2 Prophylactics				
7.2.1	Propranolol HCl ¹¹⁰	Tablet	40mg	4
8. ANTINEOPLASTICS and IMMUNOSUPPRESSIVES				
8.1 Immunosuppressives				
<i>Specialist List</i>				
8.1.1	Azathioprine	a) PFI b) Tablet (scored)	100mg vial (sodium salt) 50mg	
8.1.2	Ciclosporin	Capsule c) Concentrate for injection ¹¹¹	a) 25mg b) 100mg 50mg/1mL amp	
8.1.3	Methylprednisolone	PFI (as sod. succinate)	a) 125mg b) 500mg	
8.1.4	Mycophenolic acid ¹¹² (as mycophenolate sod.)	Tablet (e/c)	a) 180mg b) 360mg	
8.1.5	Prednisolone	Tablet	5mg	
8.1.6	Tacrolimus	a) Concentrate for IV infusion Capsule	5mg/1mL amp b) 500 micrograms c) 1mg d) 5mg	
8.2 Cytotoxics and adjuvants				
<i>Specialist List</i>				
8.2.1	Alendronic acid ¹¹³	Tablet	70mg	
8.2.2	Allopurinol ¹¹⁴	Tablet	a) 100mg b) 300mg	
8.2.3	Asparaginase ¹¹⁵	PFI	10,000 IU vial	
8.2.4	Bleomycin ¹¹⁶	PFI	15mg vial (as sulphate)	

¹¹⁰ Use only for this indication (ie. do **not** use as an alternative antihypertensive)

¹¹¹ Use in organ transplantation

¹¹² Mycophenolate mofetil tablets 250mg & 500mg may be available as a much cheaper alternative but with a less favourable side-effects profile; the two salts are not interchangeable as they have different pharmacokinetics

¹¹³ Use as adjuvant in management of breast & prostate cancers and multiple myeloma

¹¹⁴ Use for prophylaxis of chemotherapy-induced hyperuricaemia

¹¹⁵ Use in acute lymphoblastic leukaemia; anaphylaxis treatment must be available; the type required is that produced by *Erwinia chrysanthemi* (also known as crisantaspase)

¹¹⁶ Use in Hodgkin lymphoma, Kaposi sarcoma, ovarian and testicular germ cell tumour

KEML 2016

#	Drug	Dose-form	Size/strength	Level
8.2.5	Calcium folinate ¹¹⁷	Injection	a) 10mg/mL (5mL vial)	
		Tablet	b) 15mg	
8.2.6	Capecitabine ¹¹⁸	Tablet	a) 150mg	
			b) 500mg	
8.2.7	Carboplatin ¹¹⁹	Injection	a) 10mg/mL (15mL vial)	
			b) 10mg/mL (45mL vial)	
8.2.8	Chlorambucil ¹²⁰	Tablet	2mg	
8.2.9	Cisplatin ¹²¹	Injection	1mg/mL (50mL vial)	
8.2.10	Cyclophosphamide ¹²²	PFI	a) 200mg vial	
		c) Tablet	b) 500mg vial	
8.2.11	Cytarabine ¹²³	PFI	25mg	
8.2.12	Dacarbazine ¹²⁴	PFI	100mg vial	
8.2.13	Dactinomycin ¹²⁵	PFI	200mg vial (as citrate)	
8.2.14	Daunorubicin ¹²⁶	PFI	500 micrograms vial	
8.2.15	Docetaxel ¹²⁷	Injection ¹²⁸	20mg vial (as HCl)	
			a) 20mg b) 80mg	

¹¹⁷ Use in early stage colon & rectal cancers, gestational trophoblastic neoplasia, metastatic colorectal cancer, osteosarcoma, Burkitt lymphoma; also useful in gynaecological tumours

¹¹⁸ Use in early stage colon & rectal cancers, metastatic breast & colorectal cancers

¹¹⁹ Use in early stage breast cancer, epithelial ovarian cancer, nasopharyngeal cancer, non-small cell lung cancer, osteosarcoma, retinoblastoma

¹²⁰ Use in chronic lymphocytic leukaemia

¹²¹ Use in cervical, head & nasopharyngeal cancers - as a radio-sensitizer; non-small cell lung cancer, osteosarcoma, ovarian & testicular germ cell tumours

¹²² Use in chronic lymphocytic leukaemia, diffuse large B-cell lymphoma, early stage breast cancer, gestational trophoblastic neoplasia, Hodgkin & follicular lymphomas, rhabdomyosarcoma, Ewing sarcoma, acute lymphoblastic leukaemia, Burkitt lymphoma, metastatic breast cancer

¹²³ Use in acute myelogenous, lymphoblastic & promyelocytic leukaemias, Burkitt lymphoma

¹²⁴ Use in Hodgkin lymphoma

¹²⁵ Use in gestational trophoblastic neoplasia, rhabdomyosarcoma, Wilms tumour

¹²⁶ Use in acute lymphoblastic, myelogenous & promyelocytic leukaemias

¹²⁷ Use in early stage & metastatic breast cancers, metastatic prostate cancer

¹²⁸ Both strengths may be available (as a concentrate for dilution for infusion) as either a vial of PFI + diluent or as ready-made injection solution. Selection should be based on relative availability & cost

KEML 2016

#	Drug	Dose-form	Size/strength	Level
8.2.16	Doxorubicin ¹²⁹	PFI	a) 10mg vial (as HCl) b) 50mg vial (as HCl)	
8.2.17	Etoposide ¹³⁰	Injection	20mg/mL (5mL vial)	
8.2.18	Filgrastim ¹³¹	Injection (prefilled syringe)	a) 120 micrograms/0.2mL b) 300 micrograms/0.5mL	
8.2.19	Fluorouracil ¹³²	Injection	50mg/mL (5mL vial)	
8.2.20	Gemcitabine ¹³³	PFI	a) 200mg vial b) 1g vial	
8.2.21	Hydroxycarbamide ¹³⁴ (hydroxyurea)	Capsule	a) 250mg b) 500mg	
8.2.22	Ifosfamide ¹³⁵	PFI	a) 1g vial b) 2g vial	
8.2.23	Imatinib ¹³⁶	Tablet (as mesilate)	400mg	
8.2.24	Irinotecan ¹³⁷	Injection	a) 20mg/mL (2mL vial) b) 20mg/mL (5mL vial)	
8.2.25	Mercaptopurine ¹³⁸	Tablet (scored)	50mg	
8.2.26	Melphalan ¹³⁹	Tablet	2mg	
8.2.27	Mesna ¹⁴⁰	Injection	100mg/mL (2mL amp)	

¹²⁹ Use in diffuse large B-cell lymphoma, early stage breast cancer, Hodgkin lymphoma, Kaposi sarcoma, follicular lymphoma, metastatic breast cancer, osteosarcoma, Ewing sarcoma, acute lymphoblastic leukaemia, Wilms tumour, Burkitt lymphoma

¹³⁰ Use in testicular germ cell tumour, gestational trophoblastic neoplasia, Hodgkin and Burkitt lymphomas, non-small cell lung cancer, ovarian germ cell tumour, retinoblastoma, Ewing sarcoma, acute lymphoblastic leukaemia

¹³¹ Use as primary prophylaxis in those at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy; use as secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy, to facilitate administration of dose dense chemotherapy regimens

¹³² Use in early stage breast, colon & rectal cancers, metastatic colorectal cancer, nasopharyngeal cancer

¹³³ Use in epithelial ovarian cancer, non-small cell lung cancer

¹³⁴ Use in chronic myeloid leukaemia

¹³⁵ Use in testicular & ovarian germ cell tumour, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma

¹³⁶ Use in chronic myeloid leukaemia, gastrointestinal stromal tumour

¹³⁷ Use as 2nd line agent in metastatic colorectal cancer

¹³⁸ Use in acute lymphoblastic & promyelocytic leukaemias

¹³⁹ Use in multiple myeloma

KEML 2016

#	Drug	Dose-form	Size/strength	Level
8.2.28	Methotrexate ¹⁴¹	a) PFI (as sod. salt) (preservative-free) b) Tablet	25mg/mL (2mL vial) 2.5mg (as sodium salt)	
8.2.29	Oxaliplatin ¹⁴²	Injection	a) 2mg/mL (25mL vial) b) 2mg/mL (50mL vial)	
8.2.30	Paclitaxel ¹⁴³	Injection	a) 6mg/mL (5mL vial) b) 6mg/mL (16.7mL vial) ¹⁴⁴	
8.2.31	Procarbazine	Capsule	50mg (as HCl)	
8.2.32	Rituximab ¹⁴⁵	Injection	a) 10mg/mL (10mL vial) b) 10mg/mL (50mL vial)	
8.2.33	Thalidomide ¹⁴⁶	Capsule	100mg	
8.2.34	Trastuzumab ¹⁴⁷	PFI	a) 150mg vial b) 440mg vial + diluent	
8.2.35	Vinblastine sulphate ¹⁴⁸	Injection	1mg/mL (10mL vial)	
8.2.36	Vinorelbine ¹⁴⁹	Injection	a) 10mg/mL (1mL vial) b) 10mg/mL (5mL vial)	
8.2.37	Zoledronic acid ¹⁵⁰	Injection	800 micrograms/mL (5mL vial) ¹⁵¹	
8.3 Hormones and antihormones				
Specialist List				
8.3.1	Anastrozole ¹⁵²	Tablet	1mg	
8.3.2	Bicalutamide ¹⁵³	Tablet	50mg	

¹⁴⁰ Use in testicular & ovarian germ cell tumours, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma

¹⁴¹ Use in early stage breast cancer, gestational trophoblastic neoplasia, osteosarcoma, acute lymphoblastic and promyelocytic leukaemias

¹⁴² Use in early stage colon cancer, metastatic colorectal cancer

¹⁴³ Use in epithelial ovarian cancer, early stage & metastatic breast cancers, Kaposi sarcoma, nasopharyngeal cancer, non-small cell lung cancer, ovarian germ cell tumour

¹⁴⁴ Providing a total of 100mg/vial

¹⁴⁵ Use in diffuse large B-cell and follicular lymphomas, chronic lymphocytic leukaemia

¹⁴⁶ Use (with melphalan & prednisolone) in management of multiple myeloma

¹⁴⁷ Use in early stage & metastatic HER2-positive breast cancer

¹⁴⁸ Use in Hodgkin lymphoma, Kaposi sarcoma, testicular & ovarian germ cell tumour

¹⁴⁹ Use in non-small cell lung cancer, metastatic breast cancer

¹⁵⁰ Use as adjuvant in management of breast & prostate cancers and multiple myeloma

¹⁵¹ Provides a total of 4mg per vial

¹⁵² Letrozole tablets 2.5mg may be available and used as a much cheaper alternative

¹⁵³ Use in metastatic prostate cancer

KEML 2016

#	Drug	Dose-form	Size/strength	Level
8.3.3	Dexamethasone ¹⁵⁴	a) Injection	4mg/1mL amp (as sodium phosphate)	
		b) Tablet	500 micrograms	
8.3.4	Diethylstilboestrol (DES) ¹⁵⁵	Tablet	5mg	
8.3.5	Goserelin ¹⁵⁶	Implant (in syringe applicator)	a) 3.6mg (as acetate) b) 10.8mg (as acetate)	
8.3.6	Hydrocortisone ¹⁵⁷	PFI	100mg vial (as sodium succinate)	
8.3.7	Methylprednisolone ¹⁵⁸ [c]	PFI	500mg vial	
8.3.8	Prednisolone ¹⁵⁹	a) Oral liquid [c]	15mg/5mL	
		Tablet	b) 5mg c) 25mg	
8.3.9	Tamoxifen ¹⁶⁰	Tablet	20mg (as citrate)	
8.4 Medicines for benign prostatic hyperplasia (BPH)				
<i>Specialist List</i>				
8.4.1	Finasteride	Tablet	5mg	
8.4.2	Tamsulosin HCL	Tablet	400 micrograms	
9. ANTIPARKINSONISM MEDICINES				
9.1	Benzhexol HCl	Tablet	5mg	4
9.2	Levodopa + carbidopa	Tablet	a) 100mg + 10mg b) 250mg + 25mg	4 4
<i>Specialist List</i>				
9.3	Pramipexole	Tablet (scored)	a) 180 micrograms base b) 700 micrograms base	
10. MEDICINES AFFECTING the BLOOD				
10.1 Antianaemics				
10.1.1	Ferrous salt	a) Oral liquid (drops)	25mg/mL elemental iron ¹⁶¹	2

¹⁵⁴ Use in acute lymphoblastic leukaemia

¹⁵⁵ Use in management of prostate cancer

¹⁵⁶ Use in early stage & metastatic breast cancers & metastatic prostate cancer
(leuprorelin may be available and used as an alternative)

¹⁵⁷ Use in acute lymphoblastic leukaemia

¹⁵⁸ Use in acute lymphoblastic leukaemia

¹⁵⁹ Use in chronic lymphocytic & acute lymphoblastic leukaemias; diffuse large B-cell, Hodgkin, follicular & Burkitt lymphomas

¹⁶⁰ Use in early stage & metastatic breast cancers

¹⁶¹ Eg. ferrous sulphate solution 125mg/mL

KEML 2016

#	Drug	Dose-form	Size/strength	Level
10.1.1	Ferrous salt	b) Tablet f/c	60-65mg elemental iron ¹⁶²	2
10.1.2	Ferrous salt + folic acid	Tablet f/c	60-65mg elem. iron + 400 micrograms	2
10.1.3	Folic acid	Tablet	a) 400 micrograms ¹⁶³ b) 5mg	2 4
10.1.4	Hydroxocobalamin ¹⁶⁴ (Vit B ₁₂)	Injection	1mg/1mL amp (as HCl, acetate or sulphate)	4
10.2 Medicines affecting coagulation				
10.2.1	Heparin sodium	Injection	5,000 IU/mL (5mL vial)	4
10.2.2	Phytomenadione (Vit K1)	Injection	a) 1mg/1mL amp [c] b) 10mg/mL (5mL amp)	2 4
10.2.3	Protamine sulphate	Injection	10mg/mL (5mL amp)	4
10.2.4	Tranexamic acid	Injection	100mg/mL (5mL amp)	4
10.2.5	Warfarin sodium	Tablet	a) 1mg (scored) b) 5mg (scored)	4 4
Specialist List				
10.2.6	Enoxaparin	Injection (prefilled syringe)	a) 40mg/0.4mL b) 80mg/0.8mL	
10.2.7	Heparin sodium [c]	Injection	5,000 IU/mL (5mL vial)	
10.2.8	Protamine sulphate [c]	Injection	10mg/mL (5mL amp)	
10.2.9	Warfarin sodium [c]	Tablet	a) 1mg (scored) b) 5mg (scored)	
10.3 Other medicines for haemoglobinopathies				
Specialist List				
10.3.1	Deferasirox	Tablet	a) 100mg b) 400mg	
10.3.2	Deferoxamine mesilate	PFI	500mg vial	
10.3.3	Hydroxycarbamide (hydroxyurea) ¹⁶⁵	Capsule	a) 250mg b) 500mg	

¹⁶² Eg. dried ferrous sulphate tablets 200mg

¹⁶³ Use periconceptually for prevention of first occurrence of neural tube defects

¹⁶⁴ Use cyanocobalamin (vit B₁₂) tablet 1mg as the preferred alternative (if available)

¹⁶⁵ Previously called hydroxyurea; use in management of sickle-cell disease

KEML 2016

#	Drug	Dose-form	Size/strength	Level
11. BLOOD PRODUCTS of HUMAN ORIGIN and PLASMA SUBSTITUTES				
11.1 Blood and blood components				
11.1.1	Plasma, fresh frozen			4
11.1.2	Platelets			4
11.1.3	Red blood cells			4
11.1.4	Whole blood			4
11.2 Plasma-derived medicines				
11.2.1 Human immunoglobulins (Ig)				
11.2.1.1	Anti-D (Rh ₀) Ig (human monoclonal)	PFI + diluent	750 IU/mL (2mL vial) ¹⁶⁶	4
11.2.1.2	Anti-rabies Ig (equine)	Injection	200 IU/mL (5mL vial)	2
11.2.1.3	Anti-tetanus Ig (human)	Injection	500 IU vial	4
<i>Specialist List</i>				
11.2.1.4	Normal Ig ¹⁶⁷	Injection (IV) (100mL vial)	a) 5% protein solution b) 10% protein solution	
11.2.2 Blood coagulation factors				
<i>Specialist List</i>				
11.2.2.1	Coagulation factor VIII	PFI	500 IU vial	
11.2.2.2	Coagulation factor IX	PFI	500 IU vial	
11.3 Plasma substitutes				
11.3.1	Polygeline ¹⁶⁸	IV infusion	3.5% (500mL pack)	4
12. CARDIOVASCULAR MEDICINES				
12.1 Antianginals				
12.1.1	Carvedilol	Tablet	a) 6.25mg	4
			b) 12.5mg	4
12.1.2	Glyceril trinitrate	Tablet (sublingual)	500 micrograms	4
12.1.3	Isosorbide dinitrate	Tablet	20mg	4
12.2 Antiarrhythmics				
12.2.1	Carvedilol	Tablet	a) 6.25mg	4
			b) 12.5mg	4
12.2.2	Digoxin	Oral liquid ¹⁶⁹	50 micrograms/mL	4
		Tablet	a) 62.5 micrograms b) 250 micrograms	4
12.2.3	Lidocaine HCl ¹⁷⁰	Injection	20mg/mL (5mL amp)	4

¹⁶⁶ Contains 1,500 IU = 300 micrograms per 2mL vial when reconstituted

¹⁶⁷ Use for primary immune deficiency and Kawasaki disease

¹⁶⁸ Partially degraded gelatin

¹⁶⁹ Measure doses with graduated pipette provided

¹⁷⁰ Only for IV use in ICU; preservative-free

KEML 2016

#	Drug	Dose-form	Size/strength	Level
12.2.4	Verapamil HCl	Injection	a) 2.5mg/mL (2mL amp)	4
		Tablet	b) 80mg (scored)	4
Specialist List				
12.2.5	Amiodarone HCl ¹⁷¹	Injection	50mg/mL (3mL amp)	
12.2.6	Epinephrine (adrenaline) ¹⁷²	Injection	100 micrograms/mL (10mL amp) (as HCl or acid tartrate)	
12.3 Antihypertensives				
12.3.1	Amlodipine ¹⁷³	Tablet	5mg	4
12.3.2	Carvedilol	Tablet	a) 6.25mg	4
			b) 12.5mg	4
12.3.3	Enalapril	Tablet	5mg (scored) ¹⁷⁴	4
12.3.4	Hydralazine HCl	PFI	a) 20mg	4
		Tablet	b) 25mg	4
12.3.5	Hydrochlorthiazide	Tablet (scored)	25mg	4
12.3.6	Losartan	Tablet	50mg	4
12.3.7	Methyldopa ¹⁷⁵	Tablet	250mg	4
Specialist List				
12.3.8	Sodium nitroprusside	PFI	50mg ampoule	
12.4 Medicines used in heart failure				
12.4.1	Carvedilol	Tablet	a) 6.25mg	4
			b) 12.5mg	4
12.4.2	Digoxin	Oral liquid ¹⁷⁶	50 micrograms/mL	4
		Tablet	a) 62.5 micrograms	4
12.4.3	Furosemide		b) 250 micrograms	4
		a) Injection	10mg/mL (2mL amp)	4
		b) Oral liquid [c]	20mg/5mL	4
		c) Tablet (scored)	40mg	4
12.4.4	Hydrochlorthiazide	Tablet (scored)	25mg	4
12.4.5	Spironolactone	Tablet (scored)	25mg	4
Specialist List				
12.4.6	Dopamine HCl ¹⁷⁷	Injection	40mg/mL (5mL vial)	

¹⁷¹ Only for IV use in ICU

¹⁷² *Alert* Note the strength and presentation for this indication - equivalent to 0.01% or 1 in 10,000 - this is 1/10 of the strength of the other form of epinephrine (adrenaline) listed elsewhere; must be diluted for paediatric use

¹⁷³ As besylate, maleate or mesylate

¹⁷⁴ As hydrogen maleate

¹⁷⁵ Only use for hypertension in pregnancy

¹⁷⁶ Measure doses with graduated pipette provided

KEML 2016

#	Drug	Dose-form	Size/strength	Level
12.5 Antithrombotics ¹⁷⁸				
12.5.1 Antiplatelets				
12.5.1.1	Aspirin	Tablet	75mg	4
Specialist List				
12.5.1.2	Clopidogrel	Tablet	75mg	
12.6 Lipid-lowering agents				
12.6.1	Atorvastatin ¹⁷⁹	Tablet (scored)	20mg	4
13. DERMATOLOGICALS (topical)				
13.1 Antifungals				
13.1.1	Clotrimazole	Cream	1% (15g)	1
13.1.2	Terbinafine HCl ¹⁸⁰	Cream	1% (15g)	4
13.2 Anti-infectives				
13.2.1	Aciclovir	Cream	5% (5g)	3
13.2.2	Fusidic acid ¹⁸¹	Ointment	2% (15g)	4
13.2.3	Silver sulphadiazine ¹⁸²	Cream	1% (250g)	2
Specialist List				
13.2.4	Mupirocin ¹⁸³	Ointment	2% (15g)	
13.3 Anti-inflammatories and antipruritics				
13.3.1	Betamethasone ¹⁸⁴	Ointment	0.1% (15g) (as valerate)	4
13.3.2	Crotamiton	Cream	10% (30g)	2
13.3.3	Desonide	Gel	0.05% (60g)	2
13.3.4	Hydrocortisone acetate	Ointment	1% (15g)	2
13.3.5	Mometasone furoate	Ointment	0.1% (30g)	3
Specialist List				
13.3.2	Clobetasone butyrate	Ointment	0.05% (30g)	
13.3.7	Tacrolimus (as monohydrate)	Ointment	a) 0.03% (30g)	
			b) 0.1% (30g)	
13.4 Astringents				
None selected				
13.5 Medicines affecting skin differentiation & proliferation				
13.5.1	Benzoyl peroxide	Gel	5% (30g)	3

¹⁷⁷ Only for use in ICU

¹⁷⁸ See also Section 10.2 Medicines affecting coagulation

¹⁷⁹ Use only in high-risk patients; simvastatin may be used as an alternative

¹⁸⁰ Use only for refractory infections

¹⁸¹ Use only for <10 days; sodium fusidate cream 2% may also be available/used

¹⁸² Use only in patients >2mths

¹⁸³ Use only for prevention of local infection in performing dialysis procedures

¹⁸⁴ Avoid use in neonates (hydrocortisone cream preferred)

KEML 2016

#	Drug	Dose-form	Size/strength	Level
13.5.2	Coal tar + salicylic acid	Ointment	2% + 2% (100g)	4
13.5.3	Podophyllum resin	Solution (in benzoin tincture)	15% (15mL)	3
13.6 Scabicides and pediculocides				
13.6.1	Benzyl benzoate	Lotion	25% ¹⁸⁵ (50mL)	2
13.6.2	Crotamiton	Cream	10% (30g)	2
13.6.3	Ivermectin	Tablet (scored)	6mg	4
13.7 Medicines for jiggers¹⁸⁶				
13.7.1	Benzyl benzoate	Lotion	25% (50mL)	2
13.7.2	White soft paraffin ¹⁸⁷	Topical application	100%	2
13.8 Sunscreen preparation				
13.8.1	Sunscreening agent/s ¹⁸⁸	Cream or lotion	UVB-SPF 30+	1
14. DIAGNOSTIC AGENTS				
14.1 Ophthalmic diagnostics				
14.1.1	Fluorescein	Test strip	0.6mg	4
14.1.2	Tropicamide	Eye drops	1%	4
14.2 Radiocontrast media¹⁸⁹				
<i>Specialist List</i>				
14.2.1	Amidotrizoate	Injection (solution for IV infusion)	140-420mg iodine/mL (as sodium or meglumine salt)	
14.2.2	Barium sulphate	Suspension (aq)	20-200%	
14.2.3	Iohexol	Injection (solution for IV infusion)	140-350mg iodine/mL	
14.2.4	Iopromide	Injection (solution for IV infusion)	150-370mg iodine/mL	
14.2.5	Meglumine iotroxate	Injection (solution for IV infusion)	5g iodine in 100mL bottle ¹⁹⁰	
14.3 MRI contrast media¹⁹¹				
<i>Specialist List</i>				
14.3.1	Gadobutrol	IV injection solution	1 mmol/mL ¹⁹²	
14.3.2	Gadodiamide	IV injection solution	0.5 mmol/mL ¹⁹³	

¹⁸⁵ Adult strength: dilute with equal volume of water to obtain 12.5% for paediatric use

¹⁸⁶ Tunga penetrans infestation; use both medicines in combination therapy

¹⁸⁷ Also called petroleum jelly or white petrolatum

¹⁸⁸ Must protect against both UVA and UVB; various preparations may be available

¹⁸⁹ Required presentations to be selected by the radiologist

¹⁹⁰ Equivalent to 105mg/mL

¹⁹¹ Required presentations to be selected by the radiologist

¹⁹² Equivalent to 604.72mg/mL

KEML 2016

#	Drug	Dose-form	Size/strength	Level
14.3.3	Gadopentate dimeglumine	IV injection (solution)	0.5 mmol/mL ¹⁹⁴	
15. ANTISEPTICS and DISINFECTANTS				
15.1 Antiseptics				
15.1.1	Chlorhexidine	a) Solution for dilution	5% (digluconate)	2
		b) Gel [c] ¹⁹⁵	4% (as digluconate 7.1%)	2
15.1.2	Ethanol	Solution	70% (denatured)	2
15.1.3	Povidone iodine	Solution	10% (equiv. to iodine 1%)	2
15.2 Disinfectants				
15.2.1	Alcohol-based hand rub	Solution	Isopropyl alcohol 75% (500mL dispenser)	1
15.2.2	Glutaral ¹⁹⁶	Solution	2%	2
15.2.3	Sodium hypochlorite	Solution ¹⁹⁷	4-6% chlorine ¹⁹⁸	1
16. DIURETICS				
16.1	Amiloride HCl	Tablet	5mg	4
16.2	Furosemide	a) Injection	10mg/mL (2mL amp)	4
		b) Oral liquid [c]	20mg/5mL	4
		c) Tablet (scored)	40mg	4
16.3	Hydrochlorthiazide	Tablet (scored)	25mg	4
16.4	Mannitol	Injection solution	20%	4
16.5	Spironolactone	Tablet	25mg	4
Specialist List [c]				
16.6	Hydrochlorthiazide	Tablet (scored)	25mg	
16.7	Spironolactone	Tablet	25mg	
16.8	Mannitol	Injection solution	20%	
17. GASTROINTESTINAL MEDICINES				
17.1 Antacids and other antiulcer medicines				
17.1.1	Lansoprazole [c]	Dispersible tablet	15mg	4
17.1.2	Omeprazole	a) Capsule	20mg	4

¹⁹³ Equivalent to 287mg/mL

¹⁹⁴ Equivalent to 469.01mg/mL

¹⁹⁵ Use only for umbilical cord care; ensure that it is not mistakenly used as an eye ointment

¹⁹⁶ Previously called glutaraldehyde

¹⁹⁷ Use within 6 months of date of manufacture; use only freshly made dilutions

¹⁹⁸ Provides approximately 50,000 ppm available chlorine

KEML 2016

#	Drug	Dose-form	Size/strength	Level
17.1.2	Omeprazole	b) PFI (as sod. salt)	40mg vial	4
17.2 Antiemetics				
17.2.1	Dexamethasone	Injection	4mg/1mL amp (as sodium phosphate)	4
17.2.2	Domperidone ¹⁹⁹	a) Oral liquid	5mg/5mL	4
		b) Tablet	10mg	4
17.2.3	Metoclopramide HCl ²⁰⁰	a) Injection	5mg/mL (2mL amp)	4
		b) Tablet	10mg	2
17.2.4	Ondansetron ²⁰¹	a) Injection	2mg/mL (base, as HCl) (2mL amp)	4
		b) Tablet (orally disintegrating)	4mg (base equivalent)	4
Specialist List				
17.2.5	Dexamethasone	Tablet	500 micrograms	
17.3 Anti-inflammatories				
Specialist List				
17.3.1	Mesalazine	Tablet (e/c)	400mg	
17.3.2	Prednisolone	Tablet	5mg	
17.4 Laxative				
17.4.1	Bisacodyl	a) Tablet	5mg	2
		b) Suppository	10mg	4
17.5 Medicines used in diarrhoea				
17.5.1	Oral rehydration solution (ORS)	PFOL (sachet for 500mL)	WHO low-osmolality formula	1
17.5.2	ORS + zinc sulphate	Co-pack (4 sachets + 10 tablets)	500mL sachets + zinc sulphate tab 20mg (dispersible)	2
17.5.3	Rehydration solution for malnutrition (ReSoMal)	PFOL (sachet for 1L)	WHO formula	4
17.5.4	Zinc sulphate ²⁰² [c]	Tablet (dispersible)	20mg	2

¹⁹⁹ Alternative in patients who cannot tolerate metoclopramide and in young children requiring an oral liquid antiemetic; additional restrictions apply (small increased cardiac toxicity risk)

²⁰⁰ Do not use in neonates

²⁰¹ Use only in patients >1 month

²⁰² Use with ORS in acute diarrhoea

KEML 2016

#	Drug	Dose-form	Size/strength	Level
18. HORMONES, other ENDOCRINE MEDICINES and CONTRACEPTIVES				
18.1 Adrenal hormones and synthetic substitutes				
Specialist List				
18.1.1	Fludrocortisone acetate	Tablet	100 micrograms	
18.1.2	Hydrocortisone	Tablet	5mg	
18.2 Androgens				
18.2.1	Testosterone	Gel	1%	
18.3 Contraceptives				
18.3.1 Oral hormonal contraceptives				
18.3.1.1	Ethinylestradiol + levonorgestrel	Tablet	30 micrograms + 150 micrograms	2
18.3.1.2	Levonorgestrel	Tablet	30 micrograms	2
For emergency contraception				
18.3.1.3	Levonorgestrel	Tablet	750 micrograms (pack of 2)	1
18.3.2 Injectable hormonal contraceptives				
18.3.2.1	Estradiol cypionate + medroxyprogesterone acetate	Injection	5mg + 25mg	2
18.3.2.2	Medroxyprogesterone acetate (DMPA) ²⁰³	a) Depot injection (IM)	150mg/1mL (prefilled syringe)	2
		b) Depot injection (SC) ²⁰⁴	104mg/0.65ml (prefilled syringe)	2
18.3.3 Intrauterine devices (IUD)				
18.3.3.1	Copper-containing device ²⁰⁵			2
18.3.3.2	Levonorgestrel (LNG)	LNG-releasing Intrauterine system (LNG-IUS)	Reservoir with 52mg	2
18.3.4 Barrier methods				
18.3.4.1	Male condom			1
18.3.4.2	Female condom			1
18.3.5 Contraceptive implants ²⁰⁶				
18.3.5.1	Etonorgestrel-releasing	Implant	68mg (1 rod)	2
18.3.5.2	Levonorgestrel-releasing	Implant	150mg (2 x 75mg rods)	2

²⁰³ May be used at Level 1 (Community) in areas with community midwife services

²⁰⁴ May be referred to as DMPA-SC

²⁰⁵ Different registered preparations may be available

²⁰⁶ May be used at Level 1 (Community) in areas with community midwife services

KEML 2016

#	Drug	Dose-form	Size/strength	Level
18.3.6 Intravaginal contraceptive				
18.3.6.1	Progesterone-releasing ²⁰⁷	Vaginal ring	2.074g (micronized)	2
18.4 Estrogens				
18.4.1	Conjugated oestrogens	Tablet	300 micrograms	
18.5 Insulins and other antidiabetics				
18.5.1	Glibenclamide ²⁰⁸	Tablet	5mg	4
18.5.2	Gliclazide ²⁰⁹	Tablet	40mg	4
18.5.3	Insulin, intermediate-acting (human) (70/30) ²¹⁰	Injection	100 IU/mL (10mL vial)	4
18.5.4	Insulin, soluble (human)	Injection	100 IU/mL (10mL vial)	4
18.5.5	Metformin HCl	Tablet	500mg	4
Specialist List [c]				
18.5.5	Insulin, rapid acting ²¹¹	Injection	100 IU/mL (10mL vial)	
18.5.6	Metformin HCl	Tablet	500mg	
18.6 Ovulation inducer				
Specialist List				
18.6.1	Clomifene citrate	Tablet	50mg	
18.7 Progestogens				
Specialist List				
18.7.1	Medroxyprogesterone	Tablet	5mg (acetate)	
18.8 Thyroid hormones and anti-thyroid medicines				
18.8.1	Carbimazole	Tablet	5mg	4
18.8.2	Levothyroxine sodium	Tablet	(a) 25 micrograms [c]	4
			(b) 50 micrograms	4
			(c) 100 micrograms	4
			Specialist List	
18.8.3	Lugol's iodine [c]	Oral liquid	~130mg total iodine/mL	
18.8.4	Propylthiouracil ²¹²	Tablet	50mg	

²⁰⁷ For use in women actively breastfeeding (ie. at least 4 times daily)

²⁰⁸ Do not use for patients >60 years

²⁰⁹ Use only in patients >60 years

²¹⁰ As biphasic isophane insulin (70% isophane insulin + 30% soluble insulin)

²¹¹ Use insulin lispro, insulin aspart or insulin glulisine with selection being made based on local availability and relative cost

²¹² Use as drug of choice (ie. rather than carbimazole) during 1st trimester of pregnancy and in lowest effective dose to control hyperthyroid state

KEML 2016

#	Drug	Dose-form	Size/strength	Level
18.9 Other endocrine medicines				
<i>Specialist List</i>				
18.9.1	Bromocriptine ²¹³	Tablet (scored)	2.5mg (as mesilate)	
19. IMMUNOLOGICALS				
19.1 Diagnostic agents				
19.1.1	Tuberculin, purified protein derivative (PPD) ²¹⁴	Injection (solution)	0.1mL vial (single dose) ²¹⁵	4
19.2 Sera and immunoglobulins				
19.2.1	Snake antivenom immunoglobulin ²¹⁶	PFI + diluent (for IV use)	10mL vial	2
19.3 Vaccines				
Recommended for all				
19.3.1	BCG vaccine (live attenuated)	PFI + diluent	1mL vial (10 doses) ²¹⁷	2
19.3.2	DPT + HiB + HepB vaccine (pentavalent)	Injection (suspension)	5mL vial (10 doses)	2
19.3.3	HPV vaccine ²¹⁸ (2-valent)	Injection (suspension)	1mL vial (2 doses)	2
19.3.4	Measles vaccine ²¹⁹ (live attenuated)	PFI + diluent	5mL vial (10 doses)	2
19.3.5	Measles + rubella vaccine (MR)	PFI + diluent	5mL vial (10 doses)	2
19.3.6	Polio vaccine (IPV)	Injection	5mL vial (10 doses)	2
19.3.7	Polio vaccine, oral (OPV) (live attenuated)	Oral drops	2mL vial (20 doses)	2
19.3.8	Rotavirus vaccine	Oral suspension	1.5mL (single dose)	2
19.3.9	Tetanus toxoid (adsorbed)	Injection (suspension)	20mL vial (10 doses) ²²⁰	2
Recommended for certain high-risk populations				
19.3.10	Cholera vaccine ²²¹	Oral suspension	1.5mL vial (single dose)	2

²¹³ Use for prevention or suppression of lactation

²¹⁴ For Mantoux test

²¹⁵ ≥2TU/0.1mL

²¹⁶ Minimum of 11 species mixture covering *Bitis*, *Naja*, *Echis*, *Dendroaspis* spp

²¹⁷ Dose: adults 0.1mL, child <1 year 0.05mL

²¹⁸ Human papillomavirus vaccine; for school health programme roll-out

²¹⁹ Being phased out globally and in Kenya replaced by MR vaccine in the routine vaccination programme

²²⁰ >40 IU/0.5mL dose

KEML 2016

#	Drug	Dose-form	Size/strength	Level
19.3.11	Hepatitis B vaccine (adult) ²²²	Injection (suspension)	1mL vial (single dose)	4
19.3.12	Meningococcal meningitis vaccine ²²³	PFI + diluent	0.5mL vial (single dose)	2
19.3.13	Pneumococcal vaccine (10-valent ads. conjugate)	Injection (suspension)	1mL vial (2 doses)	2
19.3.14	Rabies vaccine ²²⁴ (cell culture)	PFI + diluent	0.5mL vial (single dose) ²²⁵	2
19.3.15	Typhoid vaccine ²²⁶	Injection (solution)	0.5mL vial (single dose)	2
19.3.16	Varicella vaccine ²²⁷	PFI + diluent	0.5mL vial (single dose)	4
19.3.17	Yellow fever vaccine ²²⁸	PFI + diluent	10mL vial (20 doses) ²²⁹	2
Specialist List				
19.3.18	Pneumococcal vaccine (23-valent adsorbed conjugate) ²³⁰	Injection (suspension)	0.5mL vial (single dose)	
20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) and CHOLINESTERASE INHIBITORS				
20.1	Atracurium besilate	Injection	10mg/mL (5mL amp)	4
20.2	Cisatracurium	Injection (as besilate)	2mg/mL (10mL vial)	4
20.3	Glycopyrronium bromide + neostigmine metilsulfate ²³¹	Injection	500 micrograms + 2.5mg/1mL amp	4
20.4	Neostigmine metilsulfate	Injection	2.5mg/1mL amp	4
20.5	Pancuronium bromide	Injection	2mg/mL (2mL amp)	4
20.6	Suxamethonium chloride	Injection	50mg/mL (2mL amp)	4

²²¹ Use only in management of outbreaks

²²² Use mainly for health providers and their dependants; contains 20 micrograms antigen protein/1mL dose

²²³ Sero-type specific; use for outbreaks, asplenic patients & travellers to affected areas

²²⁴ Human diploid type may also be available & used as a more expensive alternative

²²⁵ Rabies antigen ≥ 2.5 IU/0.5 mL dose when reconstituted as a suspension

²²⁶ Use reserved for specific at risk patients, ie. nephrotics, immunosuppressed patients, travellers to typhoid prevalent areas

²²⁷ Also called chickenpox vaccine

²²⁸ Use only for health-workers during outbreaks & travellers to areas with yellow fever

²²⁹ Contains 1,000 LD₅₀ units/0.5mL dose

²³⁰ Use for patients with sickle-cell disease

²³¹ Use only for reversal of neuromuscular blockade

KEML 2016

#	Drug	Dose-form	Size/strength	Level
21. OPHTHALMOLOGICALS				
21.1 Anti-infectives				
21.1.1	Gentamicin	Eye drops	0.3% (as sulfate)	2
21.1.2	Tetracycline HCl	Eye ointment	1%	1
Specialist List				
21.1.3	Aciclovir	Eye ointment	3%	
21.1.4	Azithromycin dihydrate	Eye drops	1.5%	
21.1.5	Ciprofloxacin	Eye drops	0.3% (as HCl)	
21.1.6	Econazole	Eye drops	1%	
21.2 Anti-inflammatories				
21.2.1	Prednisolone	a) Eye drops	0.5% (sod. phosphate)	4
		b) Tablet	5mg	4
Specialist List				
21.2.2	Prednisolone	Eye drops	1% (acetate)	
21.2.3	Ketorolac trometamol	Eye drops	0.5%	
21.2.4	Methylprednisolone	PFI	1g vial (as sodium succinate)	
21.2.5	Triamcinolone acetonide	Injection ²³² (aq.suspension)	40mg/1mL amp	
21.3 Local anaesthetic				
21.3.1	Tetracaine HCl ²³³	Eye drops	0.5%	4
21.4 Miotics and anti-glaucoma medicines				
21.4.1	Acetazolamide	Tablet	250mg	4
21.4.2	Timolol	Eye drops	0.5% (as hyd. maleate)	4
Specialist List				
21.4.3	Dorzolamide	Eye drops	2% (as HCl)	4
21.4.4	Latanoprost	Eye drops	0.005% ²³⁴	4
21.5 Cycloplegics and mydriatics				
21.5.1	Atropine sulfate ²³⁵	Eye drops	0.5%	4
21.5.2	Tropicamide	Eye drops	0.5%	4
21.6 Anti-allergics				
21.6.1	Sodium cromoglicate	Eye drops	2%	4
21.7 Anti-vascular endothelial growth factor (VEGF)				
Specialist List				
21.7.1	Bevacizumab	Injection	25mg/mL (4mL vial)	

²³² Use as a depot

²³³ Previously called amethocaine; do not use in pre-term neonates

²³⁴ 50 micrograms/mL

²³⁵ Only use in patients >3 months

KEML 2016

#	Drug	Dose-form	Size/strength	Level
22. OXYTOCICS and ANTIOXYTOCICS				
22.1 Oxytocics				
22.1.1	Dinoprostone (Prostaglandin E2)	Vaginal tablet	3mg	4
22.1.2	Ergometrine ²³⁶	Injection	200 micrograms/1mL amp	2
22.1.3	Misoprostol ²³⁷	a) Tablet ²³⁸	200 micrograms	2
		b) Vaginal tablet ²³⁹	25 micrograms	4
22.1.4	Oxytocin	Injection	10 IU/1mL amp	2
Specialist List				
22.1.5	Mifepristone + misoprostol ²⁴⁰	Tablet	200mg + 200 micrograms	4
22.2 Anti-oxytocics (tocolytics)				
22.2.1	Nifedipine	Capsule	10mg (immediate-release)	4
23. DIALYSIS SOLUTIONS				
Specialist List				
23.1.1	Intraperitoneal dialysis solutions (CAPD) ²⁴¹	Parenteral solutions	Of appropriate composition ²⁴²	
23.2.2	Haemodialysis solutions			
24. MEDICINES for MENTAL and BEHAVIOURAL DISORDERS				
24.1 Antipsychotics				
24.1.1	Chlorpromazine HCl	Injection	a) 25mg/mL (2mL amp)	2
		Tablet	b) 50mg	4
			c) 100mg	4
24.1.2	Flupentixol decanoate	Injection (oily, depot)	20mg/mL (2mL amp)	4
24.1.3	Fluphenazine decanoate	Injection (oily, depot)	25mg/1mL amp	4
24.1.4	Haloperidol	a) Injection	5mg/1mL amp	4
		b) Oral liquid ²⁴³	2mg/mL	4

²³⁶ As hydrogen maleate; ensure protection from light (amber ampoules, dark storage)

²³⁷ Use with caution due to narrow safety margin

²³⁸ May be used at Level 1 (Community) in areas with community midwife services

²³⁹ Use only for induction of labour

²⁴⁰ Use only under close supervision

²⁴¹ Continuous ambulatory peritoneal dialysis (fluid)

²⁴² Various dialysis solutions & systems are available & in use; selection of the most appropriate presentations will be made by specialists

KEML 2016

#	Drug	Dose-form	Size/strength	Level
24.1.4	Haloperidol	c) Tablet (scored)	5mg	4
24.1.5	Olanzapine ²⁴⁴	PFI	10mg vial	4
24.1.6	Quetiapine	Tablet	200mg (scored)	4
24.1.7	Zuclopenthixol acetate	a) Injection (oily)	50mg/mL (2mL amp)	4
		b) Injection (depot, oily) ²⁴⁵	200mg/1mL amp	4
Specialist List				
24.1.7	Chlorpromazine HCl [c]	Injection	25mg/mL (2mL amp)	
24.1.8	Clozapine	Tablet (scored)	a) 25mg	
			b) 100mg	
24.1.9	Haloperidol [c]	a) Injection	5mg/1mL amp	
		b) Tablet (scored)	5mg	
24.1.10	Risperidone	Tablet	2mg (scored)	
24.2 Medicines used in mood disorders				
24.2.1 Medicines use in depressive disorders				
24.2.1.1	Amitriptyline HCl	Tablet	25mg	4
24.2.1.2	Fluoxetine	Tablet (scored)	20mg (as HCl)	4
Specialist List				
24.2.1.3	Fluoxetine ²⁴⁶ [c]	Tablet (scored)	20mg (as HCl)	
24.2.1.4	Venlafaxine	Capsule	75mg (as HCl)	
24.2.2 Medicines used in bipolar disorders				
24.2.2.1	Carbamazepine	Tablet	200mg (cross-scored)	4
24.2.2.2	Valproic acid (sodium valproate)	Tablet (enteric-coated)	a) 200mg	4
			b) 500mg	4
Specialist List				
24.2.2.2	Lithium carbonate	Tablet	400mg (modified release)	
24.3 Medicines used in anxiety disorders				
24.3.1	Bromazepam ²⁴⁷	Tablet (scored)	3mg	4
24.4 Medicines used in obsessive compulsive disorders				
24.4.1	Clomipramine HCl	Capsule	25mg	4
24.5 Medicine used in disorders due to psychoactive substance abuse				
24.5.1	Diazepam ²⁴⁸	Tablet	5mg	4

²⁴³ Drops with dosing pipette

²⁴⁴ Use only in patients refractory to, or intolerant of, 1st generation antipsychotics

²⁴⁵ Use only in patients refractory to, or unable to tolerate, other antipsychotics

²⁴⁶ Only use in patients >8 years

²⁴⁷ Only use in anxiety with agitation

²⁴⁸ Only use in management of alcohol dependence

KEML 2016

#	Drug	Dose-form	Size/strength	Level
24.5.2	Nicotine ²⁴⁹	Chewing gum	a) 2mg b) 4mg	4 4
Specialist List ²⁵⁰				
24.5.3	B vitamins, high potency	a) Injection IM b) Injection IV	7mL (in 2 amps) ²⁵¹ 10mL (2 x 5mL amps) ²⁵²	
24.5.4	Buprenorphine + naloxone (both as HCl)	Tablet (sublingual)	a) 2mg + 500 micrograms b) 8mg + 2mg	
24.5.5	Methadone HCl	Oral liquid	5mg/mL (concentrate)	
24.5.6	Naltrexone HCl	Tablet	50mg	
24.6 Medicine used in attention deficit hyperactivity disorder (ADHD)				
24.6.1	Methylphenidate ²⁵³	Tablet	10mg	4
25. MEDICINES for RESPIRATORY DISORDERS				
25.1 Anti-asthmatics and medicines for chronic obstructive pulmonary disease				
25.1.1	Beclometasone dipropionate ²⁵⁴	Inhalation (aerosol)	100 micrograms/ metered dose	4
25.1.2	Epinephrine (adrenaline)	Injection	1mg/1mL amp ²⁵⁵	2
25.1.3	Salbutamol (as sulphate)	a) Inhalation (aerosol)	100 micrograms/ metered dose	4
		b) Injection	50 micrograms/mL (5mL amp)	4
		c) Nebuliser solution	5mg/mL	2
Specialist List				
25.1.5	Formoterol fumarate + budesonide	Dry powder inhaler	6 micrograms + 200 micrograms/metered dose	
25.1.6	Ipratropium bromide	a) Inhalation (aerosol)	20 micrograms/metered dose	
		b) Nebuliser solution	250 micrograms/1mL unit dose vial (isotonic)	
25.1.7	Montelukast (as sodium salt)	a) Granules	4mg sachet	
		b) Tablet	10mg	

²⁴⁹ As polacrilex (polacrillin complex)

²⁵⁰ Use under close supervision within substance dependency treatment programmes

²⁵¹ Ascorbic acid 500 mg, nicotinamide 160 mg, pyridoxine hydrochloride 50 mg, riboflavin 4 mg, thiamine hydrochloride 250mg/7mL

²⁵² Ascorbic acid 500 mg, nicotinamide 160 mg, pyridoxine hydrochloride 50 mg, riboflavin 4 mg, thiamine hydrochloride 250mg/10mL

²⁵³ Use should be strictly controlled and actively monitored

²⁵⁴ Budesonide inhalation 100 micrograms/metered dose is an available alternative

²⁵⁵ As hydrochloride or hydrogen tartrate; strength also expressed as 0.1% or 1 in 1,000

KEML 2016

#	Drug	Dose-form	Size/strength	Level
26. SOLUTIONS CORRECTING WATER, ELECTROLYTE and ACID–BASE DISTURBANCES				
26.1 Oral				
26.1.1	Oral rehydration solution (ORS)	PFOL (to make 500mL)	Sachet (WHO low-osmolality formula)	1
26.1.2	ORS + zinc sulphate	Co-pack	500mL sachets (4) + zinc sulphate tablets (disp.) 20mg (10)	2
26.1.3	Rehydration solution for malnutrition (ReSoMal)	PFOL (to make 1L)	Sachet (42g) (WHO formula)	4
26.2 Parenteral				
26.2.1	Glucose	Injectable solution	a) 5% (isotonic) (500mL infusion pack)	2
			b) 10% (hypertonic) (500mL infusion pack)	2
			c) 50% (hypertonic) (50mL amp) ²⁵⁶	4
26.2.2	Potassium chloride	a) Injectable solution	11.2% (20mL amp) ²⁵⁷	4
		b) Injectable solution for dilution [c]	15% (10mL amp) ²⁵⁸	4
26.2.3	Sodium chloride	Injectable solution (infusion)	0.9% (isotonic) (500mL) ²⁵⁹	2
26.2.4	Sodium hydrogen carbonate (bicarbonate)	Injectable solution	8.4% (10mL amp) ²⁶⁰	2
26.2.5	Sodium lactate compound ²⁶¹	Injectable solution (infusion)	BP formula ²⁶² (500 mL)	2
Specialist List [c]				
26.2.6	Sodium chloride	Injectable solution	3% (hypertonic) ²⁶³ (10mL amp)	

²⁵⁶ Use only in dialysis, ICU and other central line fluids enhancement

²⁵⁷ Equivalent to K⁺ and Cl⁻ 1.5 mmol/mL

²⁵⁸ Equivalent to K⁺ and Cl⁻ 2 mmol/mL

²⁵⁹ Equivalent to Na⁺ and Cl⁻ 154 mmol/L

²⁶⁰ Equivalent to Na⁺ and HCO₃⁻ 1,000 mmol/L

²⁶¹ Ringer's lactate, Hartmann's solution

²⁶² Equivalent to Na⁺ 131, K⁺ 5, Ca²⁺ 2, Cl⁻ 111, HCO₃⁻ (as lactate) 29 mmol/L

²⁶³ Equivalent to Na⁺ and Cl⁻ 513 mmol/L; use in bronchiolitis, and in hyponatremia in renal conditions in children

KEML 2016

#	Drug	Dose-form	Size/strength	Level
26.3 Other				
26.3.1	Water for injection	Injection	10mL amp	2
27. VITAMINS and MINERALS				
27.1	Calcium carbonate	Tablet (chewable)	1.25g ²⁶⁴	4
27.2	Calcium gluconate	Injection	100mg/mL (10%) (10 mL amp)	4
27.3	Cholecalciferol (Vit D ₃)	Oral liq. (drops) [c]	400 IU/mL ²⁶⁵	4
27.4	Ergocalciferol (Vit D ₂)	Tablet	1.25mg (50,000 IU)	4
27.5	Pyridoxine HCl (Vit B ₆) ²⁶⁶	Tablet (scored)	50mg	4
27.6	Retinol (Vit A) (as palmitate)	Capsule	a) 100,000 IU	2
			b) 200,000 IU	2
27.7	Thiamine HCl (Vit B ₁) ²⁶⁷	Tablet	50mg	4
<i>Specialist List</i> ^[c]				
27.8	Cholecalciferol (Vit D ₃) ²⁶⁸	Injection IM (oily)	300,000 IU/1mL amp	
28. EAR and NOSE MEDICINES				
28.1 Ear medicines				
28.1.1	Ciprofloxacin HCl	Solution (ear drops)	0.3%	2
28.1.2	Hydrogen peroxide ²⁶⁹	Solution (ear drops)	3%	3
<i>Specialist List</i> ²⁷⁰				
28.1.3	Ciprofloxacin HCl + betamethasone sodium	Solution (ear drops)	0.3% + 0.1%	
28.1.4	Clotrimazole	Solution (ear drops)	1%	
28.2 Nose medicines				
28.2.1	Liquid paraffin	Nasal drops	100%	2
28.2.2	Sodium chloride	Solution (nasal drops)	0.9%	2
<i>Specialist List</i> ²⁷¹				
28.2.3	Budesonide	Nasal spray	100 micrograms/metered dose	

²⁶⁴ Equivalent to calcium (elemental) 500mg (Ca²⁺ 12.5 mmol)

²⁶⁵ Equivalent to 10 micrograms/mL

²⁶⁶ Only use in TB patients for isoniazid-induced neuropathy

²⁶⁷ Only use in alcohol withdrawal and properly diagnosed vitamin B deficiency

²⁶⁸ Use only where oral therapy not tolerated or adherence likely to be poor

²⁶⁹ This 3% strength is also expressed as '10-volume'. If the ear drops are unavailable, use other available forms & strengths and dilute as required to 3% for use as ear drops

²⁷⁰ Specialists here include Clinical Officer specially trained in ENT

²⁷¹ Specialists here include Clinical Officer specially trained in ENT

#	Drug	Dose-form	Size/strength	Level
29. SPECIFIC MEDICINES for NEONATAL CARE				
29.1 Medicines administered to the neonate [c]				
29.1.1	Chlorhexidine gluconate ²⁷²	Gel	7.1% (3g tube)	2
<i>Specialist List</i>				
29.1.2	Caffeine citrate	a) Injection b) Oral liq. (drops)	20mg/mL ²⁷³ (3mL vial) 20mg/mL	
29.1.3	Ibuprofen	Injection solution	5mg/mL (2mL amp)	
29.1.4	Prostaglandin E ₁ (alprostadil)	Injection solution	500 micrograms/1 mL amp (in alcohol)	
29.1.5	Surfactant	Suspension for intra-tracheal instillation	25mg/mL ²⁷⁴ or 80mg/mL ²⁷⁵	
29.2 Medicines administered to the mother				
29.2.1	Dexamethasone ²⁷⁶	Injection	4mg/mL (as sodium phosphate)	2
30. MEDICINES used in JOINT DISEASES				
30.1 Medicine for gout				
30.1.1	Allopurinol	Tablet (scored)	300mg	4
30.2 Disease-modifying agents used in rheumatoid disorders (DMARDs)				
30.2.1	Chloroquine	Tablet	150mg (phosphate or sulphate)	4
<i>Specialist List</i>				
30.2.2	Azathioprine	Tablet	50mg	
30.2.3	Leflunomide ²⁷⁷	Tablet	20mg	
30.2.4	Methotrexate	Tablet	2.5mg	
30.2.5	Sulfasalazine	Tablet	500mg	
30.3 Juvenile joint disease				
30.3.1	Aspirin ²⁷⁸	Tablet (scored)	300mg	4

²⁷² Use for umbilical cord care; delivering chlorhexidine 4% (avoid use of other presentations which resemble eye ointment)

²⁷³ Equivalent to 10mg caffeine base/mL

²⁷⁴ Beractant (bovine lung extract) (4mL single-use vial)

²⁷⁵ Poractant alpha (porcine lung phospholipid fraction) (1.5mL vial)

²⁷⁶ At Level 2, only for use by trained midwives in management of pre-term labour in Focused Antenatal Care (FANC) clinics

²⁷⁷ Use only when methotrexate and sulfasalazine cannot be used

²⁷⁸ Use in treatment of acute or chronic rheumatic fever, juvenile arthritis, Kawasaki disease

KEML 2016

#	Drug	Dose-form	Size/strength	Level
31. PREPARATIONS for PARENTERAL NUTRITION				
Specialist List				
31.1	Amino acids ²⁷⁹	Infusion	a) 5-6% with glucose [c] (100mL bottle) b) 10% (with electrolytes) (500mL bottle)	
31.2	Fat (lipid) ²⁸⁰	Infusion (emulsion)	a) 10% (500mL) b) 20% (100mL [c] & 500mL)	
31.3	Total parenteral nutrition (TPN) (amino acids + lipids + glucose + electrolytes)	Infusion (emulsion) (triple-chamber)	Composition & size according to specialist requirements	
32. PREPARATIONS for MANAGING SEVERE ACUTE MALNUTRITION				
Specialist List				
32.1	Ready to use therapeutic food (RUTF) ²⁸¹	Oral paste	Standard formula (500 kcal sachet)	
32.2	F-75 therapeutic milk ²⁸²	PFOL (for approx. 600mL)	Standard formula (102.5g sachet)	
32.3	F-100 therapeutic milk ²⁸³		Standard formula (114g sachet)	
33. MEDICINES for other CONDITIONS				
Specialist List				
33.1	Levamisole ²⁸⁴	Tablet	50mg (as HCl)	

²⁷⁹ Required product/composition to be determined by the specialist

²⁸⁰ Required product/presentation to be determined by the specialist

²⁸¹ Micronutrient-fortified peanut/milk paste providing 500 kcal per sachet

²⁸² Micronutrient-fortified milk powder for reconstitution with water; also known as Formula 75, or Phase 1 (stabilisation phase) Therapeutic Milk

²⁸³ Micronutrient-fortified milk powder for reconstitution with water; also known as Formula 100, or Phase 2 (rehabilitation phase) Therapeutic Milk

²⁸⁴ Use in treatment of nephrotic syndrome

Annex 1: Contributors to KEML 2016

Development

Following is a list of those who contributed to the various stages of KEML 2016 development as described on p.x indicating their position or area of expertise and place of work.

The National Medicines & Therapeutics Committee (NMTC 2014)

Dr Izaq Odongo	MoH, Head of DCRHS (Chair)
Dr Sarah Chuchu	MoH, Pharmaceutical Services (Secretary)
Dr Esther Ogara	MoH, Research
Dr Priscilla S Migiro	MoH, Specialised Clinical Services
Mr Micah Kisoo	MoH, General Clinical Services
Dr Josphat Mbuva	MoH, Pharmaceutical Services
Mr Fredrick Omiah	MoH, Nursing Services
Mr Francis Mwalloh	MoH, Medical Laboratory Services
Dr Elizabeth Onyiego	MoH, Oral Health Services

The Technical Working Group on KEML Review & Update

Dr Annah Wamae	Head, MoH, DFH	MoH (Chair)
Dr Josphat N Mbuva	Pharmacist (MSS)	MoH/PSU (Secretary)
Dr Chris Forshaw	Sen. Pharm. Adviser	MoH/PSU (Editor)
Dr Oduor Onyango	Pharmacist (MMU)	County HS, Garissa
Dr Bernard Makenzie	Pharmacist (MMU)	County HS, Kwale
Dr Edward Abwao	Pharmacist (MRA)	PPB
Dr John Aduda	Pharmacist (MPU)	KEMSA
Dr Jane Masiga	Pharmacist (MPU)	MEDS
Ms Teresia Kimita	Nurse (PHC)	County HS, Nairobi
Ms Veronica Wanjohi	Clinical Medicine Practitioner (PHC)	County HS, Nairobi
Dr Irene Weru	Clinical Pharmacist (Oncology)	KNH
Dr Beatrice Jakait	Pharmacist (HSCM)	MTRH
Dr Enoch Omongi	Internal Medicine Specialist/Lecturer	KNH/UoN

KEML 2016

Dr Joseph Mbuthia	Paediatric Specialist	Private Clinic, NBI
Prof Grace Irimu	Paediatric Specialist/ Lecturer	KNH/UoN/KEMRI
Dr David Githanga	Paediatric Specialist (Cardiology)	Nairobi Hosp/ KPA Chair
Dr Victor Sumbi	Pharmacist (HCM)	MSH/HCMP

Notes on areas of pharmaceutical expertise: HCM = health commodity management, HSCM = hospital supply chain management, MPU = medicines procurement & utilisation, MMU = medicines management & use, MRA = medicines regulation & assessment, MSS = medicines supply system

Other contributors

Dr Tom Menge	Chief Pharmacist/ Toxicology Specialist	KNH
Dr Susan Mutua	Clinical Pharmacist	KNH
Dr Rachel Nyamai	Paediatric Specialist	MoH, NCAHU (Head)
Dr Mariam Tatu Mwanje	Neglected Tropical Diseases Specialist	MoH, NTDU
Dr Sultani H Matendechero	Clinical Pharmacist	MoH, NTDU
Dr Michael Gichangi	Ophthalmology Specialist	MoH, Ophthalmic Services (Head)
Dr Monicah Bitok	Ophthalmology Spec.	Kikuyu Hospital
Denis Osiago	Ophthalmic Nurse	MoH, OPU
Jane Musyoka	Ophthalmic CO	KNH
Dr Zipporah Ali	Palliative Care Spec.	KEHPCA (Exec.Dir)
Dr Esther Muinga	Palliative Care Spec.	KEHPCA
Dr Asaph Kinyajui	Palliative Care Spec.	KEHPCA
Dr Esther Nafula	Palliative Care Spec.	KEHPCA
David Musyoki	Palliative Care (Nursing)	KEHPCA
Dr Simon Njuguna	Mental Health Spec.	MoH, Mental HU (Head)
Dr Catherine Syengo Mutisya	Mental Health Spec.	MoH, Mental HU
Dr Fredrick Owiti	Mental Health Spec.	Chiromo Lane MC
Dr RV Wamuhoma	Mental Health Spec.	Mathari NTRH, NBI

KEML 2016

Dr Josphine Omondi	Mental Health Spec.	KNH
Dr Beatrice Ogola	Clinical Pharmacist	Mathare Hosp, NBI
Dr Dorothy Memusi	Pharmacist	MoH, Malaria CU
Dr David Otieno	Anaesthetic Specialist	Nairobi Hosp/KSA
Dr Jacqueline Andhaga	Anaesthetic Specialist	Mama Lucy Kibaki Hospital, NBI
Dr Phenina N Kitili	Anaesthetic Specialist	KNH
Dr Hosea Waweru	Dermatology Specialist	Upper Hill MC, NBI
Prof Nicholas Othieno-Abinya	Oncology Specialist	KNH/UoN
Prof William Macharia	Oncology Specialist	AKU Hospital, NBI
Dr Fredrick Chite	Oncology Specialist	MTRH
Prof Jessie Githanga	Haematology/ Oncology Specialist	KNH/UoN
Prof Isaac M Macharia	ENT Specialist	KNH/UoN
Dr Thomas Mutie	GI Specialist	KNH
Dr John Ngigi	Renal Specialist	KNH
Diviner K Nyarera	Renal Spec. (Nursing)	KNH
Dr Patrick Mburugu	Urology Specialist	KNH
Dr Renson Mukhwana	Paediatric Endocrinology Spec.	Gertrude's Children's Hospital
Dr Kennedy Gogo	Internal Medicine Spec.	Nakuru L5 Hospital/ Egerton University
Dr Richard Muthoka	Clinical Pharmacist	MoH, TB & Lep. CU
Dr Irene Mukui	HIV Specialist	MoH, NASCOP/CTP (Head)
Dr Susan Njogo	Pharmacist	MoH, NASCOP
Dr Jonah Maina	Pharmacist	MoH, RH Unit
Dr Bartilol Kigen	Gynaecology Spec.	MoH, RH Unit
Mr Charles Mburu	Imaging Specialist	MoH, Radiology Unit
Dr Daniel Tewolde	Nutritional Feeding Sp.	UNICEF, Kenya
Dr Ndinda Kusu	Pharmacist/PH Spec.	MSH/HCMP
Dr Regina Mbindyo	Country Medicines Adviser	WHO

Contributors Abbreviations & Acronyms

AKU	Aga Khan University
CO	Clinical Officer
Cons.	Consultant
CTP	HIV Care & Treatment Programme (under NASCOP)
CU	Control Unit
DCAH	Division of Child and Adolescent Health
DCP	Deputy Chief Pharmacist
DCRHS	Department of Clinical & Rehabilitative Health Services
DFH	Division of Family Health
DLTLD	Division of Leprosy, Tuberculosis and Lung Disease
DOMC	Division of Malaria Control
DSRS	Department of Standards and Regulatory Services
GI	Gastrointestinal
HCMP	Health Commodities Management Programme
HS	Health Services
HU	Health Unit
Int.	Internal
KEMRI	Kenya Medical Research Institute/Wellcome Trust
KEMSA	Kenya Medical Supplies Agency
KEHPCA	Kenya Hospices & Palliative Care Association
KMA	Kenya Medical Association
KNH	Kenyatta National Hospital
KPA	Kenya Paediatric Association
KSA	Kenya Society of Anaesthetists
L5	Level 5
Lep	Leprosy
MC	Medical Centre
MEDS	Mission for Essential Drugs and Supplies
MoH	Ministry of Health
MSH	Management Sciences for Health
MTRH	Moi Teaching & Referral Hospital, Eldoret
NASCOP	National AIDS & STI Control Programme
Nat	National

KEML 2016

NBI	Nairobi
NCAHU	Neonatal, Child & Adolescent Health Unit
NTDU	Neglected Tropical Diseases Unit
NTRH	National Teaching & Referral Hospital
Pharm	Pharmaceutical
PHC	Primary Health Care
PPB	Pharmacy & Poisons Board
PSU	Pharmaceutical Services Unit
QA	Quality Assurance
RH	Reproductive Health
Spec or Sp	Specialist
Trop	Tropical
UoN	University of Nairobi
WHO	World Health Organization

Annex 2: References

1. *The Selection and Use of Essential Medicines* 20th Report of the WHO Expert Committee (including the 19th WHO Model List of Essential Medicines and the 5th WHO Model List of Essential Medicines for Children) WHO Technical Report Series #994, 2015 (available at http://apps.who.int/iris/bitstream/10665/189763/1/9789241209946_eng.pdf)
This is commonly referred to as the WHO Model List and is the prime reference and evidence base for the KEML.
2. *British National Formulary (BNF) 71 (March 2016)* BMJ Publishing Group and Royal Pharmaceutical Society (book and eBook)
Used to obtain information on available drug presentations and prices.
3. *Kenyatta National Hospital Formulary*, Kenyatta National Hospital (2013)
Used to obtain information on the medicines presentations currently in use at the national referral hospital in Nairobi.
4. *Kenya Drug Index 14th edition (2015-16)* ePharmacy.co.ke (available at <http://www.epharmacy.co.ke/product/kenya-drug-index-hard-copy-book-14th-edition/>)
Used to obtain information on locally available drug presentations and prices.
5. *KEMSA Customer Order Form (current version April 2015)* Kenya Essential Medical Supplies Authority, Nairobi
Used to obtain information on local (public sector) medicines presentations availability and prices.
6. *MEDS Catalogue 2016*, Mission for Essential Drugs & Supplies, Nairobi
Used to obtain information on local (FBO sector) medicines presentations availability and prices.
7. *National Guidelines for the Diagnosis, Treatment and Prevention of Malaria In Kenya* 5th edition (draft) Ministry of Health (2016)

KEML 2016

8. *National Policy Guidelines on Prevention and Control of Jigger Infestations* Division of Environmental Health Division of Environmental Health, Ministry of Health (2014)
9. *Algorithms for Managing Common STI Syndromes* National AIDS/STI Control Programme (NASCOP), Ministry of Health (current, undated)
10. *Rapid Advice on Syndromic STI Management in Kenya* National AIDS/STI Control Programme, Ministry of Health (Nov 2015)
11. *WHO Guidelines on the Pharmacological Treatment of Persisting Pain in Children with Medical Illnesses* WHO 2012 (available at http://apps.who.int/iris/bitstream/10665/44540/1/9789241548120_Guidelines.pdf)
12. *Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya*, The Gastroenterology Society of Kenya (2015) (available at <http://apps.who.int/medicinedocs/documents/s21972en/s21972en.pdf>)
13. *National Palliative Care Guidelines*, Ministry of Health (2013) (available at <http://kehpc.org/wp-content/uploads/National-Palliative-Care-Guidelines-02.10.pdf>)
14. *Integrated Management of Childhood Illness (IMCI)*, A guide for healthcare workers, Division of Child and Adolescent Health (DCAH), Department of Family Health, Ministry of Public Health & Sanitation (Aug 2012 edition)
15. *National Policy Guidelines on Immunization 2013*, Division of Vaccines & Immunization, Ministry of Health (available at <http://www.mchip.net/sites/default/files/mchipfiles/Immunization%20Policy%20Guideline.pdf>)
16. *National Family Planning Guidelines for Service Providers*, Division of Reproductive Health, Ministry of Public Health and Sanitation (2010) (available at https://www.k4health.org/sites/default/files/FP%20Guidelines%20for%20Service%20Providers%202010%20_3.pdf)

KEML 2016

17. *National Guidelines for Quality Obstetrics and Perinatal Care*, Ministry of Public Health & Sanitation and Ministry of Medical Services (undated) (available at <https://www.k4health.org/sites/default/files/National%20Guidelines%20for%20Quality%20Obstetrics%20and%20Perinatal%20Care.pdf>)
18. *National Guidelines for Cancer Management Kenya* (August 2013) Ministry of Health (available at <http://kehpc.org/wp-content/uploads/National-Cancer-Treatment-Guidelines2.pdf>)
19. *Guidelines for Management of Tuberculosis and Leprosy in Kenya* (July 2013 edition) Division of Leprosy, Tuberculosis & Lung Disease, Ministry of Health (available at <https://www.medbox.org/guidelines-for-management-of-tuberculosis-and-leprosy-in-kenya/download.pdf>)
20. *National Guidelines on Management of Tuberculosis in Children*, 2nd edition Aug 2013, Division of Leprosy, Tuberculosis & Lung Disease, Ministry of Health (available at <http://apps.who.int/medicinedocs/documents/s21974en/s21974en.pdf>)
21. *Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Rapid Advice*, National AIDS/STI Control Programme (NASCO), Ministry of Health (June 2014) (available at http://healthservices.uonbi.ac.ke/sites/default/files/centraladmin/healthservices/Rapid%20Advice%20Booklet%202014%2024%20June%2012%20noon_o.pdf)
22. *Basic Paediatric Protocols*, 4th edition (Feb 2016), Ministry of Health (available at http://www.tropicalmedicine.ox.ac.uk/_asset/file/basic-paediatric-protocols-2016.pdf)

Annex 3: KEML Amendment Proposal Form

Please complete each of the sections and submit the Form together with hard and/or soft copies of supporting evidence and any other relevant documentation to:

The Chief Pharmacist
Afya House, Cathedral Rd
Box 30016-00100, Nairobi, Kenya
Email: chiefpharmoh@gmail.com

Name of Proposer:

Designation:

Place of Work:

Address:

Tel:

Email:

1. Type of Amendment Proposed (*please tick*):

a) Addition [] b) Deletion []

c) Change of Presentation [] d) Other []

2. Details of Proposal:

>>>

3. Supporting Arguments/Evidence Base:

4. Supporting References/Relevant Documentation:

5. Signature:

6. Date:

Annex 4: Terms of Reference for the TWG on Review & Update of the KEML

- (i) Select medicines for listing on the next revised edition of the Kenya Essential Medicines List
- (ii) Apply essential medicines concepts and the principles of rational selection, affordable pricing and sustainable financing in the review process
- (iii) Make reference to the Constitution of Kenya 2010, Vision 2030, Kenya Health Policy 2014-2030, Kenya National Pharmaceutical Policy (KNPP) and the current World Health Organization (WHO) Model List of Essential Medicines and any other relevant documents in the review process.
- (iv) Adhere to the standard operating procedures (SOP) adopted by the NMTC for the review process including those for managing conflict of interests.
- (v) Engage/consult/collaborate with relevant experts and stakeholders in the review process

Annex 5: The National Medicines & Therapeutics Committee (2014)

Membership²⁸⁵:

1. Director of Medical Services (DMS) (Chair)
2. Head, Pharmaceutical Services/Chief Pharmacist (Secretary)
3. Pharmacist (Pharmaceutical Services/Medicines Supply Chain)
4. Head, Nursing Services
5. Head, Laboratory Services
6. Head, Oral Health Services
7. Head, Specialised Clinical Services
8. Head, General Clinical Services
9. Head, Research Unit
10. Head, Administration

Terms of Reference:

1. Coordinate the development and review of policies on clinical governance and use of medicines & other EHPT²⁸⁶
2. In coordination with the MoH Department of Health Standards, Quality Assurance & Regulation (DHSQAR) develop standards and guidelines on:
 - Establishment and operations of Medicines and Therapeutics Committees at various levels (national, county and institutional)
 - Appropriate prescribing and dispensing
 - Safe and cost-effective use of medicines and other EHPT, including use of evidence-based standardized approaches, adverse event monitoring and reporting, medicines information, and quality assurance
 - Clinical audits and medicines use evaluation studies
3. In coordination with DHSQAR, formulate, review and update all relevant therapeutics guidelines, including the:
 - National Clinical Guidelines
 - National Formulary
 - National Essential Medicines & Medical Supplies (Devices) lists

²⁸⁵ All MoH officers


²⁸⁶ Essential Health Products and Technologies

KEML 2016

4. In collaboration with relevant stakeholders, review medicines and therapeutics research findings and recommend appropriate interventions to inform policy development; identify, propose and commission as appropriate, areas requiring further research
5. Collaborate with the relevant National and County health authorities to plan and implement mitigation measures in the event of emergency disease outbreaks or health threats, e.g. identification of items for inclusion in buffer stocks of EHPT, coordination and use of emergency donations
6. Collaborate with relevant departments involved in the introduction of disease-based or vertical programmes in relation to the selection and use of any medicines and/or other EHPT
7. Increase awareness and understanding of the critical role, functions and activities of the NMTC and advocate for adequate support and funding
8. Provide leadership in improving awareness and education relating to the safe and appropriate use of medicines & other EHPT amongst health care professionals and consumers
9. Provide technical support to county and facility MTCs through the development and dissemination of MTC guidelines, training materials, and capacity building
10. Support the development, review and revision as necessary of pre-service, in-service and CPD training courses in therapeutics and the management and use of medicines and other EHPT
11. Perform any other relevant task as may be assigned by the appointing authority

See over for the **NMTC Organisational Structure**

Organisational Structure



Index

A

Abacavir (ABC), 26, 39
 Abacavir + lamivudine, 14, 40
 Absolute alcohol, 34
 Acetazolamide, 60
 Acetic acid, 29
 Acetylcysteine, 34
 Aciclovir, 14, 39
 cream, 19, 52
 eye, 21, 60
 Activated charcoal, 12, 34
 Adrenaline, 18, 33, 51, 63
 Air, medical, 11
 Albendazole, 12, 35
 Alendronic acid, 44
 Allopurinol, 24, 25, 44, 66
 Alprostadil, 66
 Amethocaine, 60
 Amidotrizoate, 53
 Amikacin, 38
 Amiloride, 54
 Amino acids, 67
 Aminophylline, 25
 Aminosidine, 42
 Amiodarone, 51
 Amitriptyline, 32, 62
 Amlodipine, 51
 Amoxicillin, 13, 26, 36
 Amoxicillin + clavulanic acid, 13, 26, 36
 Amphotericin B, 39, 42
 Ampicillin, 26
 Anastrozole, 17, 47
 Anti-D immunoglobulin, 50
 Anti-rabies immunoglobulin, 50
 Anti-tetanus immunoglobulin, 50
 Artemether, 27
 + lumefantrine, 15, 42
 Artesunate, 15, 42

Ascorbic acid, 29
 Asparaginase, 44
 Aspirin, 24, 32, 43, 52, 66
 Atazanavir + ritonavir, 14, 40
 Atenolol, 28
 Atorvastatin, 19, 52
 Atracurium, 21, 59
 Atropine, 31, 34
 eye, 22, 29, 60
 Azathioprine, 44, 66
 Azithromycin, 37
 eye, 21, 60

B

B vitamins, 23, 63
 Barium sulphate, 53
 BCG vaccine, 58
 Beclometasone inhaler, 63
 Beclomethasone inhalation, 29
 Bedaquiline, 13, 38
 Benzathine benzylpenicillin, 13, 36
 Benzathine penicillin, 26
 Benzhexol, 48
 Benzoyl peroxide, 19, 52
 Benzyl benzoate, 53
 Benzylpenicillin, 26, 36
 Beractant, 66
 Betamethasone (topical), 52
 Bevacizumab, 22, 60
 Bicalutamide, 17, 47
 Biperiden, 28
 Biphasic isophane insulin, 57
 Bisacodyl, 20, 32, 55
 Bleomycin, 44
 Blood (whole), 18, 50
 Bromazepam, 23, 62
 Bromocriptine, 58
 Budesonide (nose), 24, 65
 Budesonide inhalation, 63

Bupivacaine, 25, 31
Buprenorphine + naloxone, 23, 63

C

Caffeine citrate, 66
Calamine, 28
Calcium carbonate, 24, 65
Calcium folinate, 45
Calcium gluconate, 65
Capecitabine, 16, 45
Capreomycin, 13, 38
Carbamazepine, 29, 34, 62
Carbimazole, 57
Carboplatin, 16, 45
Carvedilol, 18, 50, 51
Cefazolin, 13, 36
Cefixime, 36
Ceftazidime, 36
Ceftriaxone, 36
Cefuroxime, 26
Cetirizine, 12, 33
Charcoal (activated), 12, 34
Chickenpox vaccine, 59
Chlorambucil, 45
Chloramphenicol, 26
Chlorhexidine, 19, 54, 66
Chloroquine, 66
Chlorphenamine, 11, 25, 31, 33
Chlorpromazine, 22, 61, 62
Cholecalciferol, 24, 29, 65
Cholera vaccine, 21, 58
Ciclosporin, 15, 44
Ciprofloxacin, 13, 37
 + *betamethasone (ear)*, 24, 65
 ear, 65
 eye, 21, 60
Cisatracurium, 21, 29, 59
Cisplatin, 45
Clarithromycin, 37
Clindamycin, 37
Clobetasone, 19, 52
Clofazamine, 13, 38
Clomifene, 57

Clomipramine, 23, 62
Clonidine, 29
Clopidogrel, 19, 52
Clotrimazole
 ear, 24, 65
 topical, 52
 vaginal, 14, 26, 39
Clozapine, 22, 62
Coagulation factor IX, 50
Coagulation factor VIII, 50
Coal tar, 28
 + *salicylic acid*, 19, 53
Co-amoxiclav, 36
Codeine, 32
Condom (female), 56
Condom (male), 56
Conjugated oestrogens, 20, 57
Copper-containing device (IUD), 56
Cotrimoxazole, 37, 43
Crisantaspase, 44
Crotamiton, 19, 52, 53
Cyanocobalamin, 49
Cyclizine, 25
Cyclophosphamide, 16, 45
Cycloserine, 13, 38
Cytarabine, 45

D

Dacarbazine, 16, 28, 45
Dactinomycin, 45
Dapsone, 27, 38
Darunavir, 14, 40
Daunorubicin, 45
Deferasirox, 12, 18, 34, 49
Deferoxamine, 18, 34, 49
Dehydrated alcohol, 34
Delamanid, 13, 38
Desonide, 19, 52
Dexamethasone, 17, 20, 24, 32, 33, 48, 55, 66
Dextran 70, 28
Diazepam, 11, 12, 23, 25, 26, 29, 32, 35, 62

Diclofenac, 25
 Didanosine, 26
 Diethylcarbamazine, 13, 35
 Diethylstilboestrol, 17, 48
 Digoxin, 50, 51
 Dihydroartemisinin + piperazine, 15, 42
 Diloxanide, 41
 Dimercaprol, 34
 Dimercaptosuccinic acid, 34
 Dinoprostone, 61
 Dithranol, 28
 DMPA-SC, 56
 DMSA, 34
 Docetaxel, 16, 45
 Docusate, 25
 Domperidone, 20, 55
 Dopamine, 51
 Dorzolamide, 22, 60
 Doxorubicin, 16, 46
 Doxycycline, 27, 37, 43
 DPT + HiB + HepB vaccine (pentavalent), 58

E

Econazole (eye), 21, 60
 Efavirenz, 14, 27, 40
 + emtricitabine + tenofovir, 27
 + lamivudine + tenofovir, 14, 40
 Enalapril, 51
 Enoxaparin, 18, 49
 Epinephrine, 18, 33, 51, 63
 eye, 22
 Ergocalciferol, 24, 29
 Ergometrine, 61
 Erythromycin, 26
 Estradiol + medroxyprogesterone, 56
 Estradiol + medroxyprogesterone acetate, 20
 Ethambutol, 26, 38
 Ethanol, 12, 34, 54
 Ethinylestradiol + levonorgestrel, 56
 Ethinylestradiol + norethisterone, 29

Ethosuximide, 26
 Etonorgestrel implant, 56
 Etoposide, 28, 46
 Etravirine (ETV), 40

F

Fat emulsion, 67
 Female condom, 56
 Fentanyl, 11, 32
 Ferrous salt, 17, 48
 + folic acid, 49
 Ferrous sulphate, 48
 Filgrastim, 16, 46
 Finasteride, 17, 48
 Flucloxacillin, 36
 Fluconazole, 39
 Fludrocortisone, 56
 Flumazenil, 12, 34
 Fluorescein, 19, 53
 Fluorouracil, 46
 Fluoxetine, 23, 62
 Flupentixol, 22, 61
 Fluphenazine, 61
 Folic acid, 17, 49
 Fomepizole, 12, 34
 Food (therapeutic), 24, 67
 Formoterol fumarate + budesonide, 23, 63
 Furosemide, 18, 19, 51, 54
 Fusidic acid, 52

G

Gabapentin, 11, 12, 33, 35
 Gadobutrol, 53
 Gadodiamide, 53
 Gadopentate dimeglumine, 54
 Ganciclovir, 15, 41
 Gelatin, 50
 Gemcitabine, 16, 46
 Gentamicin, 37
 eye, 60
 Glibenclamide, 57

Gliclazide, 20, 57
 Glucose, 64
 Glutaral, 54
 Glutaraldehyde, 54
 Glyceryl trinitrate, 50
 Glycopyrronium bromide +
 neostigmine metilsulfate, 21, 59
 Goserelin, 17, 48
 Griseofulvin, 39

H

Haemodialysis solutions, 22, 61
 Haloperidol, 11, 22, 33, 61, 62
 Halothane, 31
 Hand rub, 19, 54
 Heparin, 49
 Hepatitis B vaccine, 59
 HPV vaccine, 58
 Hydralazine, 51
 Hydrochlorthiazide, 51, 54
 Hydrocortisone, 33, 48, 56
 topical, 52
 Hydrogen peroxide (ear), 24, 65
 Hydroxocobalamin, 49
Hydroxycarbamide, 16, 18, 46, 49
Hydroxyurea, 16, 18, 46, 49
 Hyoscine butylbromide, 11, 33
Hyoscine hydrobromide, 25, 33

I

Ibuprofen, 32, 43, 66
Ifosfamide, 16, 46
Imatinib, 16, 46
Imipenem + cilastin, 13, 36
Immunoglobulin
 anti-D, 50
 anti-rabies, 50
 anti-tetanus, 50
 normal, 18, 50
 snake antivenom, 58
Insulin
 aspart, 57

biphasic isophane, 57
glulisine, 57
 intermediate-acting, 57
lispro, 57
 rapid acting, 20, 57
 soluble, 57
Intraperitoneal dialysis solutions, 61
Iohexol, 53
Iopromide, 53
Ipratropium, 23, 63
Irinotecan, 16, 46
 Isoflurane, 11, 31
 Isoniazid, 26, 38
 Isoniazid + ethambutol, 38
 Isosorbide dinitrate, 50
 Ivermectin, 19, 26, 53

K

Kanamycin, 38
 Ketamine, 31
Ketorolac, 21, 60

L

Lactulose, 11, 33
Lamivudine, 39
 + nevirapine + stavudine, 27
 + nevirapine + zidovudine, 41
 + stavudine, 27
 + tenofovir, 14, 41
 + zidovudine, 14, 41
Lamotrigine, 12, 35
Lansoprazole, 19, 54
Latanoprost, 22, 60
Leflunomide, 24, 66
Levamisole, 67
 Levodopa + carbidopa, 17, 48
Levofloxacin, 13, 39
 Levonorgestrel, 20, 56
 implant, 56
 Levothyroxine, 57
 Lidocaine, 11, 31, 50
 + epinephrine, 31

topical, 11, 31
 Lignocaine, 25
 + adrenaline, 25
 dental, 25
 topical, 25
Linezolid, 13, 39
 Liquid paraffin (nasal), 24, 65
 Lithium, 23, 29, 62
 Loperamide, 11, 33
 Lopinavir + ritonavir, 27, 40
 Lorazepam, 12, 35
 Losartan, 18, 51
Lugol's iodine, 21, 57

M

Magnesium sulphate, 35
 Magnesium trisilicate, 28
 Male condom, 56
 Mannitol, 28, 54
 Measle + rubella vaccine, 58
 Measles vaccine, 58
 Medical air, 11, 31
 Medroxyprogesterone acetate, 20, 21, 56, 57
Meglumine iotroxate, 53
Melarsoprol, 43
Melphalan, 16, 46
 Meningococcal meningitis vaccine, 59
Mercaptopurine, 46
Mesalazine, 20, 55
Mesna, 16, 46
 Metformin, 57
Methadone, 63
Methotrexate, 47, 66
 Methyl dopa, 51
 Methylphenidate, 23, 63
Methylprednisolone, 15, 17, 28, 44, 48
 eye, 21, 60
 Metoclopramide, 12, 33, 55
 Metronidazole, 26, 37, 41
 Midazolam, 11, 12, 31, 33
Mifepristone + misoprostol, 61
Milk (therapeutic), 24, 67

Misoprostol, 61
 Mometasone, 19, 52
Montelukast, 23, 63
 Morphine, 11, 25, 32
Moxifloxacin, 13, 39
Mupirocin, 19, 52
Mycophenolic acid, 15, 44

N

Naloxone, 34
Naltrexone, 23, 63
 Neostigmine, 59
Nevirapine (NVP), 40
 Niclosamide, 26
 Nicotinamide, 29
 Nicotine, 23, 63
 Nifedipine, 61
 Nitrofurantoin, 37
 Nitrous oxide, 31
 Norethisterone enantate, 29
Normal immunoglobulin, 18, 50
 Nystatin, 39

O

Ofloxacin, 26
 Olanzapine, 22, 62
 Omeprazole, 19, 54
 Ondansetron, 12, 20, 33, 55
 Oral rehydration solution, 55, 64
 + zinc sulphate, 20, 23, 55, 64
Oxaliplatin, 16, 47
 Oxygen, 31

P

Paclitaxel, 16, 47
p-aminosalicylic acid, 13, 39
 Pancuronium, 21, 59
 Paracetamol, 11, 15, 25, 32, 43
 Paraffin
 liquid (nasal), 24, 65

Paraffin (soft white), 53
 Paromomycin, 42
 PAS, 39
 Pegylated interferon, 15, 41
 Penicillamine, 34
 Pentamidine, 43
 Petroleum jelly, 53
 Phenobarbital, 12, 35
 Phenoxymethylpenicillin, 13, 36
 Phenytoin, 35
 Phytomenadione, 17, 28, 49
 Pilocarpine, 29
 Plasma (fresh frozen), 18, 50
 Platelets, 18, 50
 Pneumococcal vaccine, 21, 59
 Podophyllum resin, 53
 Polio vaccine (IPV), 21, 58
 Polio vaccine oral (OPV), 58
 Polygeline, 18, 50
 Polyvidone iodine (mouthwash), 29
 Poractant, 66
 Potassium chloride, 23, 29, 64
 Povidone iodine, 54
 Pralidoxime, 12, 34
 Pramipexole, 17, 48
 Praziquantel, 35
 Prednisolone, 15, 17, 20, 21, 25, 28, 33, 44, 48, 55
 eye, 21, 60
 Primaquine, 15, 43
 Procarbazine, 47
 Progesterone (vaginal ring), 20, 57
 Promguanil, 15, 43
 Promethazine, 25, 28
 Propofol, 11, 31
 Propranolol, 44
 Propylthiouracil, 21, 57
 Prostaglandin E₁, 66
 Prostaglandin E₂, 61
 Protamine, 12, 34, 49
 Prothionamide, 14, 39
 Pyrazinamide, 38
 Pyridoxine, 24, 29, 65
 Pyrimethamine, 27

Q

Quetiapine, 22, 62
 Quinine, 43

R

Rabies vaccine, 59
 Raltegravir, 14, 40
 Ranitidine, 28
 Red blood cells, 18, 50
 ReSoMal, 20, 23, 55, 64
 Retinol, 65
 Ribavirin, 15, 41
 Rifabutin, 14, 39
 Rifampicin, 38
 + isoniazid, 38
 + isoniazid + ethambutol, 38
 + isoniazid + pyrazinamide, 13, 38
 + isoniazid + pyrazinamide +
 ethambutol, 38
 Risperidone, 22, 62
 Ritonavir, 14, 40
 Rituximab, 16, 47
 Rotavirus vaccine, 21, 58
 RUTF, 24

S

Salbutamol, 29, 63
 Salicylic acid, 28
 Silver sulphadiazine, 52
 Simvastatin, 52
 Snake antivenom immunoglobulin, 58
 Sodium bicarbonate, 29, 64
 Sodium calcium edetate, 34
 Sodium chloride, 64
 hypertonic, 24, 64
 nose, 24, 65
 Sodium cromoglicate, 60
 eye, 22
 Sodium fusidate, 52
 Sodium hydrogen carbonate, 29, 64
 Sodium lactate compound, 64

Sodium nitrite, 12, 34
 Sodium nitroprusside, 51
 Sodium stibogluconate, 42
 Sodium thiosulphate, 12, 34
 Sodium valproate, 23, 35, 62
 Soft paraffin (white), 53
 Spironolactone, 19, 51, 54
 Stavudine, 27
 Streptokinase, 28
 Succimer, 34
 Sulfadoxine + pyrimethamine, 15, 43
 Sulfamethoxazole + trimethoprim, 37
 Sulfasalazine, 28, 66
 Sulphadiazine, 27
 Sunscreening agent, 19, 53
 Suramin, 43
 Surfactant, 66
 Suxamethonium, 59

T

Tacrolimus, 15, 19, 44, 52
 Tamoxifen, 17, 48
 Tamsulosin, 17, 48
 Tenofovir, 15, 27, 41
 Terbinafine, 19, 52
 Testosterone, 20, 56, 57
 Tetanus toxoid (adsorbed), 58
 Tetanus vaccine, 58
 Tetracaine, 60
 Tetracycline, 60
 Thalidomide, 17, 47
 Therapeutic food, 24, 67
 Therapeutic milk, 24, 67
 Thiamine, 65
 Thiopental, 31
 Timolol, 29, 60
 Tinidazole, 13, 37, 42
 Tranexamic acid, 18, 49
 Trastuzumab, 17, 47
 Triamcinolone (eye), 21, 60
 Tropicamide, 22, 53, 60
 Tuberculin (purified protein derivative), 58

Typhoid vaccine, 59

V

Vaccine
 BCG, 58
 chickenpox, 59
 cholera, 21, 58
 DPT + HiB + HepB (pentavalent), 58
 hepatitis B, 59
 HPV, 58
 measles, 58
 measles + rubella, 58
 meningococcal meningitis, 59
 oral polio (OPV), 58
 pneumococcal, 21, 59
 polio, 21
 polio (IPV), 58
 rabies, 59
 rotavirus, 21, 58
 tetanus, 58
 typhoid, 59
 varicella, 21, 59
 yellow fever, 59
 Valproic acid, 23, 35, 62
 Vancomycin, 37
 Varicella vaccine, 21, 59
 Vecuronium, 29
 Venlafaxine, 23, 62
 Verapamil, 18, 28, 51
 Vinblastine, 17, 47
 Vincristine, 28
 Vinorelbine, 17, 47
 Vit D₃, 24
 Vitamin A, 65
 Vitamin B₁, 65
 Vitamin B₃, 29
 Vitamin B₆, 24, 29, 65
 Vitamin D₂, 24, 65
 Vitamin D₃, 24, 65
 Vitamin K₁, 28, 49
 Vitamins B, 23, 63

W

Warfarin, 49
Water for injection, 65
White petrolatum, 53
White soft paraffin, 19, 53
Whole blood, 18, 50

Y

Yellow fever vaccine, 59

Z

Zidovudine, 27
Zinc sulphate, 55
Zoledronic acid, 17, 47
Zuclopenthixol, 22, 62

The **Kenya Essential Medicines List 2016** is an indispensable guide to the medicines recommended for the management of common conditions in Kenya. It is primarily directed at health care providers and medicines supply managers in the public and non-public health sectors. It should be used together with the current versions of updated national clinical guidelines for those conditions for which such guidelines exist.

As technical and administrative guides for the health sector, these documents should also be of great interest and usefulness to healthcare trainers, trainees, interns and researchers as well others who may have an interest in, or responsibility for, the national health system.

The medicines recommended in the KEML have been carefully and systematically selected using a meticulous process, applying well-defined criteria and based on the latest available and internationally accepted evidence on best therapeutic practice.

Therefore, they are the optimum set of medicines needed to ensure provision of the Kenya Essential Package for Health (KEPH), which is part of the sector's comprehensive approach for health services delivery to the population. The KEML is published in the context of ongoing health reforms aimed at *reversing the declining trends in the national health status*, by ensuring equitable access to healthcare services.

The KEML is an indispensable guide for ensuring access to Essential Medicines, aimed at stimulating investment in local pharmaceutical production, procurement and supply systems, improved prescribing and dispensing of medicines, as well as strategies for healthcare financing and for Appropriate Medicines Use (AMU). Routine use as recommended can be expected to have a major positive impact on the health status of Kenyans.